

HYDROGEN SULFIDE MODULATES HEPATIC OXYGEN AVAILABILITY AND
MICROCIRCULATION DURING SEPSIS

by

Eric J. Norris

A dissertation submitted to the faculty of
The University of North Carolina at Charlotte
in partial fulfillment of the requirements
for the degree of Doctor of Philosophy in
Biology

Charlotte

2012

Approved by:

Dr. Mark G. Clemens

Dr. Didier Dréau

Dr. Kenneth L. Bost

Dr. Pinku Mukherjee

Dr. Cynthia A. Gibas

© 2012
Eric J. Norris
ALL RIGHTS RESERVED

ABSTRACT

ERIC J. NORRIS. Hydrogen sulfide modulates hepatic oxygen availability and microcirculation during sepsis. (Under the direction of DR. MARK G. CLEMENS)

A mismatch between O₂ supply and demand leads to the development of tissue hypoxia which contributes to hepatic dysfunction and injury during sepsis. Previously, we reported that hepatic microcirculatory failure is a major contributor to hypoxia and hepatic dysfunction during sepsis. Recent evidence suggests that hepatic H₂S levels are increased during sepsis. Moreover, the inhibition of endogenous H₂S synthesis significantly improves survival in septic mice; however, the exact mechanism is not known. The present study was designed to investigate the effect of H₂S on hepatic O₂ availability and microcirculation during sepsis. We hypothesized that H₂S contributes to hepatic dysfunction during sepsis by reducing hepatic oxygen availability, via O₂ dependent oxidation of H₂S, and by potentiating microvascular dysfunction. We demonstrate that the liver is a central regulator of H₂S via mitochondrial oxidation during sepsis. Additionally, we show that the oxidation of H₂S lowers hepatic O₂ levels *in vivo*. In the second half of this study, we demonstrate that H₂S differentially affects the hepatic vascular response to phenylephrine and endothelin-1 which suggests that H₂S differentially affects presinusoidal and sinusoidal sites in the hepatic microcirculation. Using intravital microscopy, we show that portal infusion of H₂S is associated with sinusoidal constriction and that inhibition H₂S synthesis attenuates the sensitization of the sinusoids to the constrictor effect of endothelin-1 which improves perfusion. We conclude that the contribution of H₂S to hepatic tissue hypoxia and microcirculatory dysfunction is partially responsible for its detrimental effects during sepsis.

DEDICATION

To my beautiful and loving wife, Amy Roeder Norris.

ACKNOWLEDGEMENTS

First and foremost, I would like to thank the National Institutes of Health for providing the funding for this research. My dissertation would not have been possible without the help of many individuals. I am especially grateful to my mentor Dr. Mark Clemens for providing the opportunity to work in his lab. His mentorship, insight, and knowledge have been an invaluable asset throughout my doctoral research. I would like to extend a special thanks to Dr. Didier Dreau for always being available to discuss experimental design and troubleshoot an innumerable amount of issues. I would also like to thank the rest of the members of my dissertation committee, Dr. Kenneth Bost, Dr. Pinku Mukherjee, and Dr. Cynthia Gibas for their guidance and criticism throughout the dissertation process.

I appreciate the help I have received from all the members of the Clemens lab throughout my tenure especially, Dr. Sang Ho Lee, Dr. Willson Kwok, Sebastian Larion, and Sriram Narasimhan. I appreciate the opportunity to collaborate with Min Shin, Thomas Fasciano, and Rich Nguyen of the computer science at UNCC. I would like to thank the faculty and staff of UNC Charlotte. I am particularly thankful to our lab manager Catherine Culberson. Roll Tide.

I would like to thank my parents and sisters for always believing in me and supporting me through the years. I am grateful for parents whom provided me every opportunity to attain the best education possible.

Lastly, I cannot accurately describe how grateful I am to my wife Amy. Her love and dedication is incalculable. She worked twice as hard to provide the opportunity for me to do what I love to do. I will be forever indebted to her for her kindness and support.

TABLE OF CONTENTS

LIST OF FIGURES	viii
LIST OF TABLES	xi
LIST OF ABBREVIATIONS	xii
CHAPTER 1: INTRODUCTION	1
1.1 Overview	1
1.2 Hydrogen sulfide	3
1.3 Hepatic hydrogen sulfide oxidation and sepsis	6
1.4 Hepatic microcirculation during sepsis	7
CHAPTER 2: THE LIVER AS A CENTRAL REGULATOR OF HYDROGEN SULFIDE	12
2.1 Abstract	12
2.2 Introduction	13
2.3 Materials and Methods	15
2.4 Results	20
2.5 Discussion	26
2.6 Figures	33
CHAPTER 3: HYDROGEN SULFIDE DIFFERENTIALLY AFFECTS THE HEPATIC VASCULATURE RESPONSE TO PHENYLEPHRINE AND ENDOTHELIN-1 DURING ENDOTOXEMIA.	47
3.1 Abstract	47
3.2 Introduction	48
3.3 Materials and Methods	51
3.4 Results	53

3.5	Discussion	56
3.6	Figures	64
CHAPTER 4: ENDOGENOUS HYDROGEN SULFIDE CONTRIBUTES TO SINUSOIDAL HYPERCONSTRICTION AND FOCAL TISSUE HYPOXIA DURING ENDOTOXEMIA.		76
4.1	Abstract	76
4.2	Introduction	77
4.3	Materials and Methods	80
4.4	Results	86
4.5	Discussion	89
4.6	Figures	98
CHAPTER 5: DISCUSSION		111
CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS		122
REFERENCES		129

LIST OF FIGURES

FIGURE 1: Percent removal of H ₂ S from perfusate by isolated and perfused liver.	33
FIGURE 2: Total removal of H ₂ S from perfusate by isolated and perfused liver.	34
FIGURE 3: Isolated heart shows very limited capacity for H ₂ S clearance.	35
FIGURE 4: Hydrogen Sulfide metabolism produces a biphasic oxygen consumption response.	36
FIGURE 5: Individual tracings of biphasic oxygen consumption response to H ₂ S.	37
FIGURE 6: Oxygen availability is a requirement for H ₂ S metabolism at physiological concentrations.	38
FIGURE 7: Hydrogen sulfide attenuates phenylephrine-induced increase in portal pressure.	39
FIGURE 8: Hydrogen sulfide has no effect on stimulation of glucose production by phenylephrine.	40
FIGURE 9: Hydrogen sulfide potentiates the increase in O ₂ consumption following phenylephrine treatment.	41
FIGURE 10: Cecal ligation and puncture does not affect percent hepatic H ₂ S clearance ability.	42
FIGURE 11: Cecal ligation and puncture does not affect total hepatic H ₂ S clearance ability.	43
FIGURE 12: Cecal ligation and puncture does not affect hepatic O ₂ consumption.	44
FIGURE 13: H ₂ S infusion is associated with an increase in NADH autofluorescence.	45
FIGURE 14: H ₂ S infusion is associated with a decrease in hepatic O ₂ content.	46
FIGURE 15: LPS attenuates the hepatic vascular response to phenylephrine.	64
FIGURE 16: LPS potentiates the hepatic vascular response to endothelin-1.	65
FIGURE 17: H ₂ S attenuates the increase in portal pressure caused by PE.	66
FIGURE 18: H ₂ S has no effect on the increase in portal pressure caused by ET-1.	67

FIGURE 19: H ₂ S potentiates LPS-induced vascular hypo-responsiveness to PE.	68
FIGURE 20: H ₂ S does not affect LPS-induced vascular hyper-responsiveness to ET-1.	69
FIGURE 21: PAG treatment increases sensitivity of the hepatic vasculature to PE.	70
FIGURE 22: PAG treatment increases sensitivity of the hepatic vasculature to ET-1.	71
FIGURE 23: PAG treatment reverses hepatic vascular hypo-responsiveness to PE during endotoxemia.	72
FIGURE 24: PAG does not potentiate the hepatic vascular response to ET-1 during endotoxemia.	73
FIGURE 25: Effect of H ₂ S on hepatic O ₂ consumption in control and endotoxemic livers.	74
FIGURE 26: Effect of PAG on hepatic O ₂ consumption in control and endotoxemic livers.	75
FIGURE 27: Effect of portal infusion of Na ₂ S on portal pressure <i>in vivo</i> .	98
FIGURE 28: Effect of portal infusion of Na ₂ S on sinusoidal diameters.	100
FIGURE 29: Effect of portal infusion of Na ₂ S on heterogeneity of sinusoidal diameters.	101
FIGURE 30: Effect of dl-propargylglycine (PAG) on portal pressure during infusion of ET-1 during endotoxemia.	103
FIGURE 31: Effect of dl-propargylglycine (PAG) on mean sinusoidal diameter during infusion of ET-1 during endotoxemia.	104
FIGURE 32: Effect of dl-propargylglycine (PAG) on mean sinusoidal diameter heterogeneity during infusion of ET-1 during endotoxemia	105
FIGURE 33: The effect of ET-1 infusion on the hepatic sinusoids following PAG treatment in endotoxemia.	106
FIGURE 34: Distribution of sinusoidal flow velocities.	107
FIGURE 35: Effect of PAG treatment on sinusoidal perfusion percentage following ET-1 infusion during endotoxemia.	108

FIGURE 36: Effect of PAG treatment on hepatic redox potential following ET-1 infusion during endotoxemia.	109
FIGURE 37: Representative micrographs of NADH autofluorescence before and after ET-1 infusion during endotoxemia.	110
FIGURE 38: Proposed Mechanism of Deleterious Effect of H ₂ S during Sepsis.	125
FIGURE 39: Effect of PAG on serum alanine aminotransferase levels during endotoxemia.	126
FIGURE 40: PAG treatment attenuates the increase in HIF-1 α .	127
FIGURE 41: GYY 4137 reduces mitochondrial reactive oxygen species production by isolated rat hepatocytes during hypoxia.	128

LIST OF TABLES

TABLE 1: Effect of portal infusion of Na ₂ S on mean arterial pressure (MAP) and heart rate (HR).	99
TABLE 2: Effect of portal infusion of ET-1 on mean arterial pressure (MAP) and heart rate (HR).	102

LIST OF ABBREVIATIONS

3-MST	3-mercaptopyruvate sulfurtransferase
ANOVA	analysis of variance
ATP	adenosine triphosphate
BAEC	bovine arterial endothelial cells
CAV-1	caveolin 1
CBS	cystathionine beta-synthase
cGMP	cyclic 3'-5' guanosine monophosphate
CLP	cecal ligation and puncture
CO	carbon monoxide
CSE	cystathionine λ lyase
DO ₂	delivered O ₂
eNOS	endothelial nitric oxide synthase
ET-1	endothelin-1
ET _A	endothelin A receptor
ET _B	endothelin B receptor
FITC	fluorescein isothiocyanate
GY4137	H ₂ S donor, (p-methoxyphenyl)morpholino-phosphinodithioic acid
H ₂ DCF-DA	2',7'-dichlorodihydrofluorescein diacetate
H ₂ S	hydrogen sulfide
HO-1	heme oxygenase 1
HSC	hepatic stellate cells
IACUC	Institutional Animal Care and Use Committee

iNOS	inducible nitric oxide synthase
K _{ATP}	ATP sensitive-potassium channel
KC	kupffer cells
L-NAME	N ^G -nitro-L-arginine methyl ester
LPS	lipopolysaccharide
MODS	multiple organ dysfunction syndrome
MOF	multiple organ failure
Na ₂ S	sodium sulfide
NaHS	sodium hydrosulfide
NAD ⁺	nicotinamide adenine dinucleotide (oxidized form)
NADH	nicotinamide adenine dinucleotide (reduced form)
NE	norepinephrine
NO	nitric oxide
NOS	nitric oxide synthase
O ₂	oxygen molecule
PAG	dl-propargylglycine
PE	phenylephrine
PO ₂	partial pressure of oxygen
SEC	sinusoidal endothelial cells
SEM	standard error of the mean
SIRS	systemic inflammatory response syndrome
Ru(phen) ₃ ²⁺	tris (1, 10-phenanthroline) ruthenium (II) chloride hydrate
VSMC	vascular smooth muscle cell

CHAPTER 1: INTRODUCTION

1.1 Overview

Hepatic failure is a significant complication during the late stages of sepsis; however, the first signs of hepatocellular dysfunction are observed early during disease progression and gradually progress to liver failure [19-20]. In the early stages of sepsis, cardiovascular function is characterized by a hyper-dynamic state, consisting of increased cardiac output and modest peripheral vasodilation [134]. During this period, overall delivery of O₂ (DO₂) to the liver is increased [27]. Despite the increase in DO₂, there is ample evidence demonstrating that hepatic injury is due in part to hypoxic stress [13, 28, 34, 41, 94]. While there is likely a contribution of mitochondrial dysfunction during sepsis [32], previous work from our lab and others demonstrate that disturbances in the hepatic microcirculation following inflammatory stress are a major contributor to hepatic dysfunction [12, 22, 63, 131]. During sepsis, the manifestations of hepatic microcirculatory dysfunction include heterogeneous tissue perfusion, focal hypoxia, and cell death. Eventually, an inability of the hepatic microcirculation to match O₂ supply with tissue demand can lead to hepatocellular injury, liver failure and the progression of sepsis.

As opposed to the macrocirculation which is responsible for transporting blood between organs, the microcirculation consists of smaller vessels (<100µm) that distribute blood within individual tissues. Arterioles are the primary resistance vessels in the

microcirculation, and due to their pre-capillary, location are responsible for modulating tissue perfusion [80]. Vascular smooth muscle cells (VSMCs) surround arterioles and act in functional syncytium in response to various stimuli to contract or relax, leading to a change in the vessel luminal diameter. This change in vascular resistance can increase (relaxation) or decrease (contraction) perfusion through the capillaries. Since the resistance of a fluid to flow is inversely proportional to the fourth power of the luminal diameter, small changes in vessel diameter can have profound effects on tissue perfusion.

Originally, it was thought that hepatic portal blood flow was solely regulated by total splanchnic drainage and pre-sinusoidal resistance vessels; however, it is now known that the hepatic sinusoid is also an important site of hepatic blood flow regulation. During sepsis, sinusoidal hyperconstriction results from the hypersensitization of the hepatic sinusoid to the vasoconstrictive effect of endothelin-1 (ET-1) [12, 94]. Sinusoidal hyperconstriction is associated with heterogeneous blood flow through the sinusoids resulting in a mismatch between O₂ supply and demand [13]. As a consequence, microcirculatory failure contributes to focal hypoxia and organ injury during sepsis.

The “gasotransmitters”, NO and carbon monoxide (CO), are important modulators of the hepatic microcirculation, particularly during sepsis [98, 108]. Recently, hydrogen sulfide (H₂S) has been added to the class of small, biologically active gases known as “gasotransmitters” [135]. It is now established that there are several biological functions common between H₂S, NO and CO, in particular their ability to cause VSMC relaxation and vasodilation [135]. Despite this common feature, the effect of H₂S on the hepatic oxygenation and microcirculation during sepsis remains unclear. As a vasodilator, one would predict that H₂S improves hepatic O₂ availability and microvascular function

following inflammatory stress. In support of this hypothesis, several studies demonstrate that H₂S provides a protective effect following ischemia/reperfusion injury [54, 73, 116, 127]. On the contrary, endogenous H₂S contributes to disease progression during sepsis [5, 144]. Since H₂S has been shown to alter cellular O₂ levels and modulate vascular resistance, the present study was designed to investigate the contribution of H₂S to hepatic oxygen availability and microvascular dysfunction during sepsis. Overall, we hypothesize that H₂S is metabolized in the liver at the expense of hepatic O₂ availability and contributes to hepatic sinusoidal sensitization to ET-1 and tissue hypoxia during sepsis. The findings of this study may provide evidence to partially explain why H₂S is deleterious during sepsis, despite being protective in several other pathophysiological conditions.

1.2 Hydrogen Sulfide

H₂S is a small, lipophilic gas commonly associated with the characteristic smell of rotten eggs. The first reports of a biological effect of H₂S predate those of the other “gasotransmitters”. Nevertheless, only recently has H₂S garnered similar attention as a potential mediator in physiological processes [135]. Initial reports documented the lethality of exposure to elevated levels of the noxious gas, which was subsequently shown to result from potent inhibition of mitochondrial respiration. In a manner similar to cyanide poisoning, H₂S inhibits the activity of cytochrome *c* oxidase in the electron transport chain thereby preventing proper ATP synthesis [87].

For centuries, the toxicity of H₂S was the only known physiological effect in mammals. H₂S was simply considered metabolic waste produced by two pyridoxal 5' phosphate dependent enzymes, cystathionine β synthase (CBS) and cystathionine γ lyase

(CSE), during cysteine metabolism [18, 123]. The discovery that other gases act as important mediators in mammals led to the hypothesis that endogenous H₂S could be physiologically relevant. Support for this hypothesis was first provided by Abe and coworkers who demonstrated that low concentrations of the H₂S donor NaHS facilitated long term potentiation in rat hippocampus slices suggesting a function of H₂S in the nervous system [1]. A potential role in the cardiovascular system was demonstrated by Hosoki et al who reported H₂S caused relaxation of isolated aortic rings [48]. The observation that CSE^{-/-} mice spontaneously develop hypertension confirmed that endogenous H₂S is a physiologically relevant mediator [140]. It is now well established that endogenous H₂S is an important mediator in the nervous, cardiovascular, gastrointestinal, pulmonary, and immune systems [136].

Even though there is a scientific consensus that H₂S is endogenously synthesized and a physiological important mediator, there is still considerable debate about several basic concepts in H₂S biology. First and foremost, the biologically active form of H₂S is not known. H₂S is a weak acid in aqueous solution with a pK_{a1} between 6.6 and 7.1 and pK_{a2} > 12 depending on experimental conditions [136]. Therefore, under physiological conditions, H₂S is in equilibrium with the deprotonated form, HS⁻, with negligible amounts of S²⁻. It is possible that H₂S, HS⁻, or both exert biological functions. The different chemical properties of each form of sulfide may produce differential effects. For instance, the lipophilicity of H₂S allows for diffusion mediated movement across lipid membranes, whereas HS⁻ is not freely permeable, allowing for the possibility of compartmentalization of sulfide. Whether H₂S and HS⁻ exert differential effects has yet to

be determined. Therefore, as is currently used in H₂S biology, the terms H₂S and sulfide, are used to refer to both H₂S and HS⁻, collectively, in this study [92].

The physiological concentration of H₂S *in vivo* remains unknown [92]. Because methods to measure H₂S levels are still developing, initial reports that identified the physiological circulating range to be between 10-300μM appear to be an overestimation [92]. Since even the lowest concentrations in this range would produce the characteristic rotten egg smell of H₂S in exhaled breath and blood, it is likely that circulating plasma H₂S levels are much lower or H₂S is bound in an undetectable form. In preliminary experiments, we were unable to detect any H₂S immediately after adding it to whole blood with the commonly used methylene blue H₂S assay. Interestingly, H₂S was easily detectable when added to plasma alone, suggesting an interaction between red blood cells and H₂S.

It is now thought that the level of H₂S *in vivo* is the result of local rates of H₂S production and disposal, which may be affected during disease states. The primary source of H₂S in the nervous system is CBS, while CSE is the main source of H₂S in the cardiovascular system and liver [1, 140]. Recently, a third enzyme, β mercaptopyruvate transferase (3MST), has been shown to produce a small amount of H₂S; however, the functional significance of this enzyme on total H₂S levels remains unclear [114]. CSE is constitutively expressed in the liver in several different cells including hepatocytes, hepatic stellate cells (HSC) and kupffer cells (KC) [33]. In addition, we have observed expression of CSE in isolated rat sinusoidal endothelial cells (data not shown). As the primary recipient of blood flow, the liver is subjected to a secondary source of H₂S from bacteria in the GI tract which synthesize H₂S as a metabolic byproduct producing H₂S

concentrations into the millimolar range [15]. This large, potentially toxic amount of sulfide is mostly sequestered and disposed in the feces; however, a small portion can escape the intestinal epithelial barrier and enter the portal circulation. Due to the combination of endogenous and exogenous sources of H₂S, it is likely that the liver is exposed to elevated levels of H₂S, particularly during sepsis. However, how the liver disposes of H₂S during sepsis remains unclear.

1.3 Hepatic hydrogen sulfide oxidation and sepsis

Treatment with bacterial endotoxin (LPS) leads to an increase in CSE expression in the macrophage like RAW 246.7 cell line suggesting that H₂S levels may increase during an inflammatory response [149]. In different *in vivo* models of sepsis, both cecal ligation and puncture and endotoxin treatment cause an increase in hepatic CSE expression which resulted in an increased hepatic capacity to synthesize H₂S [144]. In addition to elevated endogenous H₂S levels, damage to the intestinal cells has been shown to reduce their ability to detoxify H₂S which may permit more diffusion of H₂S into the portal circulation [129]. Moreover, in preliminary studies, we were able to detect measurable amounts of H₂S in the peritoneal fluid of rats following CLP supporting the hypothesis that there are elevated levels of bacterial derived H₂S during peritonitis.

Given that oxidative catabolism of toxins in the circulation is a main function of the liver, it is possible that the liver has the ability to dispose of H₂S to protect itself from toxic accumulation and prevent H₂S entry into the systemic circulation. Recently, Lagoutte et al reported that colonic epithelial cells metabolize H₂S via mitochondrial oxidation which protects them from toxic levels of sulfide derived from the gut bacteria [68]. Early studies on sulfide detoxification show that oxidation of H₂S occurs in a

recirculating isolated, perfused liver system with a concomitant increase in hepatic O₂ consumption [8]. Accordingly, several studies have demonstrated an inverse relationship between O₂ and H₂S levels in various experimental settings [91, 93, 138]. This led to the hypothesis that H₂S acts as a cellular oxygen sensor. When O₂ levels fall, H₂S oxidation is inhibited allowing for the accumulation of H₂S. At sufficient levels, H₂S would exert a biological function to raise O₂ levels. One possibility would be vasodilation of resistance vessels leading to an increase in tissue perfusion which would raise cellular O₂ levels. Once O₂ levels reach adequate levels, H₂S oxidation can resume and H₂S levels would fall [91]. In this scenario, the balance struck between O₂ and H₂S ensures adequate tissue perfusion. However, this scenario may be potentially detrimental in the septic liver.

During sepsis, impaired O₂ delivery and mitochondrial dysfunction leads to inefficient ATP production [13, 23]. Any physiological process that consumes hepatic O₂ may contribute to hepatic hypoxic stress. This raises the possibility that hepatic oxidation of H₂S during sepsis may exacerbate the hepatic tissue hypoxia. On the contrary, if the capacity to metabolize H₂S is inhibited during sepsis, then H₂S may accumulate to toxic levels and contribute to hepatic mitochondrial dysfunction via inhibition of cytochrome c oxidase. Therefore, the first part of this study was designed to test the capacity of the liver to metabolize H₂S and to determine if H₂S oxidation remains a priority during sepsis.

1.4 H₂S and hepatic microcirculation during sepsis

It is known that failure of the microcirculation is a major contributor to the progression of sepsis. Previous work from our lab and others focused on the important contribution of NO in both systemic and hepatic microcirculatory dysfunction [47, 95-97,

124]. Under normal conditions, resistance vessels respond to local and humoral vasoregulators to modulate tissue perfusion. During sepsis, the resistance vessels become hyporesponsive to the vasoconstrictive effect of catecholamines due to the excessive production of vasodilators. In an isolated, perfused liver, treatment with endotoxin attenuates the increase in intrahepatic resistance in response to phenylephrine (PE) [97]. This effect was reduced when livers were treated with the nitric oxide synthase (NOS) inhibitor L-N^G-nitroarginine methyl ester (L-NAME), indicating the important role of NO in the hyporesponsiveness to catecholamine signaling. The dysregulation of blood flow distribution leads to heterogeneous organ perfusion which contributes to organ failure during sepsis [52]. While clinical trials targeting NO production have demonstrated a decrease in systemic hypotension, they have failed to significantly improve septic patient outcomes [77].

The regulation of sinusoidal perfusion is more complex than capillary perfusion in other vascular beds. At presinusoidal sites, the resistance of portal terminal venules and hepatic arterioles is modulated by the contractility of VSMCs similar to other vascular beds. In the liver, the hepatic sinusoid participates in the regulation of tissue perfusion as well [11]. Individual sinusoids lack VSMCs; rather they are surrounded by hepatic stellate cells (HSCs) [79]. These specialized pericytes can respond to local vasoactive agents and modulate sinusoidal resistance [25, 62]. HSC contraction reduces sinusoidal diameter and decreases flow through individual sinusoids [146]. As a consequence, sinusoidal constriction is characterized by the juxtaposition of constricted and dilated sinusoids and heterogeneous sinusoidal flow [57].

ET-1 is a potent 21 amino acid vasoactive peptide which is synthesized by SECs, HSCs, and KCs in the liver [106, 139]. The physiological effects of ET-1 are dependent on two receptor subtypes, ET_A and ET_B receptors, which are heterogeneously distributed in the liver [42]. HSCs primarily express ET_A receptors, while SECs express both ET_A and ET_B receptors [49]. ET-1/ET_A interaction primarily mediates vasoconstriction, while ET-1/ET_B interaction produces both vasoconstriction and vasodilation [10, 46]. Importantly, ET-1 levels are elevated following inflammatory stress, including sepsis, and are correlated with disease severity [3, 119]. Extensive work from our lab has demonstrated the importance of the antagonistic relationship between ET-1 and NO in modulating the hepatic microcirculation [98].

Zhang et al was the first to demonstrate that sinusoidal constriction in response to ET-1 co-localizes with HSCs *in vivo* [146]. ET-1 and PE both increased hepatic resistance and decreased portal inflow; however, only ET-1 had an effect on sinusoidal diameter. Moreover, inflammatory stress primes the liver to the vasoconstrictive effect of ET-1 [94, 107]. The potentiated response of the hepatic sinusoid to ET-1 leads to microcirculatory dysfunction and impaired O₂ delivery [12]. Additionally, hypersensitization to ET-1 during sepsis is associated with an increase in the heterogeneity of sinusoidal perfusion resulting in focal hypoxia and hepatic injury [13].

Mechanistic studies have demonstrated the importance of eNOS-derived NO from SECs in maintaining sinusoidal tone [112]. Under normal conditions, the vasoconstrictive effect of ET-1 in HSCs is mitigated by NO produced in SECs [98]. The ET-1/ET_B interaction increases the activity of eNOS in isolated, sinusoidal endothelial cells and maintains tissue oxygenation *in vivo* [67, 98]. During sepsis, the balance between the

vasoregulatory effects of ET-1 is skewed resulting in hypersensitization of the hepatic sinusoid to the vasoconstrictive action of ET-1. This imbalance is largely due to an impairment of ET-1 stimulated eNOS activation [67]. While there is an increase in the ratio of ET_B receptors to ET_A receptors, an increase in the structural protein caveolin-1 inhibits eNOS activity and NO bioavailability [113, 119]. The importance of ET_B receptor activation during sepsis is supported by studies which demonstrate a beneficial effect in the hepatic microcirculation of an ET_B agonist in LPS-treated animals [98]. Moreover, administration of the nitric oxide donor, sodium nitroprusside, improves microcirculatory dysfunction following injury suggesting the importance of NO in maintaining sinusoidal perfusion [41].

In livers isolated from normal and cirrhotic rats, Fiorucci et al demonstrated that H₂S attenuates the vasoconstrictive effect of norepinephrine (NE) via its actions as a vasodilator. Since portal hypertension is a significant complication during cirrhosis and fibrosis, the decrease in intrahepatic resistance would be beneficial [33]. Unlike cirrhosis, portal hypertension is not a significant complication during sepsis. Rather, impaired O₂ delivery due to sinusoidal hyperconstriction is the major complication in liver injury during sepsis. As a vasodilator, one would predict that H₂S would mitigate sinusoidal constriction. However, sinusoidal constriction is observed in the hepatic microcirculation despite elevated H₂S levels. Therefore, it is possible that H₂S does not act as a vasodilator in the hepatic sinusoid.

H₂S-mediated vasodilation is mainly the result of activation of K_{ATP} channels expressed in VSMCs [148]. K_{ATP} channel activation produces hyperpolarization and relaxation [103]. H₂S would only be beneficial in the liver during sepsis if it acts as a

vasodilator on the sinusoids; however, the hepatic sinusoids lack VSMCs. Therefore, H₂S may exert a different effect in the sinusoid. Moreover, there are several reports that H₂S can produce vasoconstriction [74, 76]. If H₂S exerts a different effect on presinusoidal and sinusoidal sites of regulation, then it would differentially affect the vascular responses to site specific vasoactive molecules in an isolated perfused liver. Therefore, the second part of this study was designed to investigate the effect of H₂S on PE and ET-1 infusion during endotoxemia to determine if there is a differential effect of H₂S at presinusoidal and sinusoidal sites of hepatic blood flow regulation.

To determine if H₂S differentially regulated presinusoidal and sinusoidal sites, we used an isolated, perfused liver system. The advantage of this experimental technique is that it allows for accurate monitoring of changes in intrahepatic resistance during constant flow perfusion. PE acts on VSMC cells in the portal terminal venules, whereas ET-1 exerts its effect at sinusoidal and presinusoidal sites. Since endotoxemia produces hypersensitization of the sinusoids to ET-1, we can identify the location of an H₂S effect by comparing the effects of PE and ET-1 infusion. However, since changes in inflow pressure correlate to total intrahepatic resistance, we could not directly assess the sinusoids. Moreover, heterogeneous sinusoidal flow is a critical component in the development of focal hypoxia and liver injury during sepsis. *In vivo* microscopy is a more laborious technique that allows for the direct visualization of the hepatic microvasculature and determination of flow through the sinusoids. Therefore, the last part of this study was performed to test the contribution of endogenous H₂S to hypersensitization of the hepatic sinusoid to ET-1 and hepatic tissue perfusion heterogeneity during endotoxemia.

CHAPTER 2: THE LIVER AS A CENTRAL REGULATOR OF HYDROGEN SULFIDE

2.1 Abstract

The liver is likely exposed to high levels of H₂S from endogenous hepatic synthesis and exogenous sources from the gastrointestinal tract. Little is known about the consequence of H₂S exposure on the liver or hepatic regulation of H₂S levels. We hypothesized that the liver has a high capacity to metabolize H₂S and that H₂S oxidation is decreased during sepsis; a condition in which hepatic O₂ is limited and H₂S synthesis is increased. Using a non-recirculating isolated and perfused liver system, we demonstrated rapid hepatic H₂S metabolism up to an infusion concentration of 200 μM H₂S. H₂S metabolism was associated with an increase in O₂ consumption from a baseline 96.7 ± 7.6 μmoles O₂/min/kg to 109 ± 7.4 μmoles O₂/min/kg at an infusion concentration of 150 μM H₂S (P<0.001). Removal of O₂ from the perfusate decreased H₂S clearance from a maximal 97% to only 23%. Livers isolated from rats subjected to cecal ligation and puncture (CLP) did not differ significantly from control livers in their capacity to metabolize H₂S suggesting that H₂S oxidation remains a priority during sepsis. To test whether H₂S induces O₂ consumption *in vivo*, intravital microscopy was utilized to monitor the oxygen content in the hepatic microenvironment. Infusion of H₂S increased the NADH/NAD⁺ ratio (645 grey scale unit increase, P=0.035) and decreased hepatic O₂ availability visualized with Ru(Phen)₃²⁺ (439 grey scale unit increase, P=0.040). We conclude that the liver has a high hepatic capacity for H₂S metabolism. Moreover, H₂S

oxidation consumes available oxygen and may exacerbate the tissue hypoxia associated with sepsis.

2.2 Introduction

For centuries, hydrogen sulfide (H_2S) has been known almost exclusively as a toxic gas associated with the characteristic smell of rotten eggs. However, recent evidence now demonstrates that H_2S is an endogenously produced biologically active gaseous molecule [135]. Numerous studies have identified H_2S as an important mediator in several biological systems including neurological, cardiovascular, and gastrointestinal systems [15, 29, 122, 140]. The role of H_2S in inflammation remains poorly defined [84, 116, 142-145]. H_2S is synthesized during cysteine metabolism via two pyridoxal - 5'-phosphate dependent enzymes; cystathionine β -synthase (CBS) primarily in the brain and cystathionine γ -lyase (CSE) primarily in the vasculature and liver [18, 123]. Additionally, the synthesis of H_2S by the microflora of the gastrointestinal system provides an exogenous source of H_2S that may enter the portal circulation [15]. The liver is uniquely positioned to be exposed to high levels of H_2S ; however, how the liver responds to elevated hydrogen sulfide levels is unclear. Several studies have observed circulating hydrogen sulfide levels between < 1 and $300 \mu\text{M}$. Anecdotal evidence suggests that it is unlikely that H_2S circulates in the blood within this range as neither blood nor expired air smell of the characteristic rotten egg odor that would be expected from these levels of H_2S [92]. Therefore, we propose that the liver, as a consequence of its location, is a key regulator of H_2S levels by maintaining a high capacity for H_2S clearance from the circulation

Despite extensive research, sepsis remains a significant clinical problem today accounting for 1.3 percent of all hospitalizations [78]. Sepsis is associated with an inflammatory cascade resulting in hepatic dysfunction [19]. Failure of the hepatic microcirculation results in inadequate perfusion resulting in heterogeneous oxygen distribution and tissue hypoxia [12, 121]. Several studies have demonstrated cellular metabolism of H₂S via oxidation in the mitochondria [8, 68]. The oxidation of H₂S during sepsis could have detrimental unintended consequences during sepsis as it would compete for already limited oxygen resources. Moreover, in the absence of mitochondrial oxidation, H₂S levels could accumulate to potentially toxic levels in the liver and enter the general circulation.

Currently there is very little of information in the literature regarding the effect of H₂S on the hepatic microenvironment, particularly during pathological conditions, such as sepsis, where oxygen availability is limited and H₂S synthesis is increased [144]. The role of H₂S during sepsis is still unclear and a better understanding is vital for the potential development of targeted therapeutic intervention [45] Therefore, the aim of the present study was to assess the capacity of the liver to metabolize H₂S with particular emphasis on the relationship between H₂S oxidation and hepatic oxygen availability. The study was also designed to investigate whether the capacity for H₂S oxidation would be greatly decreased during sepsis due to hepatocellular dysfunction and limited oxygen availability. The findings of this study highlight the delicate balance between H₂S clearance and hepatic oxygen availability.

2.3 Materials and Methods

Animals: Male Sprague-Dawley rats (Charles River Laboratories, Fayetteville, NC) were housed in a temperature-controlled setting under 12-hour light/dark cycles. Rats were maintained on standard rat chow or fasted overnight with free access to water depending on experimental conditions. All animal manipulation was in strict adherence with National Institutes of Health guidelines and experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of North Carolina at Charlotte.

Isolated and perfused liver preparation: Preparation of the non-recirculating liver perfusion system followed that of Sugano et al with slight modifications [125]. Briefly, rats were anesthetized under light isoflurane. A laparotomy was performed to expose the abdominal cavity. Heparin (1000 units/kg body) was injected into the inferior vena cava. The portal vein was cannulated and perfused with warm, oxygenated Krebs' Henseleit buffer [NaCl 118.95mM, MgSO₄ 1.2mM, KH₂PO₄ 1.2 mM, KCl 4.65 mM, NaHCO₃ 25 mM, EDTA 0.1 mM, CaCl₂ 2.5mM, C₃H₆O₃ (lactic acid) 5mM, C₃H₃O₃Na (pyruvic acid) 1 mM, C₆H₁₂O₆ (glucose) 5mM, pH= 7.4] [2]. The flow rate was held constant and calculated as 16ml/minute/100 grams body weight. The thorax was opened and a cannula was inserted into the inferior vena cava to allow for collection and monitoring of the effluent. Lastly, the vena cava was ligated above the renal vein to close the system and ensure perfusate through the effluent cannulation. The liver was perfused *in situ* with warm, oxygenated Krebs' buffer for a period of 20 minutes to allow for stabilization. Oxygen consumption and temperature were monitored during the stabilization period to ensure proper preparation. Only livers that demonstrated stable O₂ consumption during

the stabilization period were considered satisfactory preparations and used in future experiments.

Na₂S preparation: The H₂S donor Na₂S (Sigma-Aldrich, St. Louis, MO) was used in all experiments. Na₂S completely dissociates in water to the weak conjugate base S²⁻ which combines with available H⁺ ions to establish an equilibrium between H₂S ↔ HS⁻ + H⁺ at physiological pH. It remains unclear which form of H₂S is biologically active. For clarity, the term H₂S will be used to represent all sulfide added to the system from Na₂S. Na₂S was dissolved in the appropriate buffer immediately before use as H₂S is a volatile gas with a short half life. All standard curves were made at the time of experimental collection and all samples were stored in the exact conditions.

H₂S clearance: Following the stabilization period, H₂S was infused into the influent at a rate of 1% of the total flow rate resulting in final H₂S concentrations between 0-500 μM in 50 μM increments. Preliminary experiments demonstrated a rapid equilibration H₂S concentration in the perfusate. Thus, infusion of H₂S lasted for 2.5 minutes. A 2.5 minute recovery period was used to give ample time to return to baseline. Inflow and outflow perfusates were sampled in duplicate 90 seconds after H₂S infusion began. Samples were immediately transferred into 1.5 ml eppendorf tubes containing 150 μl of 1% zinc acetate to trap the H₂S in solution. All samples were frozen and stored at -80 Celsius overnight before the H₂S assay.

For experiments requiring different levels of buffer oxygenation, Krebs's buffer was bubbled with a combination of gases (N₂, O₂, CO₂) to achieve the desired level prior to the experiment. Oxygen levels were monitored for a period of 20 minutes to ensure the combination of gases resulted in a stable level of oxygenation.

Oxygen Monitoring: The oxygen content of the perfusate was monitored using an oxygen sensitive cathode connected to an oxygen monitor (YSI Life Sciences, Yellow Springs, Ohio). All measurements were recorded continuously using Biopac systems MP 100 transducer and software (Goleta, CA). Oxygen sensors were calibrated daily with distilled H₂O bubbled with ambient air. Inflow perfusate oxygen concentration was measured immediately prior to and after the experiment. Only experiments where inflow oxygen content remained constant throughout the experiment were used.

Isolated and Perfused Heart Preparation: Surgical preparation was done as described in Clemens et al with slight modifications [24]. Briefly, the excised heart was quickly transferred to a petri dish containing ice cold Krebs's buffer. The aorta was quickly cannulated and secured into position with suture material. Warm, oxygenated Krebs's buffer was perfused through the heart at a flow rate of 10 ml/min/g tissue. The pulmonary artery was cannulated to allow collection of outflow sample. The entire organ preparation was suspended inside a temperature-controlled perfusion chamber. A 20 minute period of stabilization occurred prior to the start of the experiment. Infusion with H₂S occurred in exactly the same manner as with the isolated liver perfusion preparations.

Phenylephrine Treatment: Livers isolated from 18 hour fasted rats were prepared as described. Lactate, pyruvate, and glucose were removed from the Krebs's buffer for assessment of baseline gluconeogenesis. After 20 minute of stabilization, the perfusion buffer was switched to buffer containing the gluconeogenic substrates lactate (5mM) and pyruvate (1mM) with or without 100 μM H₂S. Isolated livers were then stimulated with the alpha adrenergic agonist L-phenylephrine (PE) (Sigma-Aldrich, St. Louis, MO). A

maximum vasoconstrictor response was observed at a PE infusion concentration of 5 μ M. This concentration was chosen for comparison of gluconeogenesis and vasoactivity between control and the experimental H₂S group.

Gluconeogenesis assessment: Glucose production from isolated perfused livers was measured using effluent samples collected and stored at -80°C. The concentration of glucose in samples was determined using the colorimetric glucose oxidase and peroxidase method (PGO enzymes and dianisidine, Sigma-Aldrich, St. Louis, MO). Samples were incubated with the enzyme solutions for 30 minutes at 37°C and then read at 450nm on a Beckman Spectrophotometer. Glucose concentrations were calculated from a standard curve of known values.

H₂S assay: 75 μ l samples were immediately placed in 150 μ l of 1% zinc acetate to trap H₂S in solution. To this solution, 133 μ l of 20 mM N,N- dimethyl-p-phenylenediamine sulfate (dissolved in 7.2 M HCl) and 133 μ l 30 mM FeCl₃ (dissolved in 1.2 M HCl) was added and then the solution was vigorously vortexed. After 20 minute incubation at room temperature, addition of 300 μ l of 10% trichloroacetic acid was followed by centrifugation (10,000g, 5 min 4° Celsius) to precipitate proteins. Absorbance was measured at 670 nm. H₂S levels were calculated against a standard curve. All chemicals were purchased from Sigma-Aldrich (St. Louis, MO).

Polymicrobial sepsis model: Cecal Ligation and puncture was used to induce polymicrobial sepsis. Fasted rats were anaesthetized under light isoflurane. A small midline incision was made to allow for exteriorization of the cecum. The cecum was carefully ligated to ensure unobstructed movement of digested food through the GI tract. Double puncture of the cecum was performed using a 22 gauge needle. The cecum was

gently squeezed to extrude a small amount of feces into the peritoneal cavity. The cecum was carefully placed back into the peritoneal cavity and the incision closed. Animals received 15ml of saline subcutaneously after the surgical procedure to prevent dehydration. Implantable electronic temperature transponders (Bio Medic Data Systems, Seaford, Delaware) were placed subcutaneously to allow periodic monitoring of the animal. Sham animals received all surgical manipulations with the exception of ligation and puncture of the cecum. 24 hours after surgery was performed the liver was isolated and H₂S clearance was assessed as previously described.

Intravital Microscopy: Fasted rats were anaesthetized using sodium pentobarbital (50mg/kg) (Lundbeck Inc., Deerfield, IL). The abdominal cavity was opened to expose the liver and portal vein. The splenic vein was cannulated to allow for infusion of H₂S with minimal disruption of portal flow. The external jugular vein was cannulated for infusion of the oxygen sensor Tris (1, 10-phenanthroline) ruthenium (II) chloride hydrate (Ru(phen)₃²⁺ (Sigma-Aldrich, St. Louis) and for administration of booster doses of pentobarbital as needed. The left carotid artery was cannulated to monitor mean arterial blood pressure (Digi-Med high-pressure analyzer; Micro-Med, Louisville, KY). Heart rate and blood O₂ saturation were continuously monitored using a MouseOx pulse oximeter (Starr Life Sciences, Pittsburgh, PA) to ensure stable preparation. Prepared rats were placed on an Olympus Ix70 inverted microscope (Olympus America, Melville, NY). Saline was first infused at a rate of 50 µl/minute for 10 minutes to determine the effect of infusion on hepatic oxygen distribution. Short acting alpha adrenergic agonist phenylephrine (0.15µmoles/min/kg) was infused for ten minutes to ensure proper experimental and camera setup. Only rats that responded to PE stimulation with a clear

decrease in hepatic O₂ levels were considered satisfactory preparations. Saline was infused for 20 minutes to allow hepatic oxygen distribution and systemic indicators (mean arterial pressure, heart rate, and blood O₂ saturation) to return to baseline. H₂S was infused into the portal circulation at a rate of 2 μmoles/min/kg for 10 minutes to achieve an estimated plasma concentration of 200 μM. A 10 minute recovery period with saline infusion immediately followed H₂S infusion.

Assessment of oxygen distribution *in vivo* was performed as previously described [99]. The liver was exteriorized onto a glass coverslip to allow for epi-illumination of the surface of the left lobe. NADH fluorescence (excitation 366nm, emission 450 nm and (Ru(phen)₃²⁺)(excitation 480 nm, emission 625 nm) were captured using a Cooke Sencicam digital CCD camera (The Cooke Corporation, Romulus, MI) and PTI Imagemaster software. All gain, black level, and contrast enhancements were exactly the same throughout each experiment.

Statistical Analysis: The data are presented as means ± standard error (SE). Statistical significance was determined using ANOVA or linear regression analysis. The Student-Newman-Keuls *post hoc* test was used when ANOVA analysis detected significance. Independent and repeated measures analysis was used where appropriate. Data not passing the normality test were log transformed to achieve normality. Statistical significance was P < 0.05.

2.4 Results

The liver has a high capacity for clearance of H₂S: To determine if the liver is capable of clearing H₂S from the circulation, a non-recirculating isolated and perfused liver system was utilized. Livers isolated from rats were perfused with Kreb's buffer and

subjected to increasing infusion concentrations of the H₂S donor compound Na₂S to achieve final perfusate H₂S concentrations of 50-500 μM. The inflow and outflow perfusates were collected and sampled for H₂S levels. The H₂S clearance ratio (outflow perfusate [H₂S]/inflow perfusate [H₂S]) was used as a measure of the hepatic ability to clear H₂S at each concentration. Perfusion with Krebs's buffer alone resulted in undetectable levels of H₂S in the outflow perfusate indicating no net H₂S synthesis occurring in the liver (data not shown). Infusion of Na₂S resulting in final concentrations of 50, 100, 150, and 200 resulted in a near complete ability to clear H₂S as indicated by 97%, 95%, 97%, and 91% clearances respectively (Figure 1). Fifty percent H₂S clearance was observed at an infusion concentration of 303 ± 28 μM. At H₂S perfusate concentration greater than 400 μM, an almost complete inhibition of H₂S clearance was observed (Figure 2). To determine if H₂S clearance is a general cellular capability or potentially site specific, we employed a non-recirculating isolated and perfused heart system to compare to hepatic H₂S clearance. Na₂S was infused to achieve final perfusate concentrations in the physiological relevant range (0-200 μM). In isolated hearts, a linear correlation exists between the concentration of H₂S in the inflow perfusate and outflow perfusate (Figure 3, $R^2=0.979$, $P<0.001$). A linear regression line slope of 1 is expected if no H₂S is removed from the perfusate. For isolated hearts, the slope of the regression line was 0.751 indicating very little removal of H₂S from the perfusate by the heart. Linear regression analysis from isolated livers had a slope of 0.266 indicating nearly complete removal of H₂S from the perfusate. Importantly, this slope was not statistically different from zero over the physiological range ($R^2=0.266$, $P=0.071$).

Effect of oxygen availability on hydrogen sulfide metabolism: To investigate whether H₂S is being metabolized by the liver or simply bound and sequestered, inflow and outflow perfusate oxygen tension was monitored in isolated and perfused livers. Inflow perfusate was oxygenated for 20 minutes prior to experiment resulting in an inflow oxygen tension of 593.50 ± 28.47 mmHg. Isolated livers consumed 96.7 ± 7.6 $\mu\text{moles O}_2 / \text{min} / \text{kg}$ body weight when perfused with Krebs's buffer alone. Infusion with Na₂S resulting in final H₂S concentrations of 50, 100, 150 and 200 μM significantly increased O₂ consumption to 104 ± 7.6 ($P < 0.001$), 107 ± 7.7 ($P < 0.001$), 109 ± 7.4 ($P < 0.001$) and 105 ± 7.4 ($P < 0.001$) $\mu\text{moles O}_2 / \text{min} / \text{kg}$ body weight respectively (Figure 4). Representative tracings of oxygen consumption at infusion concentrations of 150, 250, and 350 μM demonstrate the shift from increased O₂ consumption to the toxic inhibitory effect of H₂S on oxidative metabolism. Infusion with 250 μM H₂S-induced a biphasic response with an initial increase in O₂ consumption followed by a dramatic decrease in O₂ consumption, due to the accumulation of H₂S during infusion (Figure 5). At pathological H₂S concentrations greater than 250 μM , an increasing inhibition of oxygen consumption was observed with O₂ consumption being 74% of maximal consumption at 300 μM and 46% of maximal consumption at 500 μM . The requirement of O₂ for H₂S metabolism was tested by altering the oxygen content of the perfusate. Krebs's buffer was oxygenated to establish perfusate oxygen partial pressures of 593.50 ± 28.47 , 245.72 ± 38.42 , and 21.0 ± 2.52 mmHg O₂. Isolated livers perfused with the high oxygen content perfusate metabolized 50% of the H₂S at an inflow concentration of 303 ± 29.5 μM . Perfusion with buffer containing approximately 300 mmHg O₂ resulted in a significant leftward shift in the 50% metabolism point to 221.7 ± 5.84 μM , $p < .05$ (Figure

6). Decreasing the oxygen content to 150 mmHg further lowered the 50% metabolism point to $170.0 \pm 23.6 \mu\text{M}$. An essential role of oxygen availability in H_2S metabolism was observed as Kreb's buffer bubbled with 95% N_2 / 5% CO_2 rendered the liver incapable of metabolizing 50% of the H_2S at any concentration. At the lowest H_2S infusion concentration ($50\mu\text{M}$) only 23% of the infused hydrogen was metabolized by the liver.

Hydrogen sulfide affects the vascular and metabolic response to phenylephrine: Given the rapid metabolism of H_2S by the liver, we tested whether H_2S was able to exert physiological effects on the liver during perfusion. Livers isolated from 18 hour fasted rats were treated with the alpha adrenergic agonist phenylephrine ($5\mu\text{M}$) and gluconeogenic substrates lactate (5mM) and pyruvate (1mM). After a 20 minute stabilization period with incomplete Kreb's buffer, isolated livers were perfused with complete Kreb's (addition of lactate and pyruvate) buffer containing phenylephrine. Immediately before addition of complete Kreb's buffer, baseline levels for portal pressure ($3.96 \pm 0.19 \text{ mmHg}$), oxygen consumption ($1.824 \pm 0.165 \mu\text{moles O}_2 / \text{min} / \text{g liver wet weight}$), and glucose production ($0.254 \pm 0.11 \mu\text{moles glucose} / \text{min} / \text{g liver wet weight}$) were recorded. Addition of complete Kreb's without phenylephrine did not affect portal pressure (data not shown). The addition of phenylephrine increased portal pressure to $9.3 \pm 0.6 \text{ mmHg}$ (Figure 7). In the presence of $100 \mu\text{M H}_2\text{S}$, the phenylephrine-induced increase was significantly attenuated ($5.7 \pm 0.2 \text{ mmHg}$, $P < 0.001$). The effect of H_2S on gluconeogenesis was determined by measuring the glucose levels in the outflow perfusate. Glucose production increased from baseline ($0.254 \mu\text{moles} / \text{min} / \text{g liver wet weight}$) in control to 0.957 ± 0.11 ($P < 0.001$) $\mu\text{moles} / \text{min} / \text{g liver wet weight}$ ($P < 0.001$) following stimulation with phenylephrine and gluconeogenic substrates (Figure 8).

Addition of H₂S did not significantly affect the increase in glucose output (1.314 ± 0.26 , $P=0.084$). Since vascular changes and gluconeogenesis have an effect on oxygen levels, the partial pressure of oxygen was measured to determine effects on oxygen consumption. Addition of phenylephrine and gluconeogenic substrates resulted in a 28% increase in oxygen consumption over baseline (Figure 9, $P<0.05$). A significantly greater increase in oxygen consumption was observed when H₂S was combined with phenylephrine and substrates (80% over baseline, $P=0.005$).

Hydrogen Sulfide metabolism remains a priority during sepsis: Cecal ligation and puncture (CLP) was performed to investigate whether hydrogen sulfide metabolism is altered during polymicrobial sepsis. Rats were subjected laparotomy followed by double puncture CLP with a 22 gauge needle. Sham control rats underwent laparotomy without CLP. After 24 hours, isolated livers were perfused with increasing concentrations of H₂S (50-500 μ M). Inflow and outflow perfusates were monitored for H₂S levels and oxygen tension. Isolated livers from sham and CLP treated rats showed no significant difference in hydrogen sulfide clearance or oxygen consumption. Sham and CLP treated livers had 50% clearance concentrations of 198 ± 6.7 and 196 ± 35 μ M respectively (Figure 10). Sham treated livers reached a maximal H₂S clearance rate of 17.2 ± 1.6 μ moles/ min/ kg body weight at an infusion concentration of 132 μ M (Figure 11). CLP treated livers had a maximal H₂S clearance rate of 16.9 ± 1.9 μ moles/ min/ kg body weight at an infusion concentration of 127 μ M. Similarly, the oxygen consumption in sham and CLP livers did not differ with an increase O₂ consumption at low H₂S infusion (<150 μ M) concentrations and a decrease in oxygen consumption at high H₂S levels (>200 μ M) (Figure 12).

H₂S oxidation induces hepatic tissue hypoxia *in vivo*: Experiments using a non-recirculating isolated and perfused liver system are standard practice for monitoring of hepatic function, however they are limited. Krebs' buffer is a much simpler perfusate than blood. Furthermore, non-physiological flow rates are required to provide ample oxygenation to the tissue leading to increased shear stress. Therefore, we investigated the effect of H₂S infusion on hepatic oxygen distribution *in vivo* using intravital microscopy. The splenic vein was cannulated for infusion of H₂S directly into the portal circulation for minimal disruption of portal flow. The surface of the liver was illuminated in order to assess the fluorescence of two separate markers of oxygen availability. An increase in NADH fluorescence (excitation 366nm, emission 450 nm) represents an increase in the NADH/NAD⁺ ratio. Since oxygen is the final electron acceptor in the electron transport chain, a loss of O₂ would result in an increase in the NADH/NAD⁺ ratio. As H₂S is an inhibitor of the electron transport chain, it is possible that it could raise NADH/NAD⁺ independently of available oxygen. Therefore, the oxygen sensor molecule Ru(Phen)₃²⁺ (excitation 480 nm, emission 625 nm) was used as a direct measurement of oxygen distribution. Infusion of saline alone resulted in no change in the mean micrograph grey scale level in either NADH or Ru(Phen)₃²⁺ fluorescence indicating stable oxygen distribution during infusion. When H₂S was infused at a predicted final plasma concentration of 200 μM, a significant increase in the mean micrograph grey scale level was observed in NADH fluorescence (645 grey scale unites, P=0.035, Figure 13) and Ru(Phen)₃²⁺ (439 grey scale unites, P=0.040, Figure 14) following 10 minutes of H₂S infusion, indicating that H₂S oxidation reduces the PO₂ in the hepatic microenvironment.

2.5 Discussion

Originally known for its cytotoxicity and pungent odor, H₂S is now recognized, along with nitric oxide and carbon monoxide, as the third major gasotransmitter with important physiological roles in neurological [29], cardiovascular [3], and gastrointestinal function [15]. H₂S is synthesized endogenously during cysteine metabolism via two pyridoxal - 5'-phosphate dependent enzymes: cystathionine β-synthase (CBS) primarily in the brain and cystathionine γ-lyase (CSE) primarily in the vasculature and liver, [18, 123] resulting in physiological levels of H₂S reported to be between < 1 and 300 μM [92]. Exogenous H₂S is synthesized during the normal cellular metabolism of microflora in the gastrointestinal system and may enter the portal circulation [15]. As the major recipient of gastrointestinal blood flow, the liver is uniquely positioned to be subject to high levels of H₂S from a combination of endogenous and exogenous sources. Furthermore, H₂S synthesis is increased during pathological conditions including sepsis [144]. Given that a primary function of the liver is the oxidative metabolism of toxins in the circulation, we tested the hypothesis that the liver is a critical site of metabolism of H₂S from the circulation in an oxygen dependent manner. Additionally, we investigated whether hydrogen sulfide metabolism is altered during polymicrobial sepsis; a pathology in which H₂S levels are increased and limited oxygen availability is a contributing factor [121].

The hypothesis that the liver is capable of clearing H₂S via oxidation from the circulation is not new [8]. However, those experiments were conducted using a blood recirculating isolated and perfused liver system over a period of 15 minutes making it difficult to discount any possible contribution sequestration by red blood cells on the rate

of H₂S clearance. Since circulation time in the rat is about 1 minute, we sought to measure the capacity of the liver to metabolize hydrogen sulfide dissolved in oxygenated Krebs's buffer during a single pass through an isolated liver. Our findings demonstrate that the liver clears virtually all hydrogen sulfide at perfusate concentrations below 200 μM (Figure 1). This ability appears to be constant as the liver was able to clear 100 μM H₂S from the perfusate for over an hour in preliminary experiments (data not shown); a finding in agreement with the original H₂S clearance study.

Controversy exists over the physiologically relevant concentrations of circulating H₂S in blood with values ranging two orders of magnitude [92, 127]. The findings of the present study provide strong evidence against the circulation of free sulfide in the general circulation. As the recipient of 20% of cardiac output, the liver rapidly clears any H₂S present in the circulation during a single pass at all but the highest reported physiological levels. A significant limitation of the isolated and perfused liver study is the absence of red blood cells. It has been suggested that H₂S may bind to hemoglobin or be metabolized by red blood cells into a physiologically inert form [138]. Therefore, we investigated the effect of H₂S infusion *in vivo* using intravital microscopy. Infusion of H₂S into the portal circulation via the splenic vein resulted in a significant decrease in hepatic oxygen content suggesting H₂S oxidation. Whether freely circulating or bound, our study demonstrates that hydrogen sulfide is rapidly cleared from the circulation during passage through the liver; however this clearance consumes available oxygen.

A recent study by Lagoutte et al. using isolated colonocytes demonstrated that H₂S is oxidized by the sulfide quinone reductase enzyme [68]. The study also demonstrated the capacity for H₂S oxidation from isolated mitochondria from several

different organs. Therefore, we sought to investigate whether the ability to metabolize hydrogen sulfide differed between organs. Using an isolated and perfused heart, we demonstrated that the heart has a very small capacity for H₂S oxidation, evidence that organ function and cellular environment contributes to the capacity for H₂S oxidation. Similar results were demonstrated in isolated and perfused kidneys and lungs [8]. Our results combined with those of Lagoutte et al indicate that the liver and colonic epithelial cells, cell types exposed to high levels of H₂S, are specialized for effective clearance of H₂S.

Lagoutte et al. also demonstrated that H₂S metabolism is a priority in mammalian cell types. Furthermore, oxidation of H₂S requires a significant amount of O₂ in a dose dependent manner. This finding was confirmed in our study. Low concentrations of H₂S (<200μM) resulted in a significant increase in oxygen consumption. As H₂S accumulated in the liver at higher doses a biphasic oxygen response was observed with an initial increase in oxygen consumption followed by a dramatic inhibition presumably from cytochrome oxidase c inhibition [87]. The initial increase in O₂ consumption at high doses of H₂S gradually decreased until an almost complete inhibition of O₂ consumption was observed at 500μM. It is possible that the increase in oxygen consumption observed during infusion of H₂S could be a result of the vasodilatory effect of H₂S. In order to assess the vasodilatory effect portal pressure was monitored throughout infusion of H₂S. Portal pressure remained stable throughout the entire experiment indicating that H₂S has little vasodilator contribution in the unstimulated isolated and perfused liver system (Data not shown).

Oxygen availability in the liver is subject to heterogeneous intralobular O₂ distribution which can be exacerbated during pathophysiological states such as sepsis [58]. Therefore, we tested whether alterations in O₂ availability affect H₂S metabolism. O₂ availability proved to be a requirement for H₂S metabolism as decreasing oxygen tension in the buffer resulted in a decreased ability to clear H₂S. In an extremely low O₂ environment the liver was almost incapable of clearing H₂S. Our findings are in agreement with the proposal that H₂S is a putative oxygen sensor as the levels of H₂S and O₂ are inversely related [91]. Moreover, a 2008 study by Whitfield et al demonstrated an accumulation of H₂S during periods of hypoxia that was rapidly reversed in the presence of oxygen [138]. Whether this increase in H₂S is beneficial or detrimental may rely on the specific location and stimulus of the increase. Where an increase in the vasculature would lead to the appropriate vasoactive response [93], an increase in H₂S in the liver may lead to tissue hypoxia and contribute to hepatic injury.

Due to its rapid oxidation in the liver, the possibility arises that H₂S is removed from circulation before it is able to exert a physiological effect. To test this possibility, isolated livers from fasted rats were stimulated with the alpha adrenergic agonist phenylephrine and gluconeogenic substrates, lactate and pyruvate. In agreement with other research groups, H₂S infusion resulted in an attenuation of the phenylephrine constrictor response indicating that H₂S was still biologically active [33]. Combined treatment with phenylephrine and H₂S led to greater O₂ consumption than phenylephrine alone. This was shown to be independent of gluconeogenesis as H₂S did not significantly alter phenylephrine-induced increases in gluconeogenesis, an oxygen dependent process [23]. Thus, the increase in oxygen consumption with co-treatment with phenylephrine

and H₂S is most likely a combination of increased hepatic perfusion as well as H₂S oxidation.

Hepatocellular dysfunction is known to occur in sepsis [19]. Loss of hepatocellular function leads to disease progression, however not all functions are affected equally [132]. Furthermore, hepatic oxygen availability during sepsis is decreased due to decreased hepatic perfusion resulting from an increased sensitization to vasoconstrictive mediators (e.g. ET-1) [12]. The decreased hepatocellular function combined with inadequate oxygen supply led us to hypothesize that the ability to metabolize H₂S would be greatly diminished in livers isolated from septic rats. Interestingly, our study demonstrated that metabolism of H₂S remains a priority in septic rat livers. One possible explanation could be the beneficial effect of constant flow perfusion on hepatic function. In an ischemia/reperfusion model, Chun et al demonstrated that perfusion at a constant flow maintained perfusion and prevented hepatocellular injury whereas constant pressure perfusion did not [22]. It is also important to note that these studies were done in the early stage of sepsis, prior to the development of septic shock. Our model did not produce any mortality within the 24 hour time period used; however, it is likely that some mortality would occur after several days. Importantly, our study demonstrates that the liver does not lose the capacity to metabolize H₂S during the early inflammatory phase of sepsis.

In summary, the present study demonstrates that the liver has an important role in the regulation of H₂S levels in the circulation. While the debate continues regarding physiologically relevant levels of H₂S, we provide evidence that the rapid oxidation of H₂S during a single passage through the liver maintains low systemic circulating levels of

H₂S. H₂S more likely acts as an auto- and paracrine signaling molecule [92]. However, especially during septic peritonitis, production of H₂S by intestinal bacteria is likely to increase H₂S levels in the hepatic portal blood. Excess H₂S production is removed from the circulation by the liver making it a key regulatory site for H₂S levels. The oxidation of increased levels of H₂S predisposes the liver to periods of tissue hypoxia. As hepatic O₂ levels drop, the capacity of the liver to metabolize H₂S decreases forming a detrimental positive feedback loop as more H₂S enters via the circulation. We have demonstrated that H₂S oxidation remains a priority during sepsis. H₂S oxidation could be especially detrimental during sepsis where increased H₂S levels during sepsis could exacerbate the limited oxygen available [13]. Tissue hypoxia contributes to hepatic injury through increased generation of reactive oxygen species [14, 83]. Additionally, HIF 1 alpha, a hypoxia-dependent signaling molecule, is pro-inflammatory and may contribute to hepatic injury [35, 75]. Ultimately, toxic levels of H₂S could lead to inhibition of cytochrome c oxidase. Recent studies have suggested a potential therapeutic value to an induced suspended state of animation of the cell brought about by H₂S presumably through cytochrome c oxidase inhibition [16]. Administration of H₂S has proven to provide therapeutic value in rodent models of ischemia/reperfusion injury [117], acetaminophen induced hepatotoxicity [84], and sepsis [117, 122, 144]. The complexity of H₂S during sepsis cannot be overstated as inhibition of H₂S production has proved therapeutic as well [144]. These discrepancies may be due to experimental parameters or time and dose of administration. Nevertheless, it is evident that H₂S has a role in pathophysiological states. We propose that the liver is unique in the role H₂S plays in

pathophysiological states due to the priority given to modulate hydrogen sulfide levels in the circulation at the expense of hepatic oxygen availability.




Figure 1: Percent removal of H₂S from perfusate by isolated and perfused liver. The liver was perfused *in situ* via the portal vein by a flow-controlled, non-recirculating perfusion system. The H₂S donor Na₂S was infused into the inflow perfusate to achieve final concentrations of 50-500 µM. Inflow and outflow perfusates were assayed for H₂S concentrations. The percent of H₂S cleared from perfusate is plotted against the calculated [H₂S] inflow. Data are presented as means ± SEM of four separate experiments (N=4). Statistical analysis performed using one way repeated measures ANOVA with Student-Newman-Keuls *post hoc* test. *P<0.001 versus 50 µM.




Figure 2: Total removal of H₂S from perfusate by isolated and perfused liver. The total amount of H₂S cleared was determined by calculating the amount of H₂S removed from the perfusate after a single pass through an isolated liver. Data are presented as means ± SEM of three separate experiments (N=3).




Figure 3: Isolated heart shows very limited capacity for H₂S clearance. An isolated and perfused heart was used for comparison to the liver's ability to clear H₂S from perfusate. Both organs were perfused at a constant flow rate with oxygenated Kreb's buffer. H₂S donor Na₂S was infused as 1% of total portal perfusion flow to achieve final perfusate concentrations of 50-200 µM. Inflow and outflow perfusate were assayed for H₂S concentration. Data are plotted as actual [H₂S] (µM) inflow versus actual [H₂S] (µM) outflow. Linear regression analysis was performed on final perfusate concentrations considered physiologically relevant (0-200µM).




Figure 4: Hydrogen Sulfide metabolism produces a biphasic oxygen consumption response. Inflow and outflow perfusate oxygen tensions were monitored during infusion of increasing H₂S concentrations (0-500μM) using an oxygen sensitive electrode. The change in oxygen tension in the inflow versus outflow was calculated as the amount of μmoles of O₂ consumed per minute per kg of body weight. One way repeated measures ANOVA was used for statistical analysis. Analysis for physiological concentrations (0-200μM) and pathological concentrations (250-500μM) were performed independently due to the biphasic response. Data are represented as means ±SEM of three separate experiments (N=3). * P<0.01 compared to 0 μM infusion.




Figure 5: Individual tracings of biphasic oxygen consumption response to H₂S. Individual tracings of the 5 minute H₂S infusion/ recovery cycle observed at Na₂S perfusate concentrations of 150, 250, and 350 μM. Na₂S was infused for a period of 2.5 minutes followed by a 2.5 recovery period. The dotted line indicates approximate baseline consumption for each tracing (118 μmoles O₂ consumed / min / kg body weight).




Figure 6: Oxygen availability is a requirement for H₂S metabolism at physiological concentrations. To produce differential oxygen availability in an isolated liver, Kreb's buffer was continuously bubbled with a mixture of O₂, N₂, and CO₂ to achieve approximate final inflow O₂ content of 600, 300, 150, and 10 mmHg. Inflow and outflow perfusate was collected and sampled for H₂S content. Results are plotted as % H₂S clearance versus calculated [H₂S] (μM) inflow. Data are presented as means ± SEM for three separate experiments (four in 600mmHg group) (N=3).




Figure 7: Hydrogen sulfide attenuates phenylephrine-induced increase in portal Pressure. Livers were isolated from rats fasted for 18 hours prior to surgery. Krebs' buffer alone was perfused for 20 min to allow for stabilization and baseline determinations followed by addition of phenylephrine (PE) with gluconeogenic substrates lactate (5mM) and pyruvate (1mM) in the presence or absence of 100 μ M H₂S. Data are means \pm SE of 4 PE experiments and 3 H₂S separate experiments (N=4,3). Statistical analysis performed using one way repeated measures ANOVA with Student-Newman-Keuls *post hoc* test. * P<0.001 compared to control.




Figure 8: Hydrogen sulfide has no effect on stimulation of glucose production by Phenylephrine. Livers were isolated from rats fasted for 18 hours prior to surgery. Krebs's buffer alone was perfused for 20 min to allow for stabilization and baseline determinations followed by addition of phenylephrine (PE) with gluconeogenic substrates lactate (5mM) and pyruvate (1mM) in the presence or absence of 100 μ M H₂S. Data are means \pm SE of 4 PE experiments and 3 H₂S separate experiments (N=4,3). Statistical analysis performed using one way repeated measures ANOVA with Student-Newman-Keuls *post hoc* test. * P<0.001 compared to control. Outflow perfusate samples from isolated livers were collected for determination of glucose output.




Figure 9: Hydrogen sulfide potentiates the increase in O₂ consumption following phenylephrine treatment. Livers were isolated from rats fasted for 18 hours prior to surgery. Krebs' buffer alone was perfused for 20 min to allow for stabilization and baseline determinations followed by addition of phenylephrine (PE) with gluconeogenic substrates lactate (5mM) and pyruvate (1mM) in the presence or absence of 100 μ M H₂S. data are means \pm SE of 4 PE experiments and 3 H₂S separate experiments (N=4,3). Statistical analysis performed using one way repeated measures ANOVA with Student-Newman-Keuls *post hoc* test. * P<0.001 compared to control. Oxygen levels in the outflow perfusate were monitored to determine the effect of H₂S and phenylephrine on oxygen consumption.




Figure 10: Cecal ligation and puncture does not affect percent hepatic H₂S clearance ability. Fasted rats underwent cecal ligation and puncture (CLP). Sham surgery served as a control. After 24 hours, livers were isolated and subjected to increasing concentrations of H₂S (50-500μM). Inflow and outflow perfusate were collected and assayed for H₂S content. Data are presented as the percentage of H₂S cleared in a single pass through the liver. Data are presented as means ± SEM of three separate experiments (N=3).




Figure 11: Cecal ligation and puncture does not affect total hepatic H₂S clearance ability. Total H₂S clearance was measured from livers isolated from CLP and sham animals following infusion of Na₂S resulting in H₂S perfusate concentrations between 50-500 μM. The total amount of H₂S cleared is plotted against estimated inflow [H₂S]. Data are presented as means ± SEM of three separate experiments (N=3).




Figure 12: Cecal ligation and puncture does not affect hepatic O_2 consumption. Outflow perfusate from isolated livers from Sham and CLP treated rats was continuously monitored with an oxygen sensitive probe to determine the effect of H_2S on O_2 consumption. Data are presented as means \pm SE of three separate experiments (N=3).




Figure 13: H₂S infusion is associated with an increase in NADH autofluorescence. Intravital microscopy was used to assess oxygen distribution in the hepatic microenvironment. 10 min saline infusion demonstrated stable oxygen distribution before H₂S infusion. H₂S was infused into the portal circulation for 10 minutes followed by a 10 minute saline infusion recovery period. NADH fluorescence (excitation 366nm, emission 450nm) increases as the ratio of NADH/NAD⁺ increases and is an indirect measure of oxygen availability. Gray scale was converted to pseudocolor with blue representing black (low NADH/NAD⁺) and red representing white (high NADH/NAD⁺).




Figure 14: H₂S infusion is associated with a decrease in hepatic O₂ content. Intravital microscopy was used to assess oxygen distribution in the hepatic microenvironment. 10 min saline infusion demonstrated stable oxygen distribution before H₂S infusion. H₂S was infused into the portal circulation for 10 minutes followed by a 10 minute saline infusion recovery period. Ru(Phen)₃²⁺ was infused into the circulation to serve as a direct oxygen sensor using intravital microscopy. Ru(Phen)₃²⁺ fluorescence (excitation 480 nm, emission 625nm) increases in the absence of oxygen. Grayscale was converted to pseudocolor with blue representing black (high O₂) and red representing white (low O₂). Micrographs (4x objective) of one experiment are representative of three individual experiments (N=3).

CHAPTER 3: HYDROGEN SULFIDE DIFFERENTIALLY AFFECTS THE HEPATIC VASCULATURE IN RESPONSE TO PHENYLEPHRINE AND ENDOTHELIN-1 DURING ENDOTOXEMIA

3.1 Abstract

Despite being protective in many disease states, H₂S contributes to organ injury in sepsis. Like the other gasotransmitters, nitric oxide (NO) and carbon monoxide (CO), H₂S is a modulator of the microcirculation. Since microcirculatory dysfunction is a main cause of organ injury during sepsis, the present study was designed to test the effect of H₂S on microvascular dysfunction in isolated, perfused livers. In most microcirculatory beds, endotoxin activates the endothelium resulting in hyporesponsiveness to catecholamines and a derangement in blood flow distribution. We demonstrate that H₂S treatment attenuates the increase in portal pressure during infusion of the α_1 adrenergic agonist, phenylephrine (PE) (P<0.01). H₂S almost completely negated the increase in portal pressure in livers isolated from endotoxemic rats. Treatment with an inhibitor of endogenous H₂S, dl-propargylglycine (PAG), reversed LPS-induced hyporesponsiveness to PE. Since hepatic microcirculatory dysfunction is associated with excessive sinusoidal vasoconstriction and not dilation, we investigated whether H₂S affects ET-1-induced vasoconstriction in isolated livers. Contrary to PE treatment, H₂S did not affect the increase in portal pressure during infusion of ET-1 nor did it attenuate the hypersensitization of the liver to ET-1 during endotoxemia. Hepatic resistance in control rats was increased by PAG treatment during ET-1 infusion, but this increase was not

exacerbated during endotoxemia. We monitored hepatic O₂ consumption to assess the effect of vascular changes on oxygen consumption following ET-1 treatment. Low dose ET-1 infusion caused an increase in hepatic O₂ consumption, whereas low dose ET-1 infusion decreased O₂ consumption in endotoxemic livers. Interestingly, while we observed no effect of PAG on the vascular response to ET-1 infusion during endotoxemia, PAG treatment did maintain O₂ suggesting a more complex effect of H₂S inhibition. In summary, the discrepancies between the hepatic response to PE and ET-1 suggest that H₂S differentially contributes to microcirculatory dysfunction in the systemic and hepatic microcirculations. We propose that this is due to H₂S exerting a differential vasoactive function on presinusoidal and sinusoidal sites within the liver. Moreover, our findings suggest that H₂S may contribute to the progression of sepsis by contributing to microvascular failure.

3.2 Introduction

Organ failure is a common complication during sepsis and is associated with an increase in morbidity and mortality [78]. Microcirculatory dysfunction is an important contributor to organ injury [52]. In most vascular beds, sepsis attenuates vasoconstriction in response to catecholamine signaling. This contributes to intractable hypotension, inadequate tissue perfusion, and organ dysfunction. The portal venous circulation is also hyporesponsive to catecholamine signaling; however, depressed catecholamine signaling does not contribute to hepatic microvascular dysfunction [97]. Instead, sinusoidal hyperconstriction, due to increased sensitivity to the vasopressor, endothelin-1 (ET-1), results in heterogeneous perfusion and focal hypoxia which contributes to hepatic dysfunction and ultimately overall injury [12-13, 94].

H₂S is primarily produced as a byproduct of cysteine metabolism by two pyridoxal 5' phosphate (PLP) dependent enzymes: cystathionine β synthase (CBS) and cystathionine γ lyase (CSE) [18, 123]. Additionally, a third PLP independent enzyme, 3-mercaptopyruvate sulphurtransferase (3MST) synthesizes H₂S [114]. CSE is the predominant source of H₂S in the cardiovascular system and liver [123]. The liver is likely exposed to elevated levels of H₂S during bacterial peritonitis due to an increase in hepatic CSE expression and the arrival of H₂S in the portal circulation synthesized from by bacteria of the GI tract [144].

There are conflicting reports in the literature about the vasoregulatory action of H₂S [4, 48, 74, 140, 148]. The first indication that H₂S modulates the hepatic vasculature was reported by Fiorucci et al. Using an isolated perfused liver system, they demonstrated that H₂S attenuated the increase in portal pressure during infusion of norepinephrine (NE) in normal and cirrhotic livers [33]. Therefore, H₂S may be beneficial during cirrhosis and fibrosis by lowering intrahepatic resistance and reducing portal hypertension. Based on this finding, one would predict that elevated levels of H₂S would prevent sinusoidal constriction during sepsis; however, there is ample evidence demonstrating that hepatic dysfunction during sepsis is the result of sinusoidal constriction resulting in tissue hypoxia [12-13, 63, 88].

The hepatic microcirculation has multiple sites of blood flow regulation. Upstream of the sinusoids, terminal portal venules are surrounded by VSMCs and respond to vasoactive molecules similarly to other vascular beds. Unlike the capillaries in other vascular beds, the hepatic sinusoids can modulate local tissue perfusion by changing their resistance which makes them a second, functionally important site of

hepatic perfusion [146]. Unlike portal venules, the sinusoids lack VSMCs. Instead, they are surrounded by hepatic stellate cells (HSC) which can modulate perfusion through individual sinusoids by altering their contractility in response to vasoactive molecules [49, 62]. This unique organization allows regulation of overall hepatic perfusion by pre-sinusoidal regulatory and spatial distribution of hepatic blood flow within the liver lobule [57, 99]. Previous work from our lab has demonstrated that the α_1 adrenergic agonist, phenylephrine (PE) and ET-1 both increase hepatic vascular resistance [146]. Importantly, PE acts only on pre-sinusoidal sites of regulation, whereas ET-1 acts on pre-sinusoidal and sinusoidal regulatory sites [10-11, 146]. Inflammatory stress primes the liver to the vasoconstrictive effect of ET-1 resulting in sinusoidal hyperconstriction and tissue hypoxia [13, 107].

Therefore, the present study was designed to investigate the effect of H₂S on the different sites in hepatic microvasculature during endotoxemia. Using an isolated perfused liver system we investigated the effect of H₂S on total intrahepatic resistance during portal infusion of PE or ET-1 during endotoxemia. We hypothesize that H₂S acts as a vasodilator in response to PE, but has no effect on ET-1-induced vasoconstriction, particularly during endotoxemia. This study is the first to demonstrate that H₂S differentially regulates pre-sinusoidal and sinusoidal sites of hepatic perfusion. Furthermore, our finding that H₂S contributes to systemic vascular hyporesponsiveness, but does not affect sinusoidal constriction adds to the current knowledge regarding the detrimental effects of H₂S on in organ injury during sepsis [144].

3.3 Materials and Methods

Animals: Fifty Male Sprague-Dawley rats (Charles River Laboratories, Fayetteville, NC) weighing 272 ± 13.2 g were used in this study. Rats remained quarantined for four days following arrival. Rats were maintained in pairs in standard cages with bedding with free access to standard rat chow and water in a temperature-controlled setting under 12-hour light/dark cycles. Rats were removed from the vivarium on the morning of the experiment and transported to the laboratory where all surgical procedures were performed. Animals were randomly assigned to groups on the day of the experiment. All animal manipulation was in strict adherence with National Institutes of Health guidelines and experimental protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of North Carolina at Charlotte.

Materials: Sodium sulfide (Na_2S), L-phenylephrine (PE), lipopolysaccharide (LPS, Escherichia coli O26:B6), DL-propargylglycine (PAG), were purchased from Sigma-Aldrich Co. (St. Louis, MO). Endothelin-1 (ET1) was purchased from American Peptide Company (Sunnyvale, CA).

Isolated Perfused Liver: Isolated, perfused rat livers were used to investigate the effect of vasoactive modulators on hepatic portal resistance as described previously [125] with modification [89]. Briefly, rats were anesthetized under isoflurane and subjected to laparotomy. Heparin (1 USP unit/rat mass (g), Webster Veterinary, Devens, MA) was injected into the inferior vena cava. The portal vein was exposed and three loosely tied sutures were placed along the length of the vein. The portal vein was cannulated and the sutures were tightened to secure the cannula in place. The inferior vena cava and abdominal aorta were severed to prevent hypervolemia due to perfusion and to allow for

exsanguation. The pleural cavity was opened and a cannula was inserted into the right atrium and directed downward in the superior vena cava. The cannula was secured in place just below the diaphragm. Lastly, the inferior vena cava was ligated above the renal veins to block perfusate flow. This isolates the liver *in situ* during perfusion with oxygenated Krebs-Henseleit buffer. Temperature of the buffer was maintained at 37° Celsius and continuously oxygenated using 95% O₂/5% CO₂ gas. Following a 20 minute stabilization period, increasing cumulative doses of PE (0.05-20 μM) or ET-1 (0.05-1.0 nM) were infused sequentially in 5 minute intervals. Total intrahepatic resistance was determined by monitoring the pressure in the inflow tubing (portal pressure) using a Biopac Systems MP100 transducer (Goleta, CA) during constant flow perfusion (16ml/kg/min). The H₂S donor Na₂S (50 μM) was administered in the perfusate during ET-1 or PE infusions for certain animal groups. In other experiments, the CSE-inhibitor propargylglycine (PAG, 1 mg/kg) was injected intraperitoneally 30 minutes before liver isolation to inhibit endogenous H₂S production. For the endotoxin model of sepsis, rats were given an injection of LPS (1 mg/kg, ip) 6 hours before liver isolation and perfusion.

Oxygen Monitoring: The amount of O₂ extracted by the liver from the perfusate was calculated to assess hepatic oxygen consumption. The perfusate PO₂ were monitored using an oxygen sensitive Clark-type electrode connected to an oxygen monitor (YSI Life Sciences, Yellow Springs, Ohio). All measurements were recorded continuously using Biopac systems MP 100 transducer and software (Goleta, CA). Calibration of the electrode was performed on the daily using distilled water equilibrated with air and adjusted for temperature and elevation. The concentration of the inflow perfusate was measured immediately prior to and after the experiment. O₂ extraction was

calculated by as the difference between the inflow perfusate PO₂ and outflow perfusate PO₂.

Statistical Analysis: The data are presented as means ± standard error (SEM). Statistical significance was determined using 2 way ANOVA analysis. Student-Newman-Keuls *post hoc* test was used when ANOVA analysis detected significance. Independent and repeated measures analysis was used where appropriate. Statistical significance was $P < 0.05$.

3.4 Results

Effect of endotoxin on hepatic resistance in response to PE and ET-1: An isolated, perfused liver system was utilized to determine the effect of PE and ET-1 on the hepatic vasculature during endotoxemia. Baseline portal pressure in control rats was 3.2 ± 1.4 mmHg. Despite being slightly elevated, there was not a statistically significant effect of 6 hour LPS treatment (4.5 ± 1.6 mmHg, $P=0.076$). PE infusion produced an increase in portal pressure with a maximal increase of 5.5 ± 0.8 mmHg with infusion of $20 \mu\text{M}$ PE in control animals (Figure 15). LPS treatment significantly attenuated the increase in portal pressure due to PE infusion with a maximal increase in portal pressure of 4.1 ± 1.0 mmHg ($P < 0.001$, Figure 15). LPS treatment had the opposite effect on the vasculature response to ET-infusion. LPS potentiated the increase in portal pressure during ET-1 infusion ($P < 0.001$, Figure 16). Additionally, LPS caused a significantly greater maximal increase in portal pressure (15.2 ± 1.1 mmHg in control vs. 18.7 ± 2.3 mmHg in LPS, $P < 0.017$).

Effect of H₂S on hepatic resistance in response to PE and ET-1: To determine the effects of hydrogen sulfide on hepatic resistance, isolated livers were perfused with Krebs's buffer or Krebs's buffer containing the H₂S donor Na₂S ($50 \mu\text{M}$). H₂S did not

significantly affect the resting portal pressure (4.1 ± 2.7 mmHg vs. 3.2 ± 1.4 mmHg in controls, $P=NS$). H_2S treatment significantly reduced the dose dependent increases in portal pressure during PE infusions (Figure 17, $P=0.01$). H_2S had no effect on the increase in portal pressure during infusion of ET-1 (Figure 18).

Effect of combined H_2S/LPS treatment on hepatic resistance in response to PE and ET-1: LPS treatment followed by perfusion with $50 \mu M H_2S$ Krebs's buffer did not affect the resting portal pressure (4.2 ± 0.5 mmHg). Infusion of $5 \mu M$ PE increased portal pressure 5.4 ± 0.5 mmHg (Figure 19). LPS and H_2S each reduced this response to 3.3 ± 0.5 and 3.1 ± 0.4 mmHg respectively ($P < 0.05$). A synergistic interaction between LPS and H_2S produced a nearly complete attenuation of the increase in portal pressure during $5 \mu M$ PE infusion (1.6 ± 0.5 mmHg increase in H_2S/LPS $P < 0.05$). Infusion of 0.5 nM ET-1 increased portal pressure by 13.6 ± 1.0 mmHg in control rats (Figure 20). This effect was significantly increased in LPS-treated rats (19.3 ± 1.3 mmHg increase, $P < 0.01$). H_2S had no effect on the increase in portal pressure in neither control nor LPS-treated rats (15.0 ± 1.5 and 18.2 ± 1.5 mmHg respectively).

Effect of inhibition of endogenous H_2S synthesis on hepatic resistance during endotoxemia: Hepatic synthesis of H_2S was inhibited by treating rats with dl-propargylglycine (PAG) (50 mg/kg ip) 30 minutes prior to liver isolation. PAG treatment alone had no effect on the resting portal pressure when compared to controls (3.6 ± 0.9 mmHg vs. 3.2 ± 1.4 mmHg). PAG treatment caused a greater increase in portal pressure due to infusion of PE ($P < 0.001$, Figure 21) and ET-1 ($P < 0.001$, Figure 22) when compared to control animals. To test the effect of endogenous H_2S synthesis during endotoxemia, rats were treated for 6 hrs with LPS then given PAG 30 minutes prior to

isolation. The combination of PAG and LPS had no effect on baseline portal pressure when compared to controls (4.8 ± 0.7 mmHg). Infusion of $5 \mu\text{M}$ PE resulted in an increase in portal pressure of 4.7 ± 0.5 mmHg in controls which was reduced to 3.3 ± 0.6 mmHg in LPS-treated rats ($P < 0.05$, Figure 23). PAG treatment reversed the effect of LPS on PE-induced vasoconstriction during endotoxemia (6.1 ± 0.5 mmHg, $P < 0.05$). An 11.3 ± 0.8 mmHg increase in portal pressure was observed during infusion of 0.5 nM ET-1 in control rats (Figure 24). LPS and PAG treatment both caused a greater increase in portal pressure to ET-1 (16.2 ± 1.1 and 15.4 ± 1.3 mmHg respectively, $P < 0.05$). The combination of PAG and LPS was not significantly different from LPS or PAG alone (14.7 ± 1.3 mmHg).

Effect of H_2S and PAG on O_2 consumption during ET-1 infusion. There was no difference in resting hepatic O_2 consumption between any of the treatment groups prior to ET-1 infusion. For livers in H_2S treatment groups, the addition of $50 \mu\text{M}$ Na_2S to the perfusate increased O_2 consumption (7% over baseline, $P < 0.05$) which was used as a baseline for these groups. In control livers, infusion of 0.05 nM ET-1 produced a modest, but repeatable increase in O_2 consumption (6% increase over baseline, $P < 0.05$). In livers isolated from LPS-treated rats, infusion of 0.05 nM demonstrated a trend towards decreased oxygen consumption, but it was not statistically significant (100% vs. 92 %, $P = 0.058$). However, hepatic O_2 consumption during infusion of 0.05 nM ET-1 was significantly lower in the LPS group when compared to controls (90 % vs. 106 %, $P < 0.05$). The H_2S group and $\text{H}_2\text{S}/\text{LPS}$ group were not significantly different from either the control or LPS groups during infusion of 0.05 nM ET-1 (Figure 25, 99% of baseline and 98% of baseline, respectively). PAG treatment was significantly lower than controls

during 0.05 nM ET-1 infusion ($P < 0.05$, Figure 26). While PAG appeared to restore O_2 consumption in LPS-treated animals, the results were not statistically significant ($P = 0.055$). When the concentration of ET-1 was increased to 1 nM, hepatic O_2 consumption was significantly reduced in all treatment groups ($P < 0.001$). 2 way ANOVA analysis demonstrated a significant effect of H_2S on hepatic O_2 consumption which was increased over control and LPS treatment groups. PAG and PAG/LPS treatment groups were reduced during infusion of 1 nM ET-1 similar to control and LPS groups and no significant differences were observed.

3.5 Discussion

The role of H_2S in disease and inflammation is the source of considerable debate. H_2S prevents myocardial and hepatic ischemia/reperfusion injury which is partially the result of an increase in cellular antioxidant capacity via induction of antioxidant gene expression [59, 117]. On the contrary, inhibition of endogenous H_2S synthesis significantly reduces organ injury and improves survival in septic mice by attenuating the inflammatory response [72, 144]. In the earliest stages of sepsis, hepatocellular injury is initially the result of excessive cytokine release from kupffer cells (KCs) [6, 134]; however, it is now well established that continued hepatocellular dysfunction is primarily the result of hepatic microvascular failure, particularly in the sinusoids [12-13, 63, 94]. As a vasoregulatory molecule that is elevated in the liver during sepsis [144], it is possible that H_2S contributes to the dysregulation of hepatic sinusoidal perfusion.

Fiorucci et al were the first to demonstrate a vasoregulatory role of H_2S in the hepatic microcirculation. In their study, H_2S attenuated the increase in intrahepatic resistance to norepinephrine (NE) in normal and cirrhotic rats. This vasodilatory effect

would likely be beneficial during chronic conditions, like cirrhosis, by decreasing intrahepatic resistance and attenuating portal hypertension [72]. If H₂S acts as a vasodilator in the hepatic microcirculation, one would predict that H₂S could also be beneficial during sepsis via improved tissue perfusion. The hepatic microcirculation is regulated at presinusoidal and sinusoidal sites [90]. Therefore, we tested the effect of H₂S on the vascular response to phenylephrine and endothelin-1 that act at these sites, respectively, in an endotoxin model of sepsis. Our study demonstrates that H₂S differentially modulates the response of the hepatic microcirculation to vasopressor which suggests that H₂S may exert a different vasoregulatory function at different sites within the liver. Moreover, our results highlight the complex role H₂S serves in modulating the microcirculation during endotoxemia.

Several factors contribute to systemic microcirculatory dysfunction during sepsis, including activation of pro-coagulant pathways, recruitment of leucocytes, and excess production of vasoactive agents [52]. In healthy individuals, the activation of α 1 adrenergic receptors by circulating catecholamines causes vascular smooth muscle cell contraction and reduces blood flow through the vascular bed which allows for the spatial distribution of cardiac output. During sepsis, the excessive release of vasodilators suppresses the response of the endothelium to catecholamines [97]. The diffuse peripheral vasodilation contributes to systemic hypotension and organ dysfunction [47].

In this study, we first investigated the effect of H₂S on pre-sinusoidal portal venules which respond to catecholamines in a similar manner to systemic resistance vessels. Evidence to support this was provided by studies demonstrating decreased vascular responsiveness to phenylephrine in livers isolated from endotoxemic rats.

Moreover, administration of an inhibitor of NOS reversed the hyporesponsive of the hepatic vasculature suggesting the importance of increased production of vasodilatory gas NO in vascular hyporesponsiveness [97]. Like NO, H₂S acts as a vasodilator which suggests that a similar effect of H₂S should occur during endotoxemia [48]. Infusion of increasing doses of PE produced a dose dependent increase in portal pressure in isolated livers, which was significantly diminished in livers isolated from LPS-treated rats. The addition of exogenous H₂S (50μM) to the perfusate almost completely abrogated the increase in portal pressure in response to PE in livers isolated from endotoxemic rats suggesting a synergistic effect of LPS and H₂S.

We used the suicide inhibitor of CSE to block hepatic H₂S synthesis during endotoxemia to determine if endogenous H₂S production contributes to vascular hyporesponsiveness. PAG treatment alone significantly potentiated the increase in intrahepatic resistance in response to PE, suggesting that H₂S is involved in the constant regulation of hepatic blood flow. Importantly, PAG treatment reversed the hyporesponsiveness of the presinusoidal venules to PE during endotoxemia.

Given that the only target of PE in the hepatic microcirculation are pre-sinusoidal resistance vessels [146], the previous results suggest that H₂S is involved in the modulation of hepatic microvasculature at the level of portal terminal venules. Because the liver is the largest internal organ and a major recipient of cardiac output, excessive hepatic vasodilation could potentially contribute to systemic hypotension during sepsis. H₂S derived from CSE is an important regulator of systemic blood pressure [140]. Since portal venules and systemic arterioles are regulated in a similar manner by vascular smooth muscle cells (VSMCs), it is likely that H₂S contributes to hyporesponsiveness of

resistance vessels in most tissues. In support of this hypothesis, circulating H₂S levels in septic rats have been shown to be negatively correlated to blood pressure [50].

Based on our results, PAG treatment may provide a protective effect during sepsis by attenuating systemic vascular hyporesponsiveness to catecholamines; however, its effect in the hepatic sinusoid remains unclear. Previously, we showed that sinusoidal tone is modulated by hepatic stellate cells (HSCs) which contract in response to ET-1 [146]. HSCs are activated following inflammatory stress which enhances their contractility to ET-1 [107]. The priming effect of LPS on the HSCs results in sinusoidal hyperconstriction which is a main cause of tissue hypoxia and cell death [13]. In support of the importance of ET-1 in hepatic dysfunction, elevated ET-1 levels in are highly correlated to disease severity in cirrhosis [3]. Thus, the sinusoid is a critical regulatory site for hepatic perfusion during sepsis. Previous work from our lab and others demonstrated that impaired synthesis of NO contributes to sinusoidal dysfunction [67, 81, 98]. The vasoregulatory effect of H₂S in the hepatic sinusoids remains unclear. Therefore, we investigated the effect of H₂S on the sinusoids which during endotoxemia by assessing its effect on ET-1 infusion.

Infusion of increasing concentrations of ET-1 resulted in progressive increase in portal pressure. In agreement with our previous reports, the effect of ET-1 was significantly potentiated by endotoxin treatment. Based on its vasodilatory action, we hypothesized that H₂S would attenuate the hypersensitization of the hepatic sinusoid to ET-1 during endotoxemia. Surprisingly, we observed no effect of H₂S on ET-1-induced vasoconstriction in neither control nor endotoxin treated rats. Interestingly, PAG treatment increased the vascular response to ET-1 in control livers, but had no effect in

the endotoxin group. These results suggest that H₂S differentially modulates the vascular response to ET-1 when compared to PE.

This differential effect may be due to the cells responsible for modulating luminal diameter. Portal terminal venules, as well as arterioles, are modulated by VSMCs. The vasodilatory effect of H₂S is primarily the result of VSMC hyperpolarization via activation of K_{ATP} channels [103, 128, 148]. Hepatic sinusoidal resistance is regulated by HSCs which may be differentially regulated by H₂S. It has been suggested that the H₂S donor (NaHS) can prevent HSC contraction [30]. However, that study was performed in isolated HSCs over the course of 18 hours with NaHS. The spontaneous activation of HSCs following isolation may not reflect actual *in vivo* conditions [130]. Furthermore, NaHS rapidly releases H₂S which if not contained in a closed system rapidly escapes culture media and enters the atmosphere in a short period of time during incubation [71]. While the finding of that study is promising, more conclusive research is needed to assess the effect of H₂S on HSCs.

One drawback of our isolated, perfused liver system is that we are assessing total intrahepatic resistance by monitoring changing in pressure during constant flow perfusion. An anticipated consequence of this is that the vasoconstriction at one location can be counteracted by vasodilation at another location. The suppression of a response during PE clearly demonstrates a vasodilatory effect of H₂S; however the lack of an effect during ET-1 infusion may be due to a set of more complex vascular events. It is possible that H₂S can induce vasoconstriction in the hepatic sinusoid which lack VSMCs and vasodilation at presinusoidal sites.

While H₂S is generally regarded as a vasodilator, there are several reports that it can function as a vasoconstrictor. In VSMCs, H₂S has been shown to lower cAMP levels and inhibit contraction [74]. H₂S could increase the sensitivity to ET-1 by lowering cAMP levels in HSCs. cAMP has been shown to desensitize ET_A receptors on HSCs to ET-1 [104]. A second mechanism, reported by Ali et al, demonstrated that high doses of exogenous H₂S produce hypotension, whereas low dose intravenous infusion of the H₂S donor, NaSH, produced a transient increase in mean arterial pressure in rats [4]. Interestingly, no increase in MAP was observed following treatment with L-NAME, a NOS inhibitor suggesting an interaction between the two gasses. It has been proposed that H₂S may interact with NO to form a vasoinactive nitrosthiole thereby quenching the nitric oxide signal [137]. This could be of particular interest in endotoxemia as ET-1 stimulated NO synthesis in SECs is diminished [67]. It is possible in our study that the addition of exogenous H₂S may quench NO availability causing constriction in the sinusoids while also hyperpolarizing VSMCs in the terminal portal venules resulting in not net change in intrahepatic resistance.

Previously, we reported that H₂S potentiates the increase in O₂ consumption induced by PE infusion which may contribute to hypoxic stress [89]. ET-1 stimulates glycogenolysis and O₂ consumption in isolated rat hepatocytes [111, 146]. Therefore, we investigated the effect of H₂S and PAG on ET-1 stimulated O₂ consumption. Infusion of low concentrations of ET-1, which did not produce a vascular response, increase hepatic O₂ consumption in control livers. At higher doses of ET-1, O₂ consumption was significantly reduced to the excessive vasoconstriction of the sinusoids. Hepatic O₂ consumption was significantly reduced by LPS treatment most likely due to enhanced

sinusoidal vasoconstriction. This finding highlights the importance of sinusoidal integrity in maintaining proper O₂ delivery during endotoxemia. The addition of H₂S to the perfusate caused an initial increase in O₂ consumption due to hepatic oxidation of H₂S. While H₂S had no effect in control or LPS livers during 0.5 nM ET-1 infusion, it was associated with a significant increase in O₂ consumption at the highest dose of ET-1. Throughout the experiment, H₂S was undetectable in outflow perfusate indicating complete hepatic H₂S oxidation. Despite the decreased O₂ consumption during sinusoidal hyperconstriction, the liver still utilized O₂ for H₂S oxidation providing further evidence that H₂S oxidation may contribute to hypoxic stress during endotoxemia. We observed that PAG potentiated the vascular effect of ET-1, in agreement with this hepatic O₂ consumption was significantly reduced compared to controls during low dose infusion of ET-1. While the PAG results in LPS-treated animals were not statistically significant (P=.055), there was a trend toward restoring hepatic O₂ consumption to baseline levels. Since the reduction in O₂ consumption in LPS-treated animals is the result of sinusoidal constriction it is tempting to speculate that PAG treatment may improve sinusoidal perfusion during endotoxemia.

The present study sought to investigate the effect of H₂S on different regulatory sites in the hepatic microcirculation. Using an isolated, perfused organ system, we demonstrated a differential effect of H₂S on sites presinusoidal resistance vessels that respond to PE and the sinusoids which are modulated primarily by ET-1. We conclude that H₂S contributes to the loss of vasomotor control in resistance vessels subject to regulation via catecholamine signaling. While we cannot conclude that H₂S causes vasoconstriction in the sinusoids, we do demonstrate that there is no attenuation of ET-1

hypersensitization, suggesting differential regulation in the sinusoids. Additionally, we show that hepatic oxidation occurs despite limited O₂ availability due to sinusoidal hyperconstriction. This finding combined with our previous report that H₂S lowers hepatic oxygen availability *in vivo* supports the hypothesis that elevated H₂S levels may exacerbate hepatic tissue hypoxia. The discrepancy between the effects of H₂S on PE and ET-1 demonstrate the need for a better understanding of H₂S as a vascular modulator. Overall, our study demonstrates that the regulation of hepatic vascular tone by H₂S is complex and likely an important modulator in microvascular dysfunction during endotoxemia.




Figure 15: LPS attenuates the hepatic vascular response to phenylephrine. Isolated, perfused livers from control rats or rats treated for 6 hours with LPS (1mg/kg ip) were subjected to increasing doses of PE. Portal pressure was monitored during constant flow perfusion with Kreb's buffer. LPS attenuated the dose dependent increase in portal pressure caused by PE ($P < 0.001$). Data is presented as the mean increase in portal pressure over baseline \pm SEM and compared using two way ANOVA with SNK *post hoc* test. N=4 in control group, N=5 in LPS group.




Figure 16: LPS potentiates the hepatic vascular response to endothelin-1. Isolated, perfused livers from control rats or rats treated for 6 hours with LPS (1mg/kg ip) were subjected to increasing doses of ET-1. Portal pressure was monitored during constant flow perfusion with Kreb's buffer. LPS potentiates the increase in portal pressure caused by ET-1 ($P < 0.001$). Data is presented as the mean increase in portal pressure over baseline \pm SEM and compared using two way ANOVA with SNK *post hoc* test. N=7 in control group, N=4 in H₂S group.




Figure 17: H₂S attenuates the increase in portal pressure caused by PE. Isolated, perfused livers were perfused at a constant flow rate with control buffer or buffer containing 50 µM Na₂S. H₂S attenuates PE-induced increases in portal pressure ($P > 0.001$). Data is presented as the mean increase in portal pressure over baseline \pm SEM and compared using two way ANOVA with SNK *post hoc* test. N=4 in control group, N=6 in H₂S group.




Figure 18: H₂S has no effect on the increase in portal pressure caused by ET-1. Isolated, perfused livers were perfused at a constant flow rate with control buffer or buffer containing 50 μ M Na₂S. H₂S has no effect on ET-1 mediated increases in portal pressure (P=NS). Data is presented as the mean increase in portal pressure over baseline \pm SEM (3-6 rats per group) and compared using two way ANOVA with SNK *post hoc* test. N=7 in control group, N=3 in H₂S group.




Figure 19: H₂S potentiates LPS-induced vascular hypo-responsiveness to PE. Livers isolated from control and endotoxemic rats were perfused with control or 50 μ M H₂S Kreb's buffer. Graph shows mean increase in portal pressure (mmHg) during infusion of 10 μ M PE. Data is presented as mean \pm SEM and compared using two way ANOVA with SNK *post hoc* test. * P<0.05 compared to control. # P<0.05 compared to LPS and H₂S. N=4 in control group, N=5 in LPS and H₂S/LPS group, N=6 in H₂S group.




Figure 20: H₂S does not affect LPS-induced vascular hyper-responsiveness to ET-1. Livers isolated from control and endotoxemic rats were perfused with control Krebs's buffer. Graph shows mean increase in portal pressure (mmHg) during infusion of .5 nM ET-1. Data is presented as mean \pm SEM and compared using two way ANOVA with SNK *post hoc* test. * P<0.05 compared to control. N=7 in control group, N=4 in LPS group, N=3 in H₂S and H₂S/LPS groups.




Figure 21: PAG treatment increases sensitivity of the hepatic vasculature to PE. 30 minutes prior to liver isolation rats were treated with CSE inhibitor PAG (50mg/kg ip). PAG potentiates the increase in portal pressure during infusion of PE ($P < 0.001$). Data is presented as mean \pm SEM and compared using two way ANOVA with SNK *post hoc* test. N=4 in control group, N=3 in PAG group.




Figure 22: PAG treatment increases sensitivity of the hepatic vasculature to ET-1. 30 minutes prior to liver isolation rats were treated with CSE inhibitor PAG (50mg/kg ip). PAG potentiates the increase in portal pressure during infusion of ET-1 ($P < 0.001$). Data is presented as mean \pm SEM and compared using two way ANOVA with SNK *post hoc* test. N=7 in control group, N=3 in PAG group




Figure 23: PAG treatment reverses hepatic vascular hypo-responsiveness to PE during endotoxemia. Control and endotoxemic rats were treated with PAG (50mg/kg) 30 minutes prior to liver isolation. Mean increase in portal pressure (mmHg) during infusion of 10 μ M PE. Data is presented as mean \pm SEM and compared using two way ANOVA with SNK *post hoc* test. * P<0.05 compared to control. # P<0.05 compared to LPS. N=4 in controls and LPS group, N=3 in PAG and PAG/LPS groups




Figure 24: PAG does not potentiate the hepatic vascular response to ET-1 during endotoxemia. Control and endotoxemic rats were treated with PAG (50mg/kg) 30 minutes prior to liver isolation. Mean increase in portal pressure (mmHg) during infusion of 0.5 nM ET-1. Data is presented as mean \pm SEM and compared using two way ANOVA with SNK *post hoc* test. * $P < 0.05$ compared to control. N=7 in control group, N=4 in LPS group, N=3 in PAG and PAG/LPS group.




Figure 25: Effect of H₂S on hepatic O₂ consumption in control and endotoxemic livers. The PO₂ of the outflow and inflow perfusate was monitored to determine hepatic O₂ consumption during ET-1 infusion. The effect of H₂S on hepatic O₂ consumption during endotoxemia. Data is presented as mean \pm SEM and compared using two way ANOVA with SNK *post hoc* test. * P < 0.05 compared to control. # P < 0.05 compared to baseline within each treatment group.




Figure 26: Effect of PAG on hepatic O₂ consumption in control and endotoxemic livers. The PO₂ of the outflow and inflow perfusate was monitored to determine hepatic O₂ consumption during ET-1 infusion. The effect of PAG on hepatic O₂ consumption during endotoxemia. Data is presented as mean \pm SEM and compared using two way ANOVA with SNK *post hoc* test. * P<0.05 compared to control. # P<0.05 compared to baseline within each treatment group.

CHAPTER 4: HYDROGEN SULFIDE MODULATES SINUSOIDAL CONSTRICTION AND CONTRIBUTES TO HEPATIC MICROCIRCULATORY DYSFUNCTION DURING ENDOTOXEMIA

4.1 Abstract

Hydrogen sulfide (H₂S), is a mediator in the regulation of vascular resistance; however, its effect on the hepatic microcirculation has yet to be investigated. The unique regulation of hepatic microvascular resistance is perturbed during sepsis which contributes to liver injury. Therefore, the present study was designed to determine the effect of H₂S on the hepatic microcirculation and to determine the contribution of endogenous H₂S to hepatic microcirculatory dysfunction in an endotoxin model of sepsis. We show that portal infusion of H₂S is associated with an increase in portal pressure (6.8 ± 0.2 mmHg before H₂S vs. 8.6 ± 0.8 mmHg peak during H₂S infusion, $P < 0.05$). Using *intravital* microscopy, we observed a reduction in sinusoidal diameter (6.2 ± 0.27 μ m before H₂S vs. 5.7 ± 0.3 μ m after H₂S, $P < 0.05$) and an increase in sinusoidal heterogeneity during H₂S infusion ($P < 0.05$) suggesting that H₂S produces vasoconstriction of the hepatic sinusoid. Since hepatic H₂S levels are elevated during sepsis, we used the cystathionine γ lyase inhibitor (CSE), dl-propargylglycine (PAG), to determine the contribution of H₂S to the hypersensitization of the sinusoid to the vasoconstrictive effect of endothelin-1 (ET-1). Our results show that PAG treatment significantly attenuated the hepatic sinusoidal sensitization to ET-1 in endotoxin treated animals. ET-1 infusion increased portal pressure to 175% of baseline in endotoxemic animals which was reduced

to 143% following PAG treatment ($P < 0.05$). We show that PAG abrogated the increase in sinusoidal constriction after ET-1 infusion in LPS treated rats (30.9% reduction in LPS rats vs. 11.6% in PAG/LPS rats, $P < 0.05$). Moreover, PAG treatment significantly attenuated the increase in NADH fluorescence following ET-1 exposure during endotoxemia (61 grey scale units LPS vs. 21 units in PAG/LPS, $P < 0.05$) suggesting an improvement in hepatic oxygen availability. This study is the first to demonstrate a vasoconstrictive action of H_2S on the hepatic sinusoid and provides a possible mechanism for the protective effect of PAG treatment reported during sepsis.

4.2 Introduction

Perturbed hepatic sinusoidal perfusion is a critical factor in the development of focal tissue hypoxia leading to liver injury during sepsis [12-13, 63]. Sinusoidal blood flow is regulated by alterations of vascular tone by extra-sinusoidal resistance vessels, consisting of terminal portal venules and hepatic arterioles, and by the sinusoids themselves [146]. During sepsis, the excessive systemic production of vasodilatory agents, in particular nitric oxide (NO), leads to hyporesponsiveness of the extra-sinusoidal resistance vessels to the constrictor effect of catecholamines which can contribute to diffuse hypotension [97]. However, a local detrimental effect on the liver results from sinusoidal hyperconstriction and heterogeneous perfusion during sepsis [13].

Hepatic sinusoidal tone is regulated mainly by hepatic stellate cells (HSCs) which surround individual sinusoids [146]. These contractile pericytes respond to a local balance between vasoactive mediators to modulate sinusoidal tone [62]. It is now well recognized that liver injury, such as in fibrosis or cirrhosis, leads to HSC transdifferentiation of a myofibroblastic phenotype resulting in an increased contraction

in response to the vasoactive peptide endothelin-1(ET-1) [107]. However, increased HSC contractile response to ET-1 is also observed following a relatively mild inflammatory stress such as with low-dose endotoxemia or sepsis [13, 94]. Under normal conditions, ET-1 stimulated NO production in sinusoidal endothelial cells (SECs) mitigates the constrictor effect of ET-1 [98]. However, inflammatory stress impairs eNOS derived NO production in the sinusoidal endothelial cells [67]. The constrictor effect of ET-1 is not counteracted by the dilator effect of NO, producing sinusoidal constriction and microvascular dysfunction. Furthermore, exacerbation of ET-1 mediated sinusoidal constriction during sepsis is associated with an increase in heterogeneous sinusoidal perfusion, resulting in a mismatch between O₂ supply and cellular demand [13, 57]. Inefficient O₂ delivery results in the development of focal hypoxia and hepatic injury. While it is evident that NO is a significant mediator in sinusoidal tone, it is likely that it is not the only contributor to microvascular dysfunction given the plethora of other vasoactive molecules present in the hepatic microenvironment. Moreover, although exogenous NO donors can restore hepatic microcirculatory function in experimental models [41], a beneficial effect remains elusive in clinical trials [77, 121]. Therefore, more research regarding the regulation of sinusoidal perfusion is needed to identify other potential therapeutic targets.

The discovery that hydrogen sulfide (H₂S) is endogenously synthesized in mammals revived interest into the noxious gas typically associated with the smell of rotten eggs [135]. Studies show that hepatic H₂S synthesis is increased during sepsis and endotoxemia [26, 144]. Like NO, H₂S acts as a vasodilator [48]. Whereas NO-induced vasodilation is cGMP dependent [51], the primary mechanism of vasodilation induced by

H₂S is via hyperpolarization of VSMCs [148]. The effect of H₂S in the liver vasculature was first reported by Fiorucci et al. H₂S significantly attenuated the increase in intrahepatic resistance during norepinephrine (NE) infusion in isolated livers from normal and cirrhotic rats [33]. The vasodilatory effect of H₂S is likely beneficial during cirrhosis by increasing hepatic perfusion and reducing portal hypertension. Based on this finding, one would predict that as a vasodilator, H₂S would improve hepatic tissue perfusion and provide a benefit during sepsis. However, numerous studies have shown that endogenous H₂S contributes to disease progression in sepsis [5, 72, 144].

Recently, we reported that H₂S attenuates the pressor effect of phenylephrine (PE) in an isolated and perfused liver which is in agreement with the study by Fiorucci et al; however, we also showed that H₂S has no effect on ET-1-induced increases in portal pressure using the same model. Similar to NE, phenylephrine (PE) is known to act on extra-sinusoidal resistance vessels only, while ET-1 acts on extra-sinusoidal and sinusoidal sites of blood flow regulation [146]. The vasodilatory effect of H₂S during PE infusion is likely the result of VSMC hyperpolarization in the portal venules. However, sinusoidal tone in response to ET-1 is modulated by HSCs, not VSMCs. The finding that H₂S affects PE, but not ET-1 pressor effects, suggests that the vasoactivity of H₂S may be different in the hepatic sinusoid compared to the portal venules. Therefore, the present study was designed to investigate the vasoregulatory effect of H₂S on the hepatic sinusoids *in vivo*. Since H₂S has been shown to be deleterious during sepsis, we hypothesized that endogenous H₂S contributes to the hypersensitization of the hepatic sinusoid to ET-1 during sepsis. Using *intravital* microscopy, we show for the first time that infusion of endogenous H₂S is associated with net sinusoidal constriction and

increased perfusion heterogeneity in normal liver. Moreover, our study demonstrates that inhibition of endogenous H₂S production significantly reduces hepatic microvascular dysfunction in response to ET-1 during endotoxemia which leads to improved O₂ delivery to the tissue. Taken together, our results challenge the notion that H₂S solely acts as a vasodilator in the liver. Rather, the role of H₂S is likely fundamentally different in the hepatic sinusoid than it is in most resistance vessels, including the portal venules. Furthermore, we provide one possible mechanism for the protective effect of the inhibition of endogenous H₂S synthesis during sepsis.

4.3 Materials and Methods

Animals: Male Sprague-Dawley rats (Charles River Laboratories, Fayetteville, NC) weighing 253 ± 12 grams were used in this study. Rats were housed in a temperature-controlled environment on 12-hour light/dark cycles with free access to standard chow and water. All animal manipulation was in strict adherence with National Institutes of Health guidelines and experimental protocols were approved by Institutional Animal Care and Use Committee of the University of North Carolina at Charlotte.

Reagents: Sodium sulfide (Na₂S), DL-progargylglycine (PAG), fluorescein Isothiocyanate (FITC) on celite, citrate-phosphate-dextrose with adenine (CPDA) and lipopolysaccharide (LPS) (E. Coli, serotype 026:B6) were purchased from Sigma Aldrich (St. Louis, Missouri). Endothelin-1 (ET-1) was purchased from the American Peptide Company (Sunnyvale, CA).

Red Blood Cell Labeling: Red blood cells (RBCs) were fluorescently labeled as described by Zimmerhackl et al [150]. Briefly, 10-12 ml of whole blood was obtained from a donor rat and placed in a tube containing 0.5 ml of heparin (1000 usp units/ml)

(J.A. Webster Veterinary Supply, Devens, MA). Blood was centrifuged at 500g for 10 minutes at 4° Celsius. The plasma supernatant was removed and RBCs were washed 3 times (500g, 10 min, 4° Celsius) with Asevier's buffer (in g/l: 20.5 glucose, 8.0 citric acid trisodium salt, 0.55 citric acid, and 3.766 NaCl, pH =6.2) and once in bicine buffer (in g/l: 2.264 Bicine, 0.399 NaOH, 7.288 NaCl, pH=8.3). After bicine buffer wash, the RBC pellet was resuspended in a 1:1 ratio (50% hematocrit) with bicine buffer. FITC on celite (4mg/ml of RBC suspension) was dissolved in Dimethylformamide (100 µl/4 mg FITC) and combined with the RBC suspension. After 2 hour incubation with FITC, RBCs were washed once with bicine buffer, followed by 3 saline washes. Following the final wash, RBCs were resuspended to 50% hematocrit ratio with saline. For storage, citrate-phosphate-dextrose with adenine solution (CPDA, 140µl/ml RBC suspension) was added to the RBC suspension. Fluorescently labeled RBCs were kept in the dark at 4° Celsius and used within 7 days of labeling. On the day of the experiment, RBCs were washed once with bicine buffer and 3 times with saline solution. After the final wash, RBCs were resuspended to 50% hematocrit and the RBC suspension (100 µL/100g body weight) was injected into the inferior vena cava.

Intravital Microscopy: Rats were anaesthetized using 1-2% isoflurane (J. A. Webster Veterinary Supply, Devens, MA). A laparotomy was performed to expose the portal vein and associated vasculature. To prevent splenic congestion, blood flow to the spleen was occluded. The splenic vein was isolated and cannulated using a cannula made from PE-50 tubing for measurement of portal venous pressure and infusion of test substances into the portal vein. The right carotid artery was cannulated in order to monitor arterial pressure. Prior to transferring the rat to the microscope, FITC-labeled red

blood cells were injected into the inferior vena cava (100 μ L/100g body weight at 50% hematocrit).

For microscopy, rats were placed on an Olympus IX70 inverted microscope (Olympus America, Melville, NY) and situated on a motorized stage with a viewing window over the objective lens. The liver was exteriorized and the left lobe positioned over the viewing window to allow for epi-illumination. The internal organs were covered with saran wrap and saline-soaked gauze to prevent evaporative loss. The splenic cannula was connected to a blood pressure analyzer (Digi-Med low-pressure analyzer; Micro-Med, Louisville, KY) and a syringe pump (Harvard Apparatus, Holliston, MA) via a t-tube fitting to allow for simultaneous monitoring of portal pressure (PP) and infusion of treatment substances. The carotid cannula was connected to a Digi-Med high-pressure analyzer to measure mean arterial pressure (MAP) and heart rate (HR). A MouseOx pulse oximeter (Starr Life Sciences, Pittsburgh, PA) was used to monitor arterial oxygen saturation and heart rate to ensure the stability of the rat during the experiment. Two pericentral and two periportal fields were selected at random and programmed into the motorized stage. The motorized stage gives the advantage of repeated imaging of multiple fields over several time points. After selecting the four fields, rats were allowed to rest for 20 minutes before beginning one of the following experimental protocols.

H₂S Infusion: The H₂S donor Na₂S was used to investigate the effect of H₂S on the hepatic microcirculation. In order to determine the effects of infusion, saline was infused through the splenic cannula at a rate of 100 μ L/min for the first 10 minutes. Freshly prepared Na₂S (2 μ moles/kg/min) was then infused for 10 minutes, followed by a 10 minute recovery period of saline. Throughout the experiment, MAP, PP, HR, and O₂

saturation levels were monitored and recorded. The sinusoids were visualized using a FITC filter (excitation 494 nm, emission 518 nm) and 40x objective lens. Micrographs were taken every 10 minutes, with the first set taken at the beginning of the experiment. Micrographs were taken using a Cooke Sensicam digital electron multiplier CCD camera (The Cooke Corporation, Romulus, MI).

Endothelin-1 Infusion: Rats were divided into one of four treatment groups: 1. Control, 2. LPS, 3. PAG, 4. PAG/LPS. For the LPS group, rats received an intraperitoneal injection of LPS (1 mg/kg) 6 hours prior to surgery. Previous reports from our lab indicate that the CSE inhibitor PAG has an effect on the hepatic vasculature within 30 minutes of administration. At this early time point, PAG is not expected to have an effect on the development of the inflammatory response following LPS administration. The PAG group received an intraperitoneal injection of PAG (50 mg/kg) 30 minutes prior to surgery. For animals receiving both treatments, LPS was injected 5.5 hours prior to PAG, which was administered 30 minutes before surgery. After the stabilization period, saline was infused for ten minutes in order to establish baseline readings. ET-1 (125 pmoles/kg/min) was infused for 10 minutes following saline infusion. A 30 minute recovery period was allowed after ET-1 infusion, during which time, saline was infused to prevent dehydration. Throughout the entire experiment, MAP, PP, HR, and O₂ saturation levels were monitored and recorded. Micrographs were taken every ten minutes, beginning after the start of the first saline infusion. For sinusoidal diameter and RBC velocity analysis, digital videos were captured using a FITC filter and a 40x objective lens at a frame rate of 15 frames per second for a total of 60 frames. Off line analysis was performed using PTI imagemaster software.

To assess hepatic oxygen redox potential, lower magnification micrographs (4x objective) were collected to assess global NADH autofluorescence (excitation 345 nm, emission 455 nm) as previously described [99]. NADH is fluorescent at this wavelength while NAD⁺ is not. An increase in fluorescence intensity correlates with an increase in the NADH/NAD⁺ ratio. This serves as an indirect assessment of oxygen availability. All camera settings (gain, binning, black level, contrast) were the same for all NADH micrographs.

Off-line image analysis: Off-line image analysis was performed using PTI imagemaster software (Photon Technology International Inc., Birmingham, NJ). For sinusoidal diameter and heterogeneity of diameter data, 40x micrographs taken with a FITC filter were used. Four vessels were randomly selected per field. Sinusoidal diameter was determined by calculating the total area of a vessel and dividing it by the length of the vessel ($\text{Width} = \text{Area}/\text{Length}$). The mean sinusoidal diameter represents the four vessels from four different fields per animal. The standard deviation of individual vessels within one field was used to assess the heterogeneity of perfusion. Vessel data presented is the mean between two different researchers performing independent analysis.

To assess the percentage of sinusoids perfused, 4 vessels per field were randomly chosen. Vessels were considered perfused if blood flow was visible during the 60 micrograph video, irrespective of flow velocity. The mean sinusoidal perfusion for each animal is representative of four vessels from four separate fields.

Red Blood Cell Tracking for Velocity Distribution: We developed an automated method to detect and track red blood cells during video playback of micrograph sequences. To detect red blood cells, a classification model was trained to

learn the appearance of red blood cells [1]. For each frame in a given sequence, red blood cells were detected based on a set of features that detect the visual differences between pixels belonging to cells or the background. These features included mean intensity, standard deviation of intensity and the difference between the mean intensity of pixels closer to the center of patch and the pixels farther away. Using connected component labeling, cell pixels were assigned to cell regions [2]. RBCs were tracked by corresponding cell regions in successive frames using a tracking algorithm as previously described [3]. For each cell, we dynamically predicted its motion and appearance in the next frame. Tracking of cells between frames was based on the best match as determined by our prediction model. The number of red blood cells and their velocities were then determined from the tracking output of the automated tracking algorithm. For each field analyzed, vessels were grouped based upon mean RBC velocities and the distribution of velocity speeds was reported.

Statistical Analysis: All data are presented as means \pm standard error of the mean (SEM). Statistical analysis was performed using Sigma Plot 11 software (Systat Software Inc., San Jose, CA). Statistical significance was determined by one or two way ANOVA with independent and repeated measures used where appropriate. Student-Newman-Keuls *post hoc* test was used when statistical differences were detected. Log transformation was performed when data did not pass normality and equal variance tests. Statistical significance was set at $P < 0.05$.

4.4 Results

Effect of portal Infusion of H₂S on hepatic hemodynamics: We investigated the effect of portal infusion of the H₂S donor Na₂S (2 μmoles/min/kg) on hepatic hemodynamics *in vivo*. H₂S infusion increased portal pressure to 8.6 ± 0.8 mmHg from 6.8 ± 0.2 mmHg during baseline saline infusion (Figure 27, $P < 0.05$). After H₂S infusion was stopped, portal pressure returned to baseline within 10 minutes (6.9 ± 0.2 mmHg). Mean arterial pressure (MAP) and heart rate (HR) were monitored to determine the effect of H₂S infusion on systemic hemodynamics. There was a slight drop in heart rate during infusion of H₂S (317 ± 11.4 baseline vs. 305 ± 11.7 BPM during H₂S infusion, Table 1) which persisted through the recovery (302 ± 11.1 BPM). Although this decrease was statistically significant ($P < 0.05$), it is not likely to be functionally important. Infusion of H₂S did not affect MAP when compared to controls (100 ± 4.0 mmHg vs. 102 ± 2.8 mmHg, Table 1, $P = \text{NS}$); however, there was a small overall drop in MAP at the end of the recovery period (96.7 ± 4.6 mmHg, $P < 0.05$) which is likely an effect of the surgical procedure.

Because H₂S was acting locally on the hepatic hemodynamics, we used intravital microscopy to determine if H₂S infusion has an effect on the hepatic sinusoids. H₂S infusion produced a net decrease in sinusoidal diameter (5.7 ± 0.3 μm after H₂S vs. 6.2 ± 0.3 μm at baseline, Figure 28, $P < 0.05$). 10 minutes after H₂S infusion was ceased, sinusoidal diameter had nearly returned to baseline (6.0 ± 0.4 μm). Sinusoids adjacent to constricted sinusoids have been shown to be dilated following inflammatory stress. Therefore, we compared the variability between sinusoidal diameters within each field analyzed. One way ANOVA analysis demonstrated a significant effect of treatment over

the course of the experiment (Figure 29, $P < 0.05$) suggesting an increase in sinusoidal diameter heterogeneity following H_2S infusion.

Effect of PAG treatment on the hepatic microcirculation during endotoxemia: Our previous results demonstrated a modest constrictor effect of exogenous H_2S on the hepatic sinusoid. Since hyperconstriction of the sinusoid is a contributing factor to hepatic injury during endotoxemia, we used the non-competitive inhibitor of CSE, dl-propargylglycine (PAG), to investigate the contribution of endogenous H_2S to hepatic sinusoidal sensitization to the constrictor effect of ET-1 during endotoxemia. A total of twenty rats were divided evenly into four groups; control, LPS (1mg/kg ip, 6 hr), PAG (50 mg/kg ip, 30 minutes before microscopy), and cotreatment with LPS/PAG. Systemic hemodynamics (MAP and HR) were monitored throughout the experiment and no biologically significant changes were observed (Table 2). There was no significant difference in baseline portal pressure among the treatment groups. 10 minute infusion of ET-1 (125 pmoles/kg/min) resulted in an increase in portal pressure in control rats (121% of baseline pressure, Figure 30, $P < 0.05$). While PAG treatment alone had no effect on the ET-1 response, the constrictive effect of ET-1 was exacerbated in endotoxemic rats (175% of baseline, $P < 0.01$). PAG treatment significantly attenuated the increased constrictor effect of ET-1 in endotoxemic animals ($143\% \pm 6.9$, $P < 0.05$ compared to LPS alone).

Using intravital microscopy, we demonstrated that infusion of ET-1 reduced sinusoidal diameter in control and PAG treated rats by 12.6% and 12.3%, respectively (Figure 31). In LPS treated rats, the effect of ET-1 was greatly potentiated (30.9 % reduction in diameter, $P < 0.01$ vs. control) similar to our previous reports [12]. Treatment

with PAG abrogated the sensitization of the sinusoid to the constrictor effect of ET-1 resulting in a decrease in sinusoidal diameter similar to controls (11.6 % reduction). Since we previously reported the presence of constricted and dilated sinusoids following inflammatory stress, we assessed the variability of sinusoidal diameters among treatment groups. LPS produced a significant increase in the standard deviation of the means of sinusoidal diameters per field ($1.9 \pm 0.5 \mu\text{m}$ vs. $0.9 \pm 0.2 \mu\text{m}$ in controls, Figure 32, $P < 0.05$) which was attenuated by PAG treatment ($0.8 \pm 0.1 \mu\text{m}$, $P < 0.05$). Interestingly, PAG alone produced a significant increase in heterogeneity of sinusoidal diameters during ET-1 infusion ($1.5 \pm 0.3 \mu\text{m}$, $P < 0.05$ vs. control).

There was a clear difference between treatment groups in sinusoidal diameter and heterogeneity based on the visual appearance of the sinusoids (Figure 33). We wanted to investigate if these physical differences between groups produced functionally important alterations in sinusoidal perfusion. To do this, FITC-labeled RBCs were tracked as they traveled through individual sinusoids using a computer tracking algorithm we developed. For each group, we calculated the mean RBC velocity through individual sinusoids. There was no difference between treatment groups prior to ET-1 infusion. While there was no statistical difference in the mean velocities of RBC between groups following ET-1, the distribution of mean sinusoidal RBC velocities was different (Figure 34). The distribution of sinusoids with a given RBC velocity followed a standard Gaussian distribution in control animals after ET-1 infusion. In LPS treated rats there were a greater number of occluded and slow flowing sinusoids distorting the Gaussian distribution. PAG treatment restored the distribution of sinusoidal velocities in LPS treated rats making it more similar to control animals.

The presence of several completely occluded sinusoids following ET-1 infusion prompted us to determine the sinusoidal perfusion percentage before and after ET-1 infusion in each group (Figure 35). There was no difference between the groups in the percentage of sinusoids perfused (all groups > 90%) prior to infusion of ET-1. ET-1 infusion caused a decrease in sinusoidal perfusion percentage among all treatment groups (Figure 36). In the LPS group, only 63% of the sinusoids were perfused following ET-1 infusion, which was significantly less than the control group (91% perfused, $P < 0.001$). In LPS treated animals, PAG treatment significantly improved sinusoidal perfusion (78% perfused, $P < 0.05$) after ET-1 treatment.

Based on these results, we investigated whether PAG treatment increased oxygen delivery to the liver during ET-1 infusion. Using NADH autofluorescence as an indicator of cellular redox potential allows for indirect assessment of oxygen availability. NADH fluorescence remained unchanged following infusion of ET-1 in control and PAG rats (Figure 36). LPS treatment was associated with a significant increase in NADH autofluorescence (61 grey scale units vs. 9.6 units in control, Figure 37, $P < 0.05$). PAG treatment attenuated the increase in NADH fluorescence following ET-1 infusion in endotoxemic rats (21 grey scale unit increase, $P < 0.05$ vs. LPS).

4.5 Discussion

The present study investigated whether hydrogen sulfide (H_2S) modulates sinusoidal perfusion within the hepatic microcirculation. We show that portal infusion of the H_2S donor Na_2S *in vivo* causes a modest increase in hepatic resistance which is due in part to sinusoidal constriction. Furthermore, we demonstrate that treatment with PAG attenuates the hypersensitization of the hepatic sinusoid to the vasoconstrictive effect of

ET-1 during endotoxemia. Taken together, our results show that H₂S affects sinusoidal perfusion in a manner distinct from its action in the portal venules and it significantly contributes to microvascular dysregulation in endotoxemia.

Historically consisting of nitric oxide (NO) and carbon (CO), the “gasotransmitters” are a group of endogenously synthesized gases that act as mediators in a multitude of physiological and pathophysiological functions [135]. The newest recognized member of this group, H₂S, is primarily produced during cysteine metabolism by two pyridoxal 5' phosphate dependent enzymes, cystathionine β synthase (CBS) and cystathionine γ lyase (CSE) with the latter being the major source of H₂S in the liver and cardiovascular system [18, 48, 123]. Like NO and CO, H₂S participates in the regulation of the blood flow by modulating vascular resistance. Evidence for H₂S-induced vasodilation has been provided in several different experimental models, including isolated aortic rings and mesenteric artery beds [21, 48]. Whereas NO and CO mediated relaxation of VSMCs is cGMP dependent [39, 51], H₂S increases the activity of K_{ATP} channel activity in VSMCs leading to hyperpolarization and relaxation [148]. A common criticism regarding *in vitro* studies with H₂S is the large amount of exogenous H₂S required to induce vasodilation which may not reflect local concentrations *in vivo*. However, CSE^{-/-} mice spontaneously develop hypertension which provides evidence for the important contribution of endogenously produced H₂S in vasoregulation [140].

Despite the large body of evidence that demonstrates the vasodilatory action of H₂S, there are reports that H₂S can produce vasoconstriction in certain circumstances. At low concentrations, the H₂S donor NaHS reverses the relaxation of aortic rings to acetylcholine [74]. Acetylcholine vasodilation is NO dependent. Since H₂S had only a

minor effect in the absence of acetylcholine, it is likely that H₂S-induced vasoconstriction results from an interaction with NO. This study also suggested an NO independent mechanism of vasoconstriction that involves reduction of cAMP levels in the presence of NaHS [74]. *In vivo* studies demonstrate that intravenous infusion of H₂S produces a small, transient increase in blood pressure which is abrogated in mice treated with L-NAME, an inhibitor of nitric oxide synthase (NOS) [4]. Thus, the interaction between NO and H₂S is likely complex. H₂S can directly inhibit all three isoforms of recombinant NOS [65-66]; however, reports also show an increase in eNOS activity from H₂S treatment in bovine arterial endothelial cells (BAECs) [102]. In addition to an effect on NOS, H₂S may interact with NO to form a vaso-inactive nitrosothiol, quenching the NO signal [137]. Due to the ambiguous vasoactive role of H₂S in vasoregulation, we first investigated the effect of portal infusion of H₂S on hepatic vascular resistance *in vivo*. Infusion of the H₂S donor Na₂S produced a modest increase in portal pressure. Previously, we demonstrated that the liver has a high capacity to metabolize H₂S [89]. Since we infused H₂S directly into the portal circulation via the splenic vein, it is expected that H₂S would have no effect on systemic hemodynamics as all should be metabolized in a single pass through the liver. Fluctuations in portal pressure result from alterations in either splanchnic blood flow or a change in intrahepatic resistance. Since portal infusion of H₂S should have no effect on splanchnic blood flow, the change in portal pressure is most likely due to an increase in intrahepatic resistance. Using intravital microscopy, we observed a reduction in sinusoidal diameter during infusion of H₂S. Kamoun et al reported that ET-1 stimulated sinusoidal constriction produces heterogeneous blood flow at the level of individual sinusoids [57]. In our study, H₂S

infusion increased the heterogeneity of sinusoidal diameters indicative of increased heterogeneity of flow. These findings imply that the increase in portal pressure observed during infusion of H₂S is the result of increased intrahepatic resistance resulting from modest net sinusoidal constriction.

The finding that H₂S causes constriction of the sinusoids suggests a fundamentally different mechanism of vascular tone regulation in the sinusoid compared to other resistance vessels. H₂S hyperpolarizes vascular smooth muscles cells (VSMC) via activation of the K_{ATP} channel which leads to relaxation and vasodilation [128]. Importantly, H₂S-induced vasodilation is reversible with treatment of the K_{ATP} channel inhibitor, glibenclamide [148]. Within the liver, VSMCs are present around the portal terminal venules and hepatic arterioles. Accordingly, studies have shown that H₂S attenuates norepinephrine (NE) induced vasoconstriction in isolated livers and increases the hepatic arterial buffer response (HABF) [33, 115]. However, these findings suggest that H₂S acts as a vasodilator in the liver at sites where VSMCs are present. The hepatic sinusoids lack VSMCs. Rather, sinusoidal tone is primarily regulated by hepatic stellate cells (HSCs). These specialized pericytes surround individual sinusoids and respond to local balances between vasodilators and vasoconstrictors [62]. An imbalance between vasoactive molecules can cause HSC contraction or relaxation and alter sinusoidal tone. During sepsis, an imbalance between NO and the vasoconstrictive effect of ET-1 produces sinusoidal hyperconstriction [12]. In an isolated, perfused liver, Fiorucci et al demonstrated that H₂S attenuated catecholamine-induced vasoconstriction and may be beneficial during cirrhosis by reducing portal hypertension and increasing hepatic perfusion [33]. One would predict that the vasodilatory effect of H₂S would also be

beneficial during sepsis; however, we recently reported that H₂S differentially modulates the effect of PE and ET-1 in an isolated, perfused liver. It is possible that H₂S may have a different effect on the hepatic sinusoids than on the portal venules. Since sinusoidal hyperconstriction and heterogeneous perfusion contribute to liver injury during sepsis [12-13], we hypothesized that the inhibition of the H₂S-producing enzyme, CSE, would attenuate hepatic sinusoidal dysfunction in an endotoxin model of sepsis.

In the sinusoid, the vasoconstrictive effect of ET-1 results from an interaction with ET_A and ET_B receptors expressed in hepatic stellate cells (HSCs) [49]. Under normal conditions, this vasoconstrictive effect is counteracted by ET-1 interaction with ET_B receptors in sinusoidal endothelial cells (SECs) which increases eNOS activity [98]. ET-1 levels increase following inflammatory stress [3, 109]; however, more importantly ET-1 stimulated NO production from SECs is impaired, in part, due to an increase in caveolin 1 which has been shown to inhibit eNOS activity [67]. This leads to sinusoidal hypersensitization to the vasoconstrictive effect of ET-1. A consequence of sinusoidal constriction is the development of heterogeneous sinusoidal flow and focal hypoxia [57]. Individual constricted sinusoids are under-perfused, resulting in local ischemia, while neighboring sinusoids are dilated and over-perfused. While total hepatic blood flow may remain constant, the heterogeneous blood flow fails to match O₂ supply with demand, producing hepatic dysfunction and injury.

For this study, we used a mild inflammatory stress (LPS 1mg/kg ip, 6 hours) to assess the effect of PAG treatment on the early changes in hepatic microcirculation during endotoxemia. There was no effect on systemic hemodynamics at this dose and time point (Table 2). Therefore, the results represent a local hepatic effect rather than a

consequence of systemic alterations. Despite our prior result that demonstrated an effect of intraportal infusion of H₂S on the hepatic sinusoid, PAG treatment did not alter the hepatic microcirculation before or after ET-1 infusion in control animals. Since the liver has a high capacity to metabolize H₂S, it is likely that endogenous H₂S levels are prevented from accumulating to levels sufficient to exert a vasoactive function under normal conditions. However, there is an increase in hepatic CSE expression and H₂S synthesis during sepsis [144]. Therefore, it is possible that elevated H₂S levels are sufficient to contribute to sinusoidal dysfunction in endotoxemic rats.

A study by Zhang et al demonstrated that ET-1 causes sinusoidal constriction which colocalizes with HSCs [146]. Kamoun and coworkers observed that portal infusion of ET-1 increased the heterogeneity of perfusion through the sinusoids [57]. Several studies demonstrated that inflammatory stress, including sepsis, enhances the vasoconstrictive effect of ET-1 in the hepatic microcirculation [12, 58, 94]. Furthermore, Baveja et al demonstrated that sinusoidal hyperconstriction and heterogeneous blood flow lead to impaired O₂ delivery to hepatic cells resulting in tissue hypoxia and injury [13]. In the present study, we demonstrate that endotoxin significantly increases sinusoidal constriction and heterogeneity of sinusoidal perfusion. Additionally, there were more non-perfused sinusoids in LPS treated rats following ET-1 infusion when compared to control. These effects were reversed by a single injection of PAG 30 minutes prior to experimental treatments. In endotoxin treated animals, PAG treatment attenuated sinusoidal hyperconstriction and decreased perfusion heterogeneity following ET-1 infusion. PAG treatment also reduced the number of non-perfused sinusoids after ET-1 infusion.

Since PAG treatment significantly improved microcirculatory function after ET-1 infusion in LPS treated rats, we investigated if it also improved O₂ delivery to the liver tissue. Using intravital microscopy, we can exploit the fact that the reduced form of the cellular electron carrier, nicotinamide adenine dinucleotide (NADH), is fluorescent when excited with UV light, while the oxidized form, NAD⁺ is not. Because O₂ is the final electron acceptor in the electron transport chain, a deficiency in O₂ will lead to an increase in NADH/NAD⁺. Previous work from our lab demonstrated that hepatic NADH autofluorescence is highly correlated to tissue PO₂ [99]. Therefore, we can interpret an increase in fluorescence as a decrease in hepatic O₂ availability. In the present study, infusion of ET-1 caused a significant increase in NADH fluorescence in animals treated with endotoxin. ET-1 infusion increased NADH fluorescence in all animals with the greatest increase occurring in LPS treated rats. In agreement with our sinusoidal parameters, PAG treatment reduced the increase in NADH fluorescence in LPS treated animals suggesting improved O₂ delivery to the hepatic tissue.

While NADH is an indirect assessment of hepatic O₂ availability, our finding is in agreement with previous reports from our lab. Using an isolated, perfused liver system, we demonstrated that infusion of low concentrations of ET-1 increased O₂ consumption in control livers. In LPS treated animals, O₂ consumption was inhibited by infusion of low concentration of ET-1 due to an increase in vascular resistance (presumably sinusoidal) and impaired O₂ delivery. In endotoxemic livers, PAG treatment restored O₂ consumption following low dose ET-1 treatment. Taken together, our findings suggest that PAG maintains O₂ delivery to the liver during endotoxemia.

Our results demonstrate one possible protective mechanism of CSE inhibition during sepsis. It is possible that a portion of the protective effect of PAG occurs independently of H₂S. However, several other studies show that the protective effect of PAG is reversible with treatment with the rapid releasing H₂S donor NaHS [5, 143, 145]. Furthermore, H₂S likely does not circulate in the blood; rather, endogenous H₂S levels are the summation of continuous local production and disposal [92]. Therefore, we focused on inhibiting endogenous H₂S synthesis to study the effect of H₂S during endotoxemia because it is more likely to be physiologically relevant than the high concentrations of H₂S needed to observe *in vivo* effects.

Importantly, several studies show a protective effect of PAG pre-treatment on the inflammatory response during sepsis [143]. We specifically chose to treat with PAG for 30 minutes immediately before all microscopy or liver isolation surgery. By administering PAG five and a half hours after LPS treatment, we likely mitigate the difference in the inflammatory response between the LPS and PAG/LPS groups. Therefore, we can interpret our results as the acute effect of the presence of H₂S in the hepatic sinusoid and not as the consequence of an altered inflammatory response.

There are conflicting reports of the vasoregulatory actions of H₂S in the microcirculation. H₂S likely provides a beneficial effect during fibrosis and cirrhosis. In these chronic conditions, H₂S, acting as a vasodilator in the portal venules, likely improves hepatic perfusion and reduces portal hypertension. However, during sepsis, the failure of the hepatic microcirculation occurs primarily at the level of the sinusoids which are hyperconstricted. For the first time, we directly demonstrate an effect of H₂S in the regulation of sinusoidal tone. The vasoconstrictive effect of H₂S in the sinusoids is

fundamentally different than the previously reported dilatory effect of H₂S in presinusoidal resistance vessels. Furthermore, because endotoxemia is associated with hepatic sinusoidal hyperconstriction, we investigated if inhibition of CSE significantly increases hepatic microcirculatory dysfunction following LPS treatment. We show that treatment with the CSE inhibitor, PAG, significantly improves hepatic microcirculatory function following ET-1 infusion during endotoxemia. Our results imply that the protective effect of PAG observed during sepsis may be due in part to improved hepatic perfusion. In summary, our results suggest that the current understanding of the role of H₂S in the hepatic microcirculation is incomplete. Rather, a more complex role is likely where H₂S acts as a vasodilatory in the presinusoidal resistance vessels and exerts a constrictor effect in the hepatic sinusoids which may contribute to hepatic microcirculatory dysfunction during sepsis.




Figure 27: Effect of portal infusion of Na₂S on portal pressure *in vivo*. Portal pressure was monitored to determine the effect of the H₂S donor Na₂S on intrahepatic resistance. The peak portal pressure during 10 minute infusion Na₂S was recorded and compared to baseline and 10 minutes following Na₂S infusion. Data are presented as the mean \pm SEM from 5 separate experiments. Statistical analysis was performed using 1 way repeated measures ANOVA. * = P<0.05.

Table 1: Effect of portal infusion of Na₂S on mean arterial pressure (MAP) and heart rate (HR). MAP and HR were monitored to determine the systemic effect of portal infusion of Na₂S. Data are presented as the mean \pm SEM from 5 separate experiments. Statistical analysis was performed using 1 way repeated measures ANOVA. * = P<0.05.

	Saline	H ₂ S	Saline
Mean Arterial Pressure (mmHg)	102 \pm 2.9	99.9 \pm 4.0	96.7 \pm 4.6 *
Heart Rate (BPM)	317 \pm 11.4	305 \pm 11.6 *	301 \pm 11.1 *




Figure 28: Effect of Na₂S on sinusoidal diameter. *In vivo* micrographs of the hepatic sinusoids were taken before, during, and 10 minutes following infusion of H₂S donor Na₂S. Infusion of Na₂S decreased sinusoidal diameter. Data are presented as the mean ± SEM from 5 separate experiments. Statistical analysis was performed using 1 way repeated measures ANOVA. * = P<0.05.




Figure 29: Effect of Na₂S on heterogeneity of sinusoidal diameters. *In vivo* micrographs of the hepatic sinusoids were taken before, during, and 10 minutes following infusion of H₂S donor Na₂S. Infusion of Na₂S decreased sinusoidal diameter. Data are presented as the mean ± SEM from 5 separate experiments. Statistical analysis was performed using 1 way repeated measures ANOVA and demonstrated a significant overall effect of treatment (P<0.05).

Table 2: Effect of portal infusion of ET-1 on mean arterial pressure (MAP) and heart rate (HR). MAP and HR were monitored to determine the systemic effect of portal infusion of ET-1 within treatment groups. Data are presented as the mean \pm SEM from 5 separate experiments. Statistical analysis was performed using 2 way ANOVA. * = $P < 0.05$ compared to baseline within treatment group, # = $P < 0.05$ between treatment groups.

Treatment		Saline	ET-1	Recovery		
				10 min	20 min	30 min
Control	Mean Arterial Pressure (mmHg)	127.1 \pm 7.2	124.3 \pm 10.3	132.3 \pm 6.9	130.2 \pm 6.5	123.9.2 \pm 6.9
	Heart Rate (BPM)	400.0 \pm 9.3	393.5 \pm 15.1	289.1 \pm 16.0	392.1 \pm 14.7	389.0 \pm 12.5
PAG	Mean Arterial Pressure (mmHg)	135.7 \pm 2.6	136.5 \pm 2.8	143.0 \pm 6.3 *	142.5 \pm 2.3	135.0 \pm 6.6
	Heart Rate (BPM)	394.3 \pm 16.0	396.7 \pm 13.4	379.2 \pm 19.0	363.6 \pm 12.1 #	388.3 \pm 19.5
LPS	Mean Arterial Pressure (mmHg)	131.3 \pm 4.3	129.3 \pm 4.8	133.2 \pm 1.8	132.4 \pm 8.4	124.4 \pm 8.4
	Heart Rate (BPM)	434.7 \pm 19.8	432.4 \pm 15.0	416.9 \pm 14.9	435.1 \pm 115.8	398.3 \pm 15.8
PAG/LPS	Mean Arterial Pressure (mmHg)	126.6 \pm 5.5	129.2 \pm 7.4	138.4 \pm 9.0 *	134.6 \pm 7.4	133.3 \pm 8.7
	Heart Rate (BPM)	387.8 \pm 19.0	391.2 \pm 18.6	384.4 \pm 20.0	362.8 \pm 21.7 #	401.9 \pm 6.2




Figure 30: Effect of dl-propargylglycine (PAG) on portal pressure during infusion of endothelin-1 (ET-1) during endotoxemia. Rats were treated with LPS for 6 hours with or without PAG treatment 30 minutes before microscopy. Portal pressure was monitored during infusion of ET-1. The percent increase over baseline is plotted as the mean \pm SEM (N=5). Statistical analysis was performed using two way ANOVA with SNK *post hoc* test. * = $P < 0.05$ compared to baseline, # = $P < 0.05$ between LPS and PAG/LPS.




Figure 31: Effect of dl-propargylglycine (PAG) on mean sinusoidal diameter during infusion of ET-1 during endotoxemia. Rats were treated with LPS for 6 hours with or without PAG treatment 30 minutes before microscopy. Micrographs of sinusoids were taken before, during, and 10 minutes after ET-1 infusion. PAG attenuates sinusoidal hyperconstriction following ET-1 infusion during endotoxemia. Data are presented as the mean \pm SEM from 5 separate experiments. Statistical analysis was performed using 2 way ANOVA with SNK *post hoc* test. * = $P < 0.05$.




Figure 32: Effect of dl-propargylglycine (PAG) on sinusoidal diameter heterogeneity during infusion of ET-1 during endotoxemia. Rats were treated with LPS for 6 hours with or without PAG treatment 30 minutes before microscopy. Micrographs of sinusoids were taken before, during, and 10 minutes after ET-1 infusion. PAG reduces the heterogeneity of sinusoidal diameter means. Data are presented as the mean \pm SEM from 5 separate experiments. Statistical analysis was performed using 2 way ANOVA with SNK *post hoc* test. * = $P < 0.05$.




Figure 33: The effect of ET-1 infusion on the hepatic sinusoids following PAG treatment in endotoxemia. Sinusoids were visualized to determine the effect of ET-1 infusion on LPS-treated rats with or without the CSE inhibitor, dl-propargylglycine (PAG). Representative micrographs are shown before and after infusion of 125 pmoles/kg/min infusion of ET-1.




Figure 34: Distribution of sinusoidal flow velocities. The distribution of flow velocities through individual sinusoids was determined by tracking FITC –labeled RBCs moving through the sinusoids. The distribution of sinusoidal velocities is plotted as the fraction of total sinusoids within a given velocity range. **A.) Control B.) LPS C.) PAG D.) PAG/LPS.**




Figure 35: Effect of PAG treatment on sinusoidal perfusion percentage following ET-1 infusion during endotoxemia. The percentage of perfused sinusoids was determined in all treatment group. Data are presented as the mean \pm SEM from 5 separate experiments. Statistical analysis was performed using 2 way ANOVA with SNK *post hoc* test. * = $P < 0.05$.




Figure 36: Effect of PAG treatment on hepatic redox potential following ET-1 infusion during endotoxemia. NADH autofluorescence was used as an indirect assessment of the effect of PAG on hepatic O₂ delivery during endotoxemia. An increase in fluorescence is correlated to an increase in NADH/NAD⁺ and indirectly a decrease in hepatic O₂ content. Data are presented as the mean ± SEM from 5 separate experiments. Statistical analysis was performed using 2 way ANOVA with SNK *post hoc* test. * = P<0.05, # = P<0.05 between LPS and PAG/LPS.




Figure 37: Representative micrographs of NADH autofluorescence before and after ET-1 infusion during endotoxemia. NADH autofluorescence is used as an indirect assessment of hepatic O₂ availability. An increase in fluorescence is associated with an increase in the NADH/NAD⁺ ratio and indirectly a decrease in hepatic O₂ availability.

CHAPTER 5: DISCUSSION

The role of hydrogen sulfide (H₂S) in inflammation and disease is poorly understood. Somewhat paradoxically, H₂S is cytoprotective following hepatic ischemia/reperfusion injury, but contributes to disease progression during sepsis [54, 144]. It is well established that hepatic dysfunction is a major early complication in sepsis [38]. Our lab previously focused on the major contribution of the gasotransmitter, nitric oxide (NO), in hepatic dysfunction during sepsis [25]. It is evident that NO has a primary role in sepsis; however, the complex septic milieu in the hepatic microenvironment suggests a more dynamic pathophysiology. Several studies have reported similarities between NO and H₂S in the cardiovascular system [135]. While the importance of NO in the liver vasculature is well documented, few have investigated the effects of H₂S in the hepatic microcirculation, particularly following inflammatory stress. Therefore, this dissertation focused on the effect of H₂S in the liver during sepsis with particular emphasis on hepatic O₂ availability and microcirculatory dysfunction.

A combination of endogenous and exogenous H₂S results in elevated hepatic sulfide exposure during sepsis. Endogenously, cystathionine λ lyase (CSE) is the primary source of H₂S in the liver [56, 147]. Following endotoxin treatment or cecal ligation and puncture (CLP), hepatic CSE levels increase which results in a greater hepatic capacity to synthesize H₂S [72, 144]. As the major recipient of gastrointestinal blood flow, the liver is exposed to an exogenous source of H₂S derived from sulfate-reducing bacteria in the

gut [15]. During septic peritonitis, it is likely that increased production of H_2S from intestinal bacteria may enter the portal circulation and increase hepatic sulfide exposure; however, the fate of elevated H_2S levels in the liver is unclear.

In the presence of toxic levels of H_2S , colonic mucosal cells rapidly detoxify H_2S generated by colonic bacteria, thereby preventing accumulation [37]. Located in the mitochondria, the sulfide quinone reductase (SQR) protein complex couples the oxidation of H_2S with complex Q of the electron transport chain [68]. The oxidation of H_2S by the SQR consumes molecular oxygen at a ratio of 1.5 moles of O_2 per 1 mole of H_2S . In isolated mitochondria from chicken livers, H_2S oxidation was associated with increased O_2 consumption and was coupled to ATP synthesis [141]. The relationship between H_2S oxidation and O_2 consumption has also been observed in a recirculating isolated and perfused liver [8]. A significant complication during sepsis is the loss of hepatic oxidative catabolism of toxic molecules [2, 64]. Whether sepsis affects hepatic sulfide oxidation is unknown. Since a diminished capacity to oxidize H_2S would be detrimental during the high sulfide levels occurring during sepsis, we hypothesized that the liver retains a high capacity to metabolize H_2S during sepsis in order to prevent toxic hepatic accumulation and to remove H_2S from the circulation.

In a non-recirculating isolated and perfused liver, we demonstrate a biphasic effect of H_2S in the liver, which was not present in an isolated and perfused heart. The liver has a high capacity to metabolize H_2S until a critical level. Above this threshold, toxic amounts of H_2S inhibit the oxidation of H_2S . H_2S clearance from the perfusate was associated with an increase in hepatic O_2 consumption. When the PO_2 of the perfusate was reduced, the oxidation of H_2S decreased proportionally, suggesting that available O_2

is obligatory for H₂S clearance. Infusion of H₂S did not alter total intrahepatic resistance indicating that the changes in O₂ consumption were not due to a vascular effect.

In vivo, erythrocytes may participate in the sequestration of H₂S via an interaction with hemoglobin [43]. It is possible that the lack of RBCs in our experimental settings does not reflect hepatic exposure to H₂S *in vivo*. To investigate this possibility, we used *in vivo* microscopy to monitor hepatic oxygen availability during portal infusion of H₂S. We demonstrated that portal exposure to H₂S is associated with a significant decrease in hepatic O₂ content and redox potential which suggests that elevated H₂S in the portal circulation is cleared by the liver. Interestingly, in preliminary studies, we were unable to detect H₂S immediately after it was added to blood. When the same experiment was performed with plasma, H₂S was detectable, suggesting that RBCs can sequester H₂S. Nevertheless, our findings clearly demonstrate that H₂S in the circulation is available for hepatic oxidation which can decrease hepatic O₂ availability.

Early cardiovascular dysfunction during sepsis is characterized by a hyperdynamic state. An increase in cardiac output and modest peripheral vasodilation leads to an increase in global DO₂ [44]. Despite this increase in DO₂, it is well established that liver dysfunction during sepsis is due in part to hypoxic injury [12, 53, 100]. The findings from the first part of this dissertation suggest that H₂S may act as a double edged sword during sepsis and contributes to hepatic dysfunction resulting from focal hypoxia. The presence of elevated hepatic H₂S levels would require greater H₂S oxidation to prevent the toxic effects. As a consequence, H₂S oxidation consumes O₂, which would exacerbate hypoxic stress. The inverse relationship between O₂ and H₂S oxidation may partially be responsible for the increase in hypoxia inducible factor (HIF-1 α) during endotoxemia

[110]. Indeed, *C. Elegans* grown in H₂S containing medium exhibit elevated levels of HIF-1 α nuclear accumulation [17]. Since HIF-1 α enhances the pro-inflammatory response during endotoxemia [75, 100], then it may be involved in the pro-inflammatory effects of H₂S during sepsis. Moreover, we have shown that as O₂ levels fall, H₂S oxidation is reduced. The development of tissue hypoxia during sepsis would lead to decreased H₂S oxidation which may allow H₂S to accumulate to toxic levels and, possibly, enter the systemic circulation and contribute to systemic cardiovascular dysfunction.

The contention that H₂S contributes to hepatic hypoxia is muddled because H₂S is a vasoactive molecule which may affect DO₂ [48]. The main vasoregulatory action of H₂S occurs via activation of K_{ATP} channels in vascular smooth muscle cells (VSMCs) which leads to relaxation of resistance vessels [148]. The vasodilatory effects of H₂S may increase hepatic tissue perfusion and O₂ delivery which could mitigate the effect of H₂S oxidation on hepatic O₂ levels during sepsis. A vasodilatory effect of H₂S on the hepatic vasculature was first demonstrated by Fiorucci et al. using livers isolated from normal and cirrhotic rats [33]. They found that H₂S attenuated the vasopressor effects of norepinephrine which was independent of NO. Portal hypertension resulting from an increase in intrahepatic resistance is the main complication during chronic conditions like fibrosis and cirrhosis [7]. The vasodilatory effect of H₂S on the hepatic vasculature would be beneficial by decreasing hepatic resistance and attenuating the development of portal hypertension. While similarities exist between vascular dysfunction in cirrhosis and sepsis, the effect of H₂S on hepatic resistance during sepsis has yet to be investigated.

Unlike the systemic circulation, where tissue perfusion is primarily regulated by VSMCs surrounding pre-capillary resistance vessels (arterioles), hepatic perfusion is regulated at pre-sinusoidal as well as sinusoidal sites [11]. The modulation of pre-sinusoidal regulatory sites is similar to other vascular beds. In these vessels, vascular dysfunction following inflammatory stress is characterized by hyporeactivity to catecholamines [97]. Ample evidence suggests that a second functionally important regulatory site of hepatic perfusion in the liver is at the level of the sinusoid, particularly following inflammatory stress [25, 63, 98, 112]. The primary modulator of sinusoidal resistance is the hepatic stellate cell (HSC) [62, 146]. These specialized pericytes contract in response to vasoactive molecules including endothelins, eicosanoids, and angiotensin II [9, 49, 60]. Inflammatory stress is associated with the activation of HSCs which leads to a myofibroblast-like phenotype and enhanced contraction in response to vasoconstrictors, particularly endothelin-1 (ET-1) [105, 107]. Moreover, inflammatory stress leads to an uncoupling of ET-1/ET_B binding and eNOS activation in SECs due, in part, to an increase in the inhibitory protein caveolin-1 [67, 81, 113]. The resulting imbalance in the antagonistic relationship between vasodilators and vasoconstrictors leads to sinusoidal hyperconstriction which is a main cause of increased intrahepatic resistance in cirrhosis and sepsis. Therefore, we investigated the effect of H₂S on intrahepatic vascular responses during infusion of the α_1 adrenergic agonist, phenylephrine (PE), and ET-1 during sepsis.

Infusion of PE or ET-1 was associated with an increase in portal pressure in livers isolated from control rats, which is indicative of an increase in total intrahepatic resistance in isolated livers during constant flow perfusion. An increase in intrahepatic

resistance is the summation of changes in resistance at both pre-sinusoidal and sinusoidal regulatory sites. Previous work from our lab demonstrated that PE and ET-1 exert their vascular effect at different sites [146]. Using *in vivo* microscopy, portal infusion of ET-1 resulted in an increase in portal pressure and sinusoidal constriction which colocalized with HSCs. While PE infusion increased portal pressure, no effect was observed in the sinusoids, suggesting that PE acts only at pre-sinusoidal regulatory sites, while ET-1 acts at sinusoidal and pre-sinusoidal sites [146].

Since microvascular dysfunction during sepsis occurs at both locations, it is important to consider the effects of H₂S in the presence of PE and ET-1. In agreement with previous studies from our lab, LPS treatment attenuated the vasoconstrictive effect of PE, whereas LPS potentiated the vasoconstrictive effect of ET-1 [94, 97]. During endotoxemia, VSMCs in portal venules become hyporesponsive to PE due to an increase in the production of vasodilatory molecules, such as NO [97]. In agreement with Fiorucci et al study, we showed that addition of the vasodilator H₂S attenuated the vasoconstrictive effect of PE in normal rats and nearly abolished the effect in LPS-treated rats. LPS treatment had the opposite effect on ET-1-induced vasoconstriction. The hepatic vasculature was hypersensitive to the vasoconstrictive effect of ET-1 during endotoxemia; however, we observed no effect of H₂S on ET-1-induced vasoconstriction in control or LPS-treated livers, suggesting that H₂S may not exert a vasoregulatory function in the sinusoids.

In vitro experiments often require large amounts of exogenous H₂S to demonstrate a biological effect which may not be reflective of *in vivo* levels [36, 138]. Therefore, we used the inhibitor of CSE, dl-propargylglycine (PAG) [126], to determine

the effect of endogenous H₂S during PE and ET-1 infusion. PAG treatment 30 minutes prior to liver isolation was associated with a significant increase in PE-induced increases in portal pressure. In septic and endotoxemic rats, arterial H₂S concentration is negatively correlated with blood pressure leading to the suggestion that H₂S contributes to the systemic hypotension [50]. Our findings tend to support this hypothesis and may indicate that the inhibition of endogenous H₂S has potential as an approach to treat diffuse hypotension during sepsis. However, a study by Collin et al showed that PAG treatment did not prevent circulatory failure in endotoxemic rats [26]. Interestingly, PAG treatment did prevent liver damage, suggesting that the deleterious effect of endogenous H₂S during sepsis may be liver specific.

The effect of PAG treatment on ET-1 infusion is more complex. PAG potentiated the effect of ET-1 infusion in control animals; however, PAG had no effect on the response to ET-1 in endotoxemic livers. Since ET-1 acts at both presinusoidal and sinusoidal sites, the increased sensitivity to ET-1 in control animals may occur at either or both sites. Therefore, it is possible that an increase in vascular resistance at presinusoidal sites by PAG, similar to PE, could be counteracted by the vasodilatory effect of PAG in the hepatic sinusoid, resulting in no net change in total intrahepatic resistance.

In support of this scenario, we observed a significant improvement in O₂ consumption following PAG treatment in LPS-treated rats. ET-1 treatment stimulates glycogenolysis in isolated hepatocytes which results in an increase in O₂ consumption [111]. In our study, infusion of low concentrations of ET-1 caused an increase in O₂ consumption in control livers. At high concentrations, ET-1-induced vasoconstriction significantly impairs O₂ delivery to hepatic tissue and decreases O₂ consumption. In LPS-

treated rats, infusion of low concentrations of ET-1 decreases O₂ consumption which is consistent with a hypersensitization of the hepatic sinusoid to the vasoconstrictive effects of ET-1. PAG treatment prevented the decrease in O₂ consumption during infusion of low concentrations of ET-1 during endotoxemia, suggesting improved sinusoidal perfusion. Therefore, we hypothesized that H₂S causes sinusoidal constriction and contributes to the sensitization of the hepatic sinusoid to the vasoconstrictive effect of ET-1 during endotoxemia.

To test this hypothesis, we used intravital microscopy which allows for the direct visualization of the hepatic sinusoids and assessment of sinusoidal perfusion *in vivo*. Portal infusion of H₂S was associated with a modest increase in portal pressure and net sinusoidal vasoconstriction. Sinusoidal constriction is associated with an increase in heterogeneity of sinusoidal perfusion [57]. The increase in sinusoidal heterogeneity is characterized by the presence of constricted sinusoids juxtaposed with dilated sinusoids producing an increase in the heterogeneity of sinusoidal diameters. Following infusion of H₂S, there was an increase in the heterogeneity of sinusoidal diameters which is consistent with heterogeneous sinusoidal perfusion. Because sinusoidal vasoconstriction is a major component of hepatic microcirculatory failure, we investigated whether endogenous H₂S contributes to the sensitization of the hepatic sinusoid to ET-1 during endotoxemia.

Infusion of ET-1 was associated with a modest increase in portal pressure in control animals. The increase in portal pressure was associated with a slight reduction in sinusoidal diameter. In LPS-treated rats, the effects of ET-1 were significantly different. LPS treatment lead to a greater increase in portal pressure and caused a significantly

greater reduction in sinusoidal diameter including several occluded sinusoids. Moreover, there was a significant increase in the heterogeneity of sinusoidal diameters. Computer automated analyses of RBC flow through the sinusoids confirmed that sinusoidal flow heterogeneity was greater in endotoxemic animals compared to controls. PAG treatment alone was similar to controls in all aspects except for a greater number of non-perfused sinusoids; however, the reasons for this are unclear. PAG treatment 30 minutes immediately before microscopy led to a significant improvement in sinusoidal flow evidenced by less sinusoidal hyperconstriction, fewer non-perfused sinusoids, and less sinusoidal flow heterogeneity following ET-1 infusion. Accordingly, these changes in sinusoidal parameters were functionally important. Using NADH autofluorescence to assess hepatic O₂ availability, ET-1 infusion in LPS-treated animals significantly increase NADH fluorescence compared to controls. While PAG treatment had no effect on these parameters in control animals, it significantly improved all parameters following ET-1 infusion during endotoxemia.

For the first time, we show that H₂S exerts a vasoconstrictive effect on the hepatic sinusoid. Currently, the mechanism of H₂S-induced vasoconstriction remains unclear, but is likely independent of K_{ATP} channel activation [74]. In the sinusoid, the vasoconstrictive effect of H₂S is the result of a shift in the balance between dilators and constrictors which regulate HSC contractility. The rapid, transient action of H₂S in the sinusoid suggests an acute effect. In HSCs, Ca²⁺ dependent and independent pathways lead to contraction [69, 101]. The activation of K_{ATP} channels by H₂S is well documented; however, H₂S also interacts with calcium channels [85]. Additionally, H₂S may modulate the activity ion channels via sulfhydration of cysteine residues [86]. H₂S has been shown to increase

cytosolic $[Ca^{2+}]$ in several cell types, including HUVECs and microglial cells [70, 82]. Therefore, it is possible that H_2S may directly cause HSC contraction via activation of Ca^{2+} channels and increased cytosolic $[Ca^{2+}]$.

H_2S causes vasoconstriction in isolated aortic rings by inhibiting the accumulation of cAMP. In HSCs, the Ca^{2+} independent pathway, in particular the Rho/ROCK pathway, has greater significance on contractility than in smooth muscle cells [61, 120]. Accumulation of cAMP inhibits the Rho/ROCK pathway in HSCs and decreases their contractility in response to ET-1 [118]. Moreover, the sensitivity of ET_A receptors to ET-1 is decreased after cAMP accumulation [104]. Therefore, H_2S may produce vasoconstriction in the sinusoid by inhibiting cAMP accumulation in HSCs.

Our lab has previously focused on the importance of NO in hepatic microvascular dysfunction during sepsis. Several studies have demonstrated a complex relationship between hydrogen sulfide and NO. *In vitro* studies show an interaction between H_2S and NO to form a vasoinactive nitrosothiol. Thus, H_2S may cause vasoconstriction via reducing the bioavailability of NO. This is an intriguing hypothesis in the septic liver where H_2S synthesis is increased and impaired NO production contributes to vascular dysfunction. Several studies support the involvement of NO in H_2S -induced vasoconstriction. The relaxation of isolated aortic rings in response to acetylcholine is dependent on NO release by an intact endothelium [40]. Treatment with NaHS, an H_2S donor, attenuates the vasorelaxant effect of acetylcholine. The constrictor effect of H_2S is lost following removal of the endothelium which suggests an interaction with endothelial-derived NO [74]. A similar effect is observed using the H_2S precursor, L-cysteine which attenuates vascular relaxation due to acetylcholine and the nitric oxide

donor, sodium nitroprusside (SNP) [31, 55]. *In vivo*, the vasopressor effect of H₂S suggests an increase in peripheral resistance. Moreover, the vasoconstrictive effect of H₂S appears to be concentration dependent. While high concentrations of H₂S cause systemic hypotension, intravenous injection of low concentrations of H₂S increases mean arterial pressure. The vasopressor effect was abrogated by treatment with an inhibitor of nitric oxide synthase (NOS) implicating the involvement of NO. A decrease in NO bioavailability via an interaction with H₂S is likely a mechanism of importance in the hepatic sinusoid, particularly during sepsis due to impaired NO production.

CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS

In conclusion, the aim of this dissertation was to investigate the effect of H₂S in the liver during sepsis. In the first section, we show that the liver is a central regulator of H₂S levels in the body. Using an isolated, perfused liver, we demonstrated a high capacity to oxidize H₂S at the expense of cellular O₂. The ability to clear H₂S from the perfusate was dependent on O₂ availability and remained a priority during sepsis. Furthermore, elevated levels of H₂S in the portal circulation decrease hepatic O₂ availability *in vivo*. In the second section, we show that H₂S differentially modulates the hepatic response to PE and ET-1, suggesting that H₂S may have a differential effect at pre-sinusoidal and sinusoidal blood flow regulatory sites. Lastly, in the final section, we show for the first time that H₂S is a constrictor in the hepatic sinusoid. Moreover, endogenous H₂S is a major contributor to the hypersensitization of the hepatic sinusoid to the constrictor effect of ET-1 during endotoxemia which contributes to tissue hypoxia.

Taken together, these findings support a deleterious role of H₂S during sepsis. We propose that the presence of H₂S in the liver during sepsis contributes to tissue hypoxia and hepatic dysfunction (Figure 38). The elevated levels of H₂S would require increased sulfide oxidation to prevent toxic accumulation at the expense of hepatic O₂. At the same time, the vasoconstrictive effect of H₂S in the hepatic sinusoid contributes to heterogeneous perfusion which impairs O₂ and further diminishes hepatic O₂ content. The resulting tissue hypoxia leads to hepatic dysfunction and cell death. Our study provides

evidence of a potential protective mechanism observed following inhibition of endogenous H₂S in sepsis.

Despite the findings presented herein, there are still several important questions that remain unanswered. The inverse relationship between H₂S and O₂ suggests that H₂S may affect the expression of the oxygen sensitive protein, hypoxia inducible factor 1 α (HIF-1 α). The level of HIF-1 α is inversely related to cellular O₂ tensions [133]. Moreover, endotoxin increases HIF-1 α in an O₂ independent manner and is pro-inflammatory [100, 110]. Therefore, it is possible that the pro-inflammatory effect of H₂S during sepsis is due in part to increased expression of HIF-1 α . In preliminary experiments in mice given a moderate dose of endotoxin (10 mg/kg ip, 6 hr), PAG treatment significantly attenuated hepatocellular injury (P<0.01, Figure 39). While not statistically significant, PAG treatment demonstrated a trend towards a decrease in HIF-1 α levels during endotoxemia (Figure 40), but had no effect on iNOS or HO-1 in endotoxemic mice (data not shown).

The effect of H₂S during hypoxia is not solely detrimental. In isolated hepatocytes, we hypothesized that H₂S would sensitize increase hypoxic stress by decreasing cellular O₂; however, we show that the H₂S donor GYY 4137 attenuated cell death during hypoxia in part due to a significant reduction in mitochondrial derived reactive oxygen species (ROS) (Figure 41). Therefore, further research is needed to characterize the effect of H₂S in the liver during hypoxia.

The effect of H₂S on NOS is also the subject of debate. In an acellular environment, H₂S inhibits the activity of all three isoforms of recombinant NOS [65-66]. On the contrary, H₂S increases NO production from eNOS in bovine arterial endothelial

cells suggesting a more complex function in physiological conditions [102]. Preliminary experiments from our lab show that Na₂S increases eNOS activity and NO levels in SECs. However, these results may be unique to the experimental conditions because Na₂S rapidly releases H₂S which escapes to the atmosphere within minutes of incubation at 37° Celsius. Therefore, it is important to perform these studies using the slow releasing H₂S donor GYY 4137. It is possible that H₂S may increase eNOS activity, but inhibits the accumulation of NO via the creation of a nitrosothiol. The importance of investigating the effect of H₂S on eNOS activity is underscored by the contribution of impaired eNOS activity to hepatic dysfunction during sepsis.

H₂S has shown promise as a potential therapy in several disease states, including acetaminophen induced hepatotoxicity, burn injury and ischemia/reperfusion injury [127]. Despite these promising findings, evidence suggests that H₂S contributes to the progression of sepsis. The purpose of this study was to investigate the effect of H₂S in the liver and its contribution to hepatic tissue hypoxia and microcirculatory dysfunction. The importance of these findings is underscored by the fact that sepsis is a common complication in several of the diseases that H₂S therapy is being proposed. The development of potential therapeutics that administers H₂S may need to be monitored closely to ensure that they do not exacerbate the progression of sepsis in this vulnerable patient population.




Figure 38: Proposed mechanism of the deleterious effect of H₂S during Sepsis. Sepsis increases hepatic exposure to hydrogen sulfide (1). The increased levels of H₂S require hepatic oxidation to prevent toxic accumulation. The oxidation of H₂S consumes molecular oxygen which reduces hepatic oxygen availability (2). Simultaneously, H₂S contributes to hepatic microvascular dysfunction which impairs hepatic O₂ delivery (3). The decrease in available oxygen reduces the oxidative capacity of the liver, producing a feed-back loop which further increases H₂S levels (4). The final result of this pathway is the potentiation of hypoxic stress which contributes to liver dysfunction during sepsis (5).




Figure 39: Effect of PAG treatment on serum alanine aminotransferase levels during endotoxemia. An intraperitoneal injection of PAG (50 mg/kg) or saline was given 30 minutes prior to LPS (10 mg/kg ip) or saline treatment. After six hours, blood was collected and analyzed for the ALT, a marker of hepatocellular injury. Data are presented as the mean \pm SEM. Statistical analysis was performed using 2 way ANOVA with SNK *post hoc* test.




Figure 40: Effect of PAG treatment on hepatic HIF-1 α levels during endotoxemia. HIF-1 α levels were determined in liver homogenates from mice treated with LPS for 6 hours with or with PAG pretreatment. N=4.




Figure 41: Effect of GYY 4137 on mitochondrial reactive oxygen species production in isolated rat hepatocytes during hypoxia. Hepatocytes were incubated under normoxic (20 % O₂) or hypoxic (< 3 % O₂) for one hour with or without the H₂S donor, GYY4137. Mitochondrial reactive oxygen species production was determined using the fluorescent dye MitoSox™ (Molecular Probes, Grand Island, NY). Data are presented as means ± SEM of 5 separate experiments. Statistical analysis was performed using 2 way ANOVA with SNK *post hoc* test. *=P<0.05 vs. control, **=P<0.05 vs. Normoxia/GYY & Hypoxia .

REFERENCES

1. Abe, K. and H. Kimura. The possible role of hydrogen sulfide as an endogenous neuromodulator. *J Neurosci* 1996; 16: 1066-71.
2. Aitken, A.E., T.A. Richardson, and E.T. Morgan. Regulation of drug-metabolizing enzymes and transporters in inflammation. *Annu Rev Pharmacol Toxicol* 2006; 46: 123-49.
3. Alam, I., N.M. Bass, P. Bacchetti, L. Gee, and D.C. Rockey. Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. *Am J Gastroenterol* 2000; 95: 199-203.
4. Ali, M.Y., C.Y. Ping, Y.Y. Mok, L. Ling, M. Whiteman, M. Bhatia, and P.K. Moore. Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide? *Br J Pharmacol* 2006; 149: 625-34.
5. Ang, S.F., S.M. Mochhala, P.A. MacAry, and M. Bhatia. Hydrogen sulfide and neurogenic inflammation in polymicrobial sepsis: involvement of substance P and ERK-NF-kappaB signaling. *PLoS One* 2011; 6: e24535.
6. Ayala, A., M.M. Perrin, P. Wang, and I.H. Chaudry. Sepsis induces an early increased spontaneous release of hepatocellular stimulatory factor (interleukin-6) by Kupffer cells in both endotoxin tolerant and intolerant mice. *J Surg Res* 1992; 52: 635-41.
7. Bari, K. and G. Garcia-Tsao. Treatment of portal hypertension. *World J Gastroenterol* 2012; 18: 1166-75.
8. Bartholomew, T.C., G.M. Powell, K.S. Dodgson, and C.G. Curtis. Oxidation of sodium sulphide by rat liver, lungs and kidney. *Biochem Pharmacol* 1980; 29: 2431-7.
9. Bataller, R., P. Gines, J.M. Nicolas, M.N. Gorbic, E. Garcia-Ramallo, X. Gasull, J. Bosch, V. Arroyo, and J. Rodes. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. *Gastroenterology* 2000; 118: 1149-56.
10. Bauer, M., I. Bauer, N.V. Sonin, N. Kresge, R. Baveja, Y. Yokoyama, D. Harding, J.X. Zhang, and M.G. Clemens. Functional significance of endothelin B receptors in mediating sinusoidal and extrasinusoidal effects of endothelins in the intact rat liver. *Hepatology* 2000; 31: 937-47.

11. Bauer, M., J.X. Zhang, I. Bauer, and M.G. Clemens. ET-1 induced alterations of hepatic microcirculation: sinusoidal and extrasinusoidal sites of action. *Am J Physiol* 1994; 267: G143-9.
12. Baveja, R., N. Kresge, J.H. Ashburn, S. Keller, Y. Yokoyama, N. Sonin, J.X. Zhang, T. Huynh, and M.G. Clemens. Potentiated hepatic microcirculatory response to endothelin-1 during polymicrobial sepsis. *Shock* 2002; 18: 415-22.
13. Baveja, R., Y. Yokoyama, K. Korneszczyk, J.X. Zhang, and M.G. Clemens. Endothelin 1 impairs oxygen delivery in livers from LPS-primed animals. *Shock* 2002; 17: 383-8.
14. Bhogal, R.H., S.M. Curbishley, C.J. Weston, D.H. Adams, and S.C. Afford. Reactive oxygen species mediate human hepatocyte injury during hypoxia/reoxygenation. *Liver Transpl* 2010; 16: 1303-13.
15. Blachier, F., A.M. Davila, S. Mimoun, P.H. Benetti, C. Atanasiu, M. Andriamihaja, R. Benamouzig, F. Bouillaud, and D. Tome. Luminal sulfide and large intestine mucosa: friend or foe? *Amino Acids* 2010; 39: 335-47.
16. Blackstone, E. and M.B. Roth. Suspended animation-like state protects mice from lethal hypoxia. *Shock* 2007; 27: 370-2.
17. Budde, M.W. and M.B. Roth. Hydrogen sulfide increases hypoxia-inducible factor-1 activity independently of von Hippel-Lindau tumor suppressor-1 in *C. elegans*. *Mol Biol Cell* 2010; 21: 212-7.
18. Bukovska, G., V. Kery, and J.P. Kraus. Expression of human cystathionine beta-synthase in *Escherichia coli*: purification and characterization. *Protein Expr Purif* 1994; 5: 442-8.
19. Cameron, D.E., I.H. Chaudry, S. Schleck, and A.E. Baue. Hepatocellular dysfunction in early sepsis despite increased hepatic blood flow. *Adv Shock Res* 1981; 6: 65-74.
20. Chaudry, I.H., S. Schleck, M.G. Clemens, T.E. Kupper, and A.E. Baue. Altered hepatocellular active transport. An early change in peritonitis. *Arch Surg* 1982; 117: 151-7.
21. Cheng, Y., J.F. Ndisang, G. Tang, K. Cao, and R. Wang. Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats. *Am J Physiol Heart Circ Physiol* 2004; 287: H2316-23.

22. Chun, K., J. Zhang, J. Biewer, D. Ferguson, and M.G. Clemens. Microcirculatory failure determines lethal hepatocyte injury in ischemic/reperfused rat livers. *Shock* 1994; 1: 3-9.
23. Clemens, M.G., I.H. Chaudry, P.H. McDermott, and A.E. Baue. Regulation of glucose production from lactate in experimental sepsis. *Am J Physiol* 1983; 244: R794-800.
24. Clemens, M.G. and T. Forrester. Appearance of adenosine triphosphate in the coronary sinus effluent from isolated working rat heart in response to hypoxia. *J Physiol* 1981; 312: 143-58.
25. Clemens, M.G. and J.X. Zhang. Regulation of sinusoidal perfusion: in vivo methodology and control by endothelins. *Semin Liver Dis* 1999; 19: 383-96.
26. Collin, M., F.B. Anuar, O. Murch, M. Bhatia, P.K. Moore, and C. Thiernemann. Inhibition of endogenous hydrogen sulfide formation reduces the organ injury caused by endotoxemia. *Br J Pharmacol* 2005; 146: 498-505.
27. Dahn, M.S., P. Lange, K. Lobdell, B. Hans, L.A. Jacobs, and R.A. Mitchell. Splanchnic and total body oxygen consumption differences in septic and injured patients. *Surgery* 1987; 101: 69-80.
28. Dahn, M.S., R.F. Wilson, P. Lange, A. Stone, and L.A. Jacobs. Hepatic parenchymal oxygen tension following injury and sepsis. *Arch Surg* 1990; 125: 441-3.
29. Dello Russo, C., G. Tringali, E. Ragazzoni, N. Maggiano, E. Menini, M. Vairano, P. Preziosi, and P. Navarra. Evidence that hydrogen sulphide can modulate hypothalamo-pituitary-adrenal axis function: in vitro and in vivo studies in the rat. *J Neuroendocrinol* 2000; 12: 225-33.
30. Distrutti, E., A. Mencarelli, L. Santucci, B. Renga, S. Orlandi, A. Donini, V. Shah, and S. Fiorucci. The methionine connection: homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats. *Hepatology* 2008; 47: 659-67.
31. Ellis, A., C.G. Li, and M.J. Rand. Differential actions of L-cysteine on responses to nitric oxide, nitroxyl anions and EDRF in the rat aorta. *Br J Pharmacol* 2000; 129: 315-22.
32. Fink, M.P. Cytopathic hypoxia. Mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. *Crit Care Clin* 2001; 17: 219-37.

33. Fiorucci, S., E. Antonelli, A. Mencarelli, S. Orlandi, B. Renga, G. Rizzo, E. Distrutti, V. Shah, and A. Morelli. The third gas: H₂S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. *Hepatology* 2005; 42: 539-48.
34. Fitch, K.A. and R.D. Rink. Hepatic oxygen supply during early and late sepsis in the rat. *Circ Shock* 1983; 10: 51-9.
35. Fitzpatrick, S.F., M.M. Tambuwala, U. Bruning, B. Schaible, C.C. Scholz, A. Byrne, A. O'Connor, W.M. Gallagher, C.R. Lenihan, J.F. Garvey, K. Howell, P.G. Fallon, E.P. Cummins, and C.T. Taylor. An intact canonical NF-kappaB pathway is required for inflammatory gene expression in response to hypoxia. *J Immunol* 2011; 186: 1091-6.
36. Furne, J., A. Saeed, and M.D. Levitt. Whole tissue hydrogen sulfide concentrations are orders of magnitude lower than presently accepted values. *Am J Physiol Regul Integr Comp Physiol* 2008; 295: R1479-85.
37. Furne, J., J. Springfield, T. Koenig, E. DeMaster, and M.D. Levitt. Oxidation of hydrogen sulfide and methanethiol to thiosulfate by rat tissues: a specialized function of the colonic mucosa. *Biochem Pharmacol* 2001; 62: 255-9.
38. Gimson, A.E. Hepatic dysfunction during bacterial sepsis. *Intensive Care Med* 1987; 13: 162-6.
39. Graser, T., Y.P. Vedernikov, and D.S. Li. Study on the mechanism of carbon monoxide induced endothelium-independent relaxation in porcine coronary artery and vein. *Biomed Biochim Acta* 1990; 49: 293-6.
40. Griffith, T.M., A.H. Henderson, D.H. Edwards, and M.J. Lewis. Isolated perfused rabbit coronary artery and aortic strip preparations: the role of endothelium-derived relaxant factor. *J Physiol* 1984; 351: 13-24.
41. Gundersen, Y., C.O. Corso, R. Leiderer, M. Dorger, P. Lilleaasen, A.O. Aasen, and K. Messmer. The nitric oxide donor sodium nitroprusside protects against hepatic microcirculatory dysfunction in early endotoxaemia. *Intensive Care Med* 1998; 24: 1257-63.
42. Haendler, B., U. Hechler, and W.D. Schleuning. Molecular cloning of human endothelin (ET) receptors ETA and ETB. *J Cardiovasc Pharmacol* 1992; 20 Suppl 12: S1-4.

43. Haouzi, P., H. Bell, and M. Philmon. Hydrogen sulfide oxidation and the arterial chemoreflex: effect of methemoglobin. *Respir Physiol Neurobiol* 2011; 177: 273-83.
44. Hayes, M.A., A.C. Timmins, E.H. Yau, M. Palazzo, D. Watson, and C.J. Hinds. Oxygen transport patterns in patients with sepsis syndrome or septic shock: influence of treatment and relationship to outcome. *Crit Care Med* 1997; 25: 926-36.
45. Hegde, A. and M. Bhatia. Hydrogen sulfide in inflammation: friend or foe? *Inflamm Allergy Drug Targets* 2011; 10: 118-22.
46. Higuchi, H. and T. Satoh. Endothelin-1 induces vasoconstriction and nitric oxide release via endothelin ET(B) receptors in isolated perfused rat liver. *Eur J Pharmacol* 1997; 328: 175-82.
47. Hollenberg, S.M., C.R. Easington, J. Osman, M. Broussard, and J.E. Parrillo. Effects of nitric oxide synthase inhibition on microvascular reactivity in septic mice. *Shock* 1999; 12: 262-7.
48. Hosoki, R., N. Matsuki, and H. Kimura. The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. *Biochem Biophys Res Commun* 1997; 237: 527-31.
49. Housset, C., D.C. Rockey, and D.M. Bissell. Endothelin receptors in rat liver: lipocytes as a contractile target for endothelin 1. *Proc Natl Acad Sci U S A* 1993; 90: 9266-70.
50. Hui, Y., J. Du, C. Tang, G. Bin, and H. Jiang. Changes in arterial hydrogen sulfide (H₂S) content during septic shock and endotoxin shock in rats. *J Infect* 2003; 47: 155-60.
51. Ignarro, L.J., R.G. Harbison, K.S. Wood, and P.J. Kadowitz. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. *J Pharmacol Exp Ther* 1986; 237: 893-900.
52. Ince, C. The microcirculation is the motor of sepsis. *Crit Care* 2005; 9 Suppl 4: S13-9.
53. James, P.E., M. Madhani, W. Roebuck, S.K. Jackson, and H.M. Swartz. Endotoxin-induced liver hypoxia: defective oxygen delivery versus oxygen consumption. *Nitric Oxide* 2002; 6: 18-28.

54. Jha, S., J.W. Calvert, M.R. Duranski, A. Ramachandran, and D.J. Lefer. Hydrogen sulfide attenuates hepatic ischemia-reperfusion injury: role of antioxidant and antiapoptotic signaling. *Am J Physiol Heart Circ Physiol* 2008; 295: H801-6.
55. Jia, L. and R.F. Furchgott. Inhibition by sulfhydryl compounds of vascular relaxation induced by nitric oxide and endothelium-derived relaxing factor. *J Pharmacol Exp Ther* 1993; 267: 371-8.
56. Kabil, O., V. Vitvitsky, P. Xie, and R. Banerjee. The quantitative significance of the transsulfuration enzymes for H₂S production in murine tissues. *Antioxid Redox Signal* 2011; 15: 363-72.
57. Kamoun, W.S., M.C. Shin, A. Karaa, and M.G. Clemens. Quantification of hepatic microcirculation heterogeneity of perfusion: effects of endothelin-1. *Microvasc Res* 2005; 69: 180-6.
58. Kamoun, W.S., M.C. Shin, S. Keller, A. Karaa, T. Huynh, and M.G. Clemens. Induction of biphasic changes in perfusion heterogeneity of rat liver after sequential stress in vivo. *Shock* 2005; 24: 324-31.
59. Kang, K., M. Zhao, H. Jiang, G. Tan, S. Pan, and X. Sun. Role of hydrogen sulfide in hepatic ischemia-reperfusion-induced injury in rats. *Liver Transpl* 2009; 15: 1306-14.
60. Kawada, N., H. Klein, and K. Decker. Eicosanoid-mediated contractility of hepatic stellate cells. *Biochem J* 1992; 285 (Pt 2): 367-71.
61. Kawada, N., S. Seki, T. Kuroki, and K. Kaneda. ROCK inhibitor Y-27632 attenuates stellate cell contraction and portal pressure increase induced by endothelin-1. *Biochem Biophys Res Commun* 1999; 266: 296-300.
62. Kawada, N., T.A. Tran-Thi, H. Klein, and K. Decker. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. *Eur J Biochem* 1993; 213: 815-23.
63. Keller, S.A., M. Paxian, J.H. Ashburn, M.G. Clemens, and T. Huynh. Kupffer cell ablation improves hepatic microcirculation after trauma and sepsis. *J Trauma* 2005; 58: 740-9; discussion 749-51.
64. Kim, T.H., S.H. Lee, and S.M. Lee. Role of Kupffer cells in pathogenesis of sepsis-induced drug metabolizing dysfunction. *FEBS J* 2011; 278: 2307-17.

65. Kubo, S., I. Doe, Y. Kurokawa, H. Nishikawa, and A. Kawabata. Direct inhibition of endothelial nitric oxide synthase by hydrogen sulfide: contribution to dual modulation of vascular tension. *Toxicology* 2007; 232: 138-46.
66. Kubo, S., Y. Kurokawa, I. Doe, T. Masuko, F. Sekiguchi, and A. Kawabata. Hydrogen sulfide inhibits activity of three isoforms of recombinant nitric oxide synthase. *Toxicology* 2007; 241: 92-7.
67. Kwok, W., S.H. Lee, C. Culberson, K. Korneszczyk, and M.G. Clemens. Caveolin-1 mediates endotoxin inhibition of endothelin-1-induced endothelial nitric oxide synthase activity in liver sinusoidal endothelial cells. *Am J Physiol Gastrointest Liver Physiol* 2009; 297: G930-9.
68. Lagoutte, E., S. Mimoun, M. Andriamihaja, C. Chaumontet, F. Blachier, and F. Bouillaud. Oxidation of hydrogen sulfide remains a priority in mammalian cells and causes reverse electron transfer in colonocytes. *Biochim Biophys Acta* 2010; 1797: 1500-11.
69. Laleman, W., L. Van Landeghem, T. Severi, I. Vander Elst, M. Zeegers, R. Bisschops, J. Van Pelt, T. Roskams, D. Cassiman, J. Fevery, and F. Nevens. Both Ca²⁺-dependent and -independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine. *Am J Physiol Gastrointest Liver Physiol* 2007; 292: G556-64.
70. Lee, S.W., Y.S. Hu, L.F. Hu, Q. Lu, G.S. Dawe, P.K. Moore, P.T. Wong, and J.S. Bian. Hydrogen sulphide regulates calcium homeostasis in microglial cells. *Glia* 2006; 54: 116-24.
71. Lee, Z.W., J. Zhou, C.S. Chen, Y. Zhao, C.H. Tan, L. Li, P.K. Moore, and L.W. Deng. The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. *PLoS One* 2011; 6: e21077.
72. Li, L., M. Bhatia, Y.Z. Zhu, Y.C. Zhu, R.D. Ramnath, Z.J. Wang, F.B. Anuar, M. Whiteman, M. Salto-Tellez, and P.K. Moore. Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. *FASEB J* 2005; 19: 1196-8.
73. Li, L., M. Salto-Tellez, C.H. Tan, M. Whiteman, and P.K. Moore. GYY4137, a novel hydrogen sulfide-releasing molecule, protects against endotoxic shock in the rat. *Free Radic Biol Med* 2009; 47: 103-13.

74. Lim, J.J., Y.H. Liu, E.S. Khin, and J.S. Bian. Vasoconstrictive effect of hydrogen sulfide involves downregulation of cAMP in vascular smooth muscle cells. *Am J Physiol Cell Physiol* 2008; 295: C1261-70.
75. Liu, F.Q., Y. Liu, V.C. Lui, J.R. Lamb, P.K. Tam, and Y. Chen. Hypoxia modulates lipopolysaccharide induced TNF-alpha expression in murine macrophages. *Exp Cell Res* 2008; 314: 1327-36.
76. Liu, Y.H. and J.S. Bian. Bicarbonate-dependent effect of hydrogen sulfide on vascular contractility in rat aortic rings. *Am J Physiol Cell Physiol* 2010; 299: C866-72.
77. Lopez, A., J.A. Lorente, J. Steingrub, J. Bakker, A. McLuckie, S. Willatts, M. Brockway, A. Anzueto, L. Holzapfel, D. Breen, M.S. Silverman, J. Takala, J. Donaldson, C. Arneson, G. Grove, S. Grossman, and R. Grover. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. *Crit Care Med* 2004; 32: 21-30.
78. Martin, G.S., D.M. Mannino, S. Eaton, and M. Moss. The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med* 2003; 348: 1546-54.
79. McCuskey, R.S. Morphological mechanisms for regulating blood flow through hepatic sinusoids. *Liver* 2000; 20: 3-7.
80. McCuskey, R.S., R. Urbaschek, and B. Urbaschek. The microcirculation during endotoxemia. *Cardiovasc Res* 1996; 32: 752-63.
81. Merkel, S.M., W. Kamoun, A. Karaa, K. Korneszczyk, L.W. Schrum, and M.G. Clemens. LPS inhibits endothelin-1-mediated eNOS translocation to the cell membrane in sinusoidal endothelial cells. *Microcirculation* 2005; 12: 433-42.
82. Moccia, F., G. Bertoni, A.F. Pla, S. Dragoni, E. Pupo, A. Merlino, D. Mancardi, L. Munaron, and F. Tanzi. Hydrogen sulfide regulates intracellular Ca²⁺ concentration in endothelial cells from excised rat aorta. *Curr Pharm Biotechnol* 2011; 12: 1416-26.
83. Mollen, K.P., C.A. McCloskey, H. Tanaka, J.M. Prince, R.M. Levy, B.S. Zuckerbraun, and T.R. Billiar. Hypoxia activates c-Jun N-terminal kinase via Rac1-dependent reactive oxygen species production in hepatocytes. *Shock* 2007; 28: 270-7.

84. Morsy, M.A., S.A. Ibrahim, S.A. Abdelwahab, M.Z. Zedan, and H.I. Elbitar. Curative effects of hydrogen sulfide against acetaminophen-induced hepatotoxicity in mice. *Life Sci* 2010; 87: 692-8.
85. Munaron, L., D. Avanzato, F. Moccia, and D. Mancardi. Hydrogen sulfide as a regulator of calcium channels. *Cell Calcium* 2012.
86. Mustafa, A.K., M.M. Gadalla, N. Sen, S. Kim, W. Mu, S.K. Gazi, R.K. Barrow, G. Yang, R. Wang, and S.H. Snyder. H₂S signals through protein S-sulfhydration. *Sci Signal* 2009; 2: ra72.
87. Nicholls, P. and J.K. Kim. Sulphide as an inhibitor and electron donor for the cytochrome c oxidase system. *Can J Biochem* 1982; 60: 613-23.
88. Nishida, J., R.S. McCuskey, D. McDonnell, and E.S. Fox. Protective role of NO in hepatic microcirculatory dysfunction during endotoxemia. *Am J Physiol* 1994; 267: G1135-41.
89. Norris, E.J., C.R. Culberson, S. Narasimhan, and M.G. Clemens. The liver as a central regulator of hydrogen sulfide. *Shock* 2011; 36: 242-50.
90. Oda, M., H. Yokomori, and J.Y. Han. Regulatory mechanisms of hepatic microcirculation. *Clin Hemorheol Microcirc* 2003; 29: 167-82.
91. Olson, K.R. Hydrogen sulfide and oxygen sensing: implications in cardiorespiratory control. *J Exp Biol* 2008; 211: 2727-34.
92. Olson, K.R. Is hydrogen sulfide a circulating "gasotransmitter" in vertebrate blood? *Biochim Biophys Acta* 2009; 1787: 856-63.
93. Olson, K.R., R.A. Dombkowski, M.J. Russell, M.M. Doellman, S.K. Head, N.L. Whitfield, and J.A. Madden. Hydrogen sulfide as an oxygen sensor/transducer in vertebrate hypoxic vasoconstriction and hypoxic vasodilation. *J Exp Biol* 2006; 209: 4011-23.
94. Pannen, B.H., M. Bauer, J.X. Zhang, J.L. Robotham, and M.G. Clemens. Endotoxin pretreatment enhances portal venous contractile response to endothelin-1. *Am J Physiol* 1996; 270: H7-15.
95. Pannen, B.H., M. Bauer, J.X. Zhang, J.L. Robotham, and M.G. Clemens. A time-dependent balance between endothelins and nitric oxide regulating portal resistance after endotoxin. *Am J Physiol* 1996; 271: H1953-61.

96. Parratt, J.R. Nitric oxide in sepsis and endotoxaemia. *J Antimicrob Chemother* 1998; 41 Suppl A: 31-9.
97. Pastor, C.M. and T.R. Billiar. Nitric oxide causes hyporeactivity to phenylephrine in isolated perfused livers from endotoxin-treated rats. *Am J Physiol* 1995; 268: G177-82.
98. Paxian, M., S.A. Keller, R. Baveja, K. Korneszczyk, T.T. Huynh, and M.G. Clemens. Functional link between ETB receptors and eNOS maintain tissue oxygenation in the normal liver. *Microcirculation* 2004; 11: 435-49.
99. Paxian, M., S.A. Keller, B. Cross, T.T. Huynh, and M.G. Clemens. High-resolution visualization of oxygen distribution in the liver in vivo. *Am J Physiol Gastrointest Liver Physiol* 2004; 286: G37-44.
100. Peyssonnaud, C., P. Cejudo-Martin, A. Doedens, A.S. Zinkernagel, R.S. Johnson, and V. Nizet. Cutting edge: Essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis. *J Immunol* 2007; 178: 7516-9.
101. Pinzani, M., P. Failli, C. Ruocco, A. Casini, S. Milani, E. Baldi, A. Giotti, and P. Gentilini. Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. *J Clin Invest* 1992; 90: 642-6.
102. Predmore, B.L., D. Julian, and A.J. Cardounel. Hydrogen sulfide increases nitric oxide production from endothelial cells by an akt-dependent mechanism. *Front Physiol* 2011; 2: 104.
103. Quayle, J.M., M.T. Nelson, and N.B. Standen. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. *Physiol Rev* 1997; 77: 1165-232.
104. Reinehr, R., R. Fischer, and D. Haussinger. Regulation of endothelin-A receptor sensitivity by cyclic adenosine monophosphate in rat hepatic stellate cells. *Hepatology* 2002; 36: 861-73.
105. Rockey, D.C., J.K. Boyles, G. Gabbiani, and S.L. Friedman. Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. *J Submicrosc Cytol Pathol* 1992; 24: 193-203.
106. Rockey, D.C., L. Fouassier, J.J. Chung, A. Carayon, P. Vallee, C. Rey, and C. Housset. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. *Hepatology* 1998; 27: 472-80.

107. Rockey, D.C. and R.A. Weisiger. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. *Hepatology* 1996; 24: 233-40.
108. Roller, J., M.W. Laschke, C. Scheuer, and M.D. Menger. Heme oxygenase (HO)-1 protects from lipopolysaccharide (LPS)-mediated liver injury by inhibition of hepatic leukocyte accumulation and improvement of microvascular perfusion. *Langenbecks Arch Surg* 2010; 395: 387-94.
109. Ros, J., A. Leivas, W. Jimenez, M. Morales, M. Bosch-Marce, V. Arroyo, F. Rivera, and J. Rodes. Effect of bacterial lipopolysaccharide on endothelin-1 production in human vascular endothelial cells. *J Hepatol* 1997; 26: 81-7.
110. Scharte, M., X. Han, T. Uchiyama, Z. Tawadrous, R.L. Delude, and M.P. Fink. LPS increases hepatic HIF-1 α protein and expression of the HIF-1-dependent gene aldolase A in rats. *J Surg Res* 2006; 135: 262-7.
111. Serradeil-Le Gal, C., C. Jouneaux, A. Sanchez-Bueno, D. Raufaste, B. Roche, A.M. Preaux, J.P. Maffrand, P.H. Cobbold, J. Hanoune, and S. Lotersztajn. Endothelin action in rat liver. Receptors, free Ca²⁺ oscillations, and activation of glycogenolysis. *J Clin Invest* 1991; 87: 133-8.
112. Shah, V., F.G. Haddad, G. Garcia-Cardena, J.A. Frangos, A. Mennone, R.J. Groszmann, and W.C. Sessa. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. *J Clin Invest* 1997; 100: 2923-30.
113. Shah, V., M. Toruner, F. Haddad, G. Cadelina, A. Papapetropoulos, K. Choo, W.C. Sessa, and R.J. Groszmann. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. *Gastroenterology* 1999; 117: 1222-8.
114. Shibuya, N., M. Tanaka, M. Yoshida, Y. Ogasawara, T. Togawa, K. Ishii, and H. Kimura. 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. *Antioxid Redox Signal* 2009; 11: 703-14.
115. Siebert, N., D. Cantre, C. Eipel, and B. Vollmar. H₂S contributes to the hepatic arterial buffer response and mediates vasorelaxation of the hepatic artery via activation of K(ATP) channels. *Am J Physiol Gastrointest Liver Physiol* 2008; 295: G1266-73.
116. Sivarajah, A., M.C. McDonald, and C. Thiemeermann. The production of hydrogen sulfide limits myocardial ischemia and reperfusion injury and contributes to the

- cardioprotective effects of preconditioning with endotoxin, but not ischemia in the rat. *Shock* 2006; 26: 154-61.
117. Sodha, N.R., R.T. Clements, J. Feng, Y. Liu, C. Bianchi, E.M. Horvath, C. Szabo, and F.W. Sellke. The effects of therapeutic sulfide on myocardial apoptosis in response to ischemia-reperfusion injury. *Eur J Cardiothorac Surg* 2008; 33: 906-13.
 118. Sohail, M.A., A.Z. Hashmi, W. Hakim, A. Watanabe, A. Zipprich, R.J. Groszmann, J.A. Dranoff, N.J. Torok, and W.Z. Mehal. Adenosine induces loss of actin stress fibers and inhibits contraction in hepatic stellate cells via Rho inhibition. *Hepatology* 2009; 49: 185-94.
 119. Sonin, N.V., J.C. Garcia-Pagan, K. Nakanishi, J.X. Zhang, and M.G. Clemens. Patterns of vasoregulatory gene expression in the liver response to ischemia/reperfusion and endotoxemia. *Shock* 1999; 11: 175-9.
 120. Soon, R.K., Jr. and H.F. Yee, Jr. Stellate cell contraction: role, regulation, and potential therapeutic target. *Clin Liver Dis* 2008; 12: 791-803, viii.
 121. Spapen, H. Liver perfusion in sepsis, septic shock, and multiorgan failure. *Anat Rec (Hoboken)* 2008; 291: 714-20.
 122. Spiller, F., M.I. Orrico, D.C. Nascimento, P.G. Czaikoski, F.O. Souto, J.C. Alves-Filho, A. Freitas, D. Carlos, M.F. Montenegro, A.F. Neto, S.H. Ferreira, M.A. Rossi, J.S. Hothersall, J. Assreuy, and F.Q. Cunha. Hydrogen sulfide improves neutrophil migration and survival in sepsis via K⁺ATP channel activation. *Am J Respir Crit Care Med* 2010; 182: 360-8.
 123. Stipanuk, M.H. and P.W. Beck. Characterization of the enzymic capacity for cysteine desulphhydration in liver and kidney of the rat. *Biochem J* 1982; 206: 267-77.
 124. Strunk, V., K. Hahnenkamp, M. Schneuing, L.G. Fischer, and G.F. Rich. Selective iNOS inhibition prevents hypotension in septic rats while preserving endothelium-dependent vasodilation. *Anesth Analg* 2001; 92: 681-7.
 125. Sugano, T., K. Suda, M. Shimada, and N. Oshino. Biochemical and ultrastructural evaluation of isolated rat liver systems perfused with a hemoglobin-free medium. *J Biochem* 1978; 83: 995-1007.
 126. Sun, Q., R. Collins, S. Huang, L. Holmberg-Schiavone, G.S. Anand, C.H. Tan, S. van-den-Berg, L.W. Deng, P.K. Moore, T. Karlberg, and J. Sivaraman. Structural

- basis for the inhibition mechanism of human cystathionine gamma-lyase, an enzyme responsible for the production of H₂S. *J Biol Chem* 2009; 284: 3076-85.
127. Szabo, C. Hydrogen sulphide and its therapeutic potential. *Nat Rev Drug Discov* 2007; 6: 917-35.
 128. Tang, G., L. Wu, W. Liang, and R. Wang. Direct stimulation of K(ATP) channels by exogenous and endogenous hydrogen sulfide in vascular smooth muscle cells. *Mol Pharmacol* 2005; 68: 1757-64.
 129. Taniguchi, E., M. Matsunami, T. Kimura, D. Yonezawa, T. Ishiki, F. Sekiguchi, H. Nishikawa, Y. Maeda, H. Ishikura, and A. Kawabata. Rhodanese, but not cystathionine-gamma-lyase, is associated with dextran sulfate sodium-evoked colitis in mice: a sign of impaired colonic sulfide detoxification? *Toxicology* 2009; 264: 96-103.
 130. van de Bovenkamp, M., G.M. Groothuis, A.L. Draaisma, M.T. Merema, J.I. Bezuijen, M.J. van Gils, D.K. Meijer, S.L. Friedman, and P. Olinga. Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu. *Toxicol Sci* 2005; 85: 632-8.
 131. Vollmar, B., J. Glasz, R. Leiderer, S. Post, and M.D. Menger. Hepatic microcirculatory perfusion failure is a determinant of liver dysfunction in warm ischemia-reperfusion. *Am J Pathol* 1994; 145: 1421-31.
 132. von Allmen, D., P.O. Hasselgren, T. Higashiguchi, and J.E. Fischer. Individual regulation of different hepatocellular functions during sepsis. *Metabolism* 1992; 41: 961-9.
 133. Wang, G.L., B.H. Jiang, E.A. Rue, and G.L. Semenza. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. *Proc Natl Acad Sci U S A* 1995; 92: 5510-4.
 134. Wang, P. and I.H. Chaudry. Mechanism of hepatocellular dysfunction during hyperdynamic sepsis. *Am J Physiol* 1996; 270: R927-38.
 135. Wang, R. Two's company, three's a crowd: can H₂S be the third endogenous gaseous transmitter? *FASEB J* 2002; 16: 1792-8.
 136. Wang, R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. *Physiol Rev* 2012; 92: 791-896.

137. Whiteman, M., L. Li, I. Kostetski, S.H. Chu, J.L. Siau, M. Bhatia, and P.K. Moore. Evidence for the formation of a novel nitrosothiol from the gaseous mediators nitric oxide and hydrogen sulphide. *Biochem Biophys Res Commun* 2006; 343: 303-10.
138. Whitfield, N.L., E.L. Kreimier, F.C. Verdial, N. Skovgaard, and K.R. Olson. Reappraisal of H₂S/sulfide concentration in vertebrate blood and its potential significance in ischemic preconditioning and vascular signaling. *Am J Physiol Regul Integr Comp Physiol* 2008; 294: R1930-7.
139. Yanagisawa, M., H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto, and T. Masaki. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature* 1988; 332: 411-5.
140. Yang, G., L. Wu, B. Jiang, W. Yang, J. Qi, K. Cao, Q. Meng, A.K. Mustafa, W. Mu, S. Zhang, S.H. Snyder, and R. Wang. H₂S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. *Science* 2008; 322: 587-90.
141. Yong, R. and D.G. Searcy. Sulfide oxidation coupled to ATP synthesis in chicken liver mitochondria. *Comp Biochem Physiol B Biochem Mol Biol* 2001; 129: 129-37.
142. Zanardo, R.C., V. Brancaleone, E. Distrutti, S. Fiorucci, G. Cirino, and J.L. Wallace. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. *FASEB J* 2006; 20: 2118-20.
143. Zhang, H., S.M. Moochhala, and M. Bhatia. Endogenous hydrogen sulfide regulates inflammatory response by activating the ERK pathway in polymicrobial sepsis. *J Immunol* 2008; 181: 4320-31.
144. Zhang, H., L. Zhi, P.K. Moore, and M. Bhatia. Role of hydrogen sulfide in cecal ligation and puncture-induced sepsis in the mouse. *Am J Physiol Lung Cell Mol Physiol* 2006; 290: L1193-201.
145. Zhang, J., S.W. Sio, S. Moochhala, and M. Bhatia. Role of hydrogen sulfide in severe burn injury-induced inflammation in mice. *Mol Med* 2010; 16: 417-24.
146. Zhang, J.X., W. Pegoli, Jr., and M.G. Clemens. Endothelin-1 induces direct constriction of hepatic sinusoids. *Am J Physiol* 1994; 266: G624-32.
147. Zhao, W., J.F. Ndisang, and R. Wang. Modulation of endogenous production of H₂S in rat tissues. *Can J Physiol Pharmacol* 2003; 81: 848-53.

148. Zhao, W., J. Zhang, Y. Lu, and R. Wang. The vasorelaxant effect of H₂S as a novel endogenous gaseous K(ATP) channel opener. *EMBO J* 2001; 20: 6008-16.
149. Zhu, X.Y., S.J. Liu, Y.J. Liu, S. Wang, and X. Ni. Glucocorticoids suppress cystathionine gamma-lyase expression and H₂S production in lipopolysaccharide-treated macrophages. *Cell Mol Life Sci* 2010; 67: 1119-32.
150. Zimmerhackl, B., N. Parekh, H. Brinkhus, and M. Steinhausen. The use of fluorescent labeled erythrocytes for intravital investigation of flow and local hematocrit in glomerular capillaries in the rat. *Int J Microcirc Clin Exp* 1983; 2: 119-29.